Posttraumatic Stress Disorder and Psychological Therapies

Submitted by Samantha Gerdes, to the University of Exeter
as a thesis for the degree of Doctor of Clinical Psychology, May 2018

This thesis is available for Library use on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement.

I certify that all material in this thesis which is not my own work has been identified and that no material has previously been submitted and approved for the award of a degree by this or any other University.
## CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contents</td>
<td>2</td>
</tr>
<tr>
<td>List of Tables and Figures</td>
<td>3</td>
</tr>
<tr>
<td>Literature Review</td>
<td>4</td>
</tr>
<tr>
<td>References</td>
<td>45</td>
</tr>
<tr>
<td>Appendices</td>
<td>54</td>
</tr>
<tr>
<td>Empirical Paper</td>
<td>78</td>
</tr>
<tr>
<td>References</td>
<td>118</td>
</tr>
<tr>
<td>Appendices</td>
<td>132</td>
</tr>
</tbody>
</table>
List of Tables

Literature Review  
Table 1. Study Characteristics  19  
Table 2. Risk of Bias in Included Studies  26  
Table 3. Results of Studies  31  

Empirical Paper  78  
Table 1. Demographic Information  104  
Table 2. TBI Results  167  
Table 3. Primary Outcome Measures  106  
Table 4. Intercorrelations, Means and Standard Deviations for Variables  168  

List of Figures

Literature Review  4  
Figure 1. PRISMA Flow Diagram  18  

Empirical Paper  78  
Figure 1. Ehlers and Clark (2000) Cognitive Model of PTSD  84  
Figure 2. Gilbert (2009a). Three Types of Affect Regulation System  89  
Figure 3. Flow of Participants through the Study  97  
Figure 4. Experimental Procedure  102
LITERATURE REVIEW

A Review of Psychological Therapies for Sleep Disturbances in Sufferers of PTSD

Trainee Name: Samantha Gerdes

Primary Research Supervisor: Dr Anke Karl
Senior Lecturer in Clinical Psychology, Mood Disorders Centre, University of Exeter

Secondary Research Supervisor: A/Professor Huw Williams
Associate Professor of Clinical Neuropsychology, University of Exeter

Target Journal: Behavior Therapy

Word Count: 6988 words (excluding abstract, table of contents, list of figures, references, footnotes, appendices)

Submitted in partial fulfilment of requirements for the Doctorate Degree in Clinical Psychology, University of Exeter
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title Page</td>
<td>4</td>
</tr>
<tr>
<td>Contents</td>
<td>5</td>
</tr>
<tr>
<td>Abstract</td>
<td>7</td>
</tr>
<tr>
<td>Introduction</td>
<td>8</td>
</tr>
<tr>
<td>Treatment for Sleep Disturbances in PTSD</td>
<td>9</td>
</tr>
<tr>
<td>Rationale</td>
<td>11</td>
</tr>
<tr>
<td>Objectives</td>
<td>13</td>
</tr>
<tr>
<td>Method</td>
<td>13</td>
</tr>
<tr>
<td>Protocol and Registration</td>
<td>13</td>
</tr>
<tr>
<td>Eligibility Criteria (PICOS)</td>
<td>14</td>
</tr>
<tr>
<td>Information Sources</td>
<td>15</td>
</tr>
<tr>
<td>Search Strategy</td>
<td>15</td>
</tr>
<tr>
<td>Study Selection</td>
<td>15</td>
</tr>
<tr>
<td>Data Collection Process</td>
<td>16</td>
</tr>
<tr>
<td>Data Items</td>
<td>16</td>
</tr>
<tr>
<td>Risk of Bias in Individual Studies</td>
<td>16</td>
</tr>
<tr>
<td>Synthesis of Results</td>
<td>17</td>
</tr>
<tr>
<td>Results</td>
<td>17</td>
</tr>
<tr>
<td>Search Results</td>
<td>17</td>
</tr>
<tr>
<td>Study Characteristics</td>
<td>18</td>
</tr>
<tr>
<td>Excluded Studies</td>
<td>25</td>
</tr>
<tr>
<td>Risk of Bias in Included Studies</td>
<td>25</td>
</tr>
<tr>
<td>Effects of Interventions/ Synthesis of Results</td>
<td>27</td>
</tr>
<tr>
<td>Overall</td>
<td>30</td>
</tr>
</tbody>
</table>
## Discussion

Strengths and Limitations 40

Further Research 42

## Conclusions

43

## References

45

## Appendices

54

Appendix A – PRISMA Statement 55

Appendix B – Search Terms 58

Appendix C – Quality Assessment Tool 60

Appendix D - Journal of Behavior Therapy – Instructions for Authors 64
Abstract

The current review presents a recent review of the effectiveness of psychological therapies to treat sleep difficulties (such as insomnia and nightmares) in sufferers of posttraumatic stress disorder (PTSD). The review also aimed to investigate whether there are differences in the effectiveness of specific psychological therapies to treat sleep disturbances in PTSD, such as between the different types of psychological therapies such as cognitive behavioural therapy for insomnia (CBT-I) and imagery rehearsal therapy (IRT). Eleven studies were included in the review that met the inclusion and exclusion criteria. Results are presented in tables and a descriptive account is included. The review demonstrates that psychological therapies are effective for the treatment of insomnia and other sleep difficulties such as nightmares. However, firm conclusions cannot be drawn about the effectiveness of different types of psychological therapies as studies predominantly used CBT and only one non-CBT study was included in the review. Comparisons between the effectiveness of different CBT approaches is also not possible as there was a large range of diversity in the study characteristics and also there were only a small number of studies for each intervention, which therefore limits the generalisability of results in the current review. It may be that different CBT interventions such as CBT-I or EERT and IRT may be better suited to treat insomnia and nightmares respectively, but further research needs to be conducted into which of these approaches are beneficial for different PTSD specific sleep difficulties.

Keywords: Sleep disturbance, insomnia, PTSD
Introduction

Rationale

Post-traumatic Stress Disorder (PTSD) affects between 7-12% in the general population (Kessler, et al., 2005) and sleep difficulties form part of the DSM-5 diagnostic criteria for PTSD (American Psychological Association, 2013). Problems with sleep can have a large impact on health and quality of life as well as daily functioning (DeViva, Zayfert, & Mellman, 2004). Sleep disturbances are arguably some of the most distressing symptoms of PTSD, due to exacerbating other symptoms and leading to daytime impairment (Nappi, Drummond, & Hall, 2012). Studies have shown that sleep difficulties affect a high proportion of people suffering from PTSD, as 70-91% of patients with PTSD have trouble falling or staying asleep and between 19-71% of patients report nightmares (Maher, Rego, & Asnis, 2006). Polysonographic studies have demonstrated that people with PTSD have objective sleep abnormalities (e.g., less slow wave sleep and greater rapid-eye-movement density) compared with people without PTSD (Kobayashi, Boarts, & Delahanty, 2007). Whilst it was originally thought that sleep difficulties were a symptom of PTSD, it is now generally accepted that sleep is largely implicated in PTSD development and maintenance (Picchioni, et al., 2010; Gehrman, Harb & Ross, 2016). Disturbed sleep prior to trauma exposure and also after trauma exposure can increase vulnerability to development of PTSD (e.g., Gehrman et al., 2013; Mellman, Bustamante, Fins, Pigeon, & Nolan, 2002) and studies have demonstrated the impact that sleep has on the severity of PTSD symptoms, even after the effect of other factors such as trauma characteristics and alcohol use are controlled for (Belleville, Guay, & Marchand, 2009). Additionally, in patients that no longer met diagnostic criteria for PTSD following treatment with psychological
therapy, approximately 50% had residual sleep disturbances (residual insomnia) (Zayfert, & DeViva, 2004). This suggests that sleep difficulties tend to become independent of PTSD over time, rather than being a symptom of PTSD which would resolve after successful treatment for PTSD (Gehrman et al., 2016).

**Sleep Disturbances in PTSD**

Differences exist in the symptom expression of PTSD sufferers, especially in regard to comorbid sleep difficulties (Wallace, Iyengar, Bramoweth, Frank, & Germain, 2015). For example, some may present with insomnia whereas others may also experience nightmares or other PTSD specific sleep difficulties (Maher, et al., 2006). Past reviews have often focused on sleep difficulties such as insomnia and sleep quality but have neglected to include findings on nightmares and PTSD specific sleep difficulties (e.g., Ho et al., 2016). Nightmares form a significant component of the PTSD symptom presentation (Maher, et al., 2006) therefore these symptoms are important to consider when examining evidence for suitable treatment approaches.

Therefore, in the current review, sleep difficulties in PTSD sufferers will be operationalised in four ways: ‘insomnia’, ‘sleep quality’, ‘PTSD specific sleep difficulties’ (such as nightmares, episodes of terror during sleep or acting out dreams such as kicking running or screaming; Germain, Hall, Krakow, Shear, & Buysse, 2005) and ‘nightmares’. Conceptualising sleep difficulties in this way may also highlight differences in treatment effectiveness for different PTSD presentations.

**Treatment for Sleep Disturbances in PTSD**

As sleep disturbances in PTSD can be debilitating, they can further contribute to the development and maintenance of PTSD and can also remain after PTSD treatment (Zayfert, & DeViva, 2004), it is important to offer sleep specific treatments
to PTSD suffers (Gehrman et al., 2016) as improving sleep can improve daytime functioning as well as PTSD symptoms (Margolies, 2011).

Pharmacological and psychological therapies are two common approaches used to treat insomnia in people with PTSD and have been used independently or in conjunction with one another (Nappi et al., 2012). Pharmacotherapy is the most common treatment for insomnia (e.g., Edinger et al., 2009) despite limited evidence of the effectiveness to treat insomnia in PTSD sufferers. A recent review suggests that aside from Prazosin (an adrenergic inhibiting agent), few pharmacological treatments demonstrate efficacious results (Lipinska, Baldwin, & Thomas, 2016).

Psychological therapies on the other hand, have demonstrated promising results in the treatment of insomnia in PTSD sufferers, including approaches such as relaxation (e.g., Edinger, et al., 2001), stimulus control (e.g., Riedel et al., 1998) and cognitive-behavioural therapy (CBT) (e.g., Ho, Chan, & Tang, 2016). Commonly used psychological therapies for insomnia include Cognitive Behavioural Therapy for insomnia (CBT-I), Imagery Rehearsal Therapy (IRT) or a combination of the two (Ulmer, Edinger, & Calhoun, 2011), and treatment is delivered individually or in group sessions (Talbot et al., 2014; Krakow et al., 2001). Novel treatments are also emerging, such as using yoga (e.g., Jindani, Turner, & Khalsa, 2015) or mind-body bridging (MBB) (e.g., Nakamura, Lipschitz, Landward, Kuhn & West, 2011).

CBT-I comprises four main techniques including stimulus control and sleep restriction (known as the sleep scheduling component), sleep hygiene and cognitive restructuring (Morin, 1993). The approach utilises behavioural techniques such as breaking habitual behaviours and associations that are not fundamental to sleep, e.g., association of the bedroom and wakefulness. Sleep is restricted to consolidate sleep over a shorter amount of time in bed, and behavioural and environmental
changes are encouraged to facilitate a good night’s sleep. Cognitive restructuring aims to change the maladaptive cognitions that people may hold about sleep (Morin, 1993).

IRT is a manualised approach used for the treatment of insomnia in PTSD sufferers (Rose, 2013), that focuses on sleep hygiene, relaxation, exposure of nightmare content and rewriting and rehearsal of rewritten nightmare content (Davis & Wright, 2006). A meta-analysis has demonstrated that studies using this approach had a large effect on reductions of nightmare frequency, sleep quality and PTSD symptoms, and effects were sustained through 6 to 12-month follow-up (Casement & Swanson, 2012).

Rationale

Previous reviews have also investigated psychological therapies to treat sleep disturbance in PTSD sufferers and the current review builds on these in the following ways. Firstly, past reviews demonstrate that sleep-specific cognitive behavioural therapy (CBT) is efficacious and feasible in remediating PTSD symptoms and depression, as well as insomnia severity and sleep quality (Ho, et al., 2016), however despite identifying studies that treat insomnia, they report overall PTSD severity as the outcome rather than insomnia. In contrast, the current review focuses on identifying studies that specifically target sleep disturbances in PTSD sufferers and assess sleep-specific variables such as insomnia, nightmares, PTSD specific sleep difficulties and sleep quality in PTSD sufferers.

In addition, the current review is original as firstly, no review has been conducted that specifically examines the effect of sleep-focused psychological treatments on sleep outcomes and secondly, past reviews that did include sleep-focused psychological treatments, have neglected sleep-specific outcomes such as
insomnia (e.g., Casement & Swanson, 2012), nightmares and PTSD specific sleep
difficulties (e.g., Ho et al., 2016). Arguably this is a significant oversight, as
nightmares and PTSD specific sleep disturbances\(^1\) are significant components of the
PTSD symptom presentation (Maher, et al., 2006) and often comprise the residual
symptoms following trauma-focused CBT (TF-CBT) (Zayfert, & DeViva, 2004).
Therefore, it is fundamental to present all sleep-specific outcomes in a review that
investigates treatments for PTSD sufferers and the current review achieves this by
including all types of sleep disturbances, i.e., ‘insomnia’, ‘sleep quality’, ‘PTSD
specific sleep difficulties’ and ‘nightmares’, whilst other reviews do not.

Additionally, until this point, no review has investigated the differences
between the effectiveness of different therapies in treating insomnia in PTSD
sufferers. Psychological therapies use different therapeutic components and
significant variability often exists even within one approach e.g., between CBT-I and
IRT. The current review also adds to past reviews, as original and broader search
terms are used in order to identify both CBT and non-CBT studies that treat sleep
disturbances in PTSD sufferers, whereas past reviews such as Ho et al., 2016, have
been limited to CBT studies only.

Although evidence supports the use of psychological therapy in the treatment
of sleep difficulties in PTSD sufferers, there is a paucity of randomised controlled
trails and there has not been a recent review of the evidence i.e., Ho, et al., (2016)
searched databases in 2014, therefore, the current review will search databases for
articles over an additional period of 3.5 years. Cochrane Guidance (2017)

\(^{1}\) (such as nightmares, episodes of terror during sleep or acting out dreams such as kicking running or
screaming; Germain, Hall, Krakow, Shear, & Buysse, 2005)
up to date evidence on the effects of an intervention to inform healthcare decisions (Higgins, Green & Scholten, 2011; Cochrane Guidance, 2017). Therefore, an updated review of the effectiveness of psychological therapies to treat sleep difficulties in PTSD sufferers is overdue.

Finally, an update in this field is vital, given that there has been increasing clinical and theoretical interest in addressing sleep disorders in trauma survivors with PTSD. For example, draft NICE Guidance (2018) for the treatment of PTSD suggests symptom-specific CBT interventions (e.g., for sleep disturbance) should be used for those who are unable or willing to engage in a trauma focused intervention or have residual symptoms after a trauma-focused intervention.

**Objectives**

The aims of the current review are firstly, to present a recent review of the effectiveness of psychological therapies to treat sleep disturbances (such as insomnia and nightmares) in PTSD sufferers. To our knowledge, a recent review has not been completed that includes studies published since 2014, nor one that presents all facets of sleep disturbances for PTSD sufferers (including nightmares) and in addition, focuses on sleep disturbances as a primary outcome rather than focusing on PTSD outcomes. The second aim of the study, is to investigate whether there are differences in the effectiveness of specific psychological therapies to treat sleep disturbances in PTSD sufferers, including the differences within specific therapy modalities, such as different CBT approaches i.e., CBT-I and IRT.

**Method**

**Protocol and Registration**

In order to support transparency of the systematic review process (Kirkham, Altman, & Williamson, 2010), a protocol was written for the current systematic
review, though this was not registered on a systematic review protocol database such as PROSPERO. However, no post hoc changes were made to the planned methodology and analysis. The PRISMA statement (Appendix A) (Moher, Liberati, Tetzlaff, & Altman, 2009) and Cochrane Handbook for Systematic Review of Interventions (Higgins & Green, 2011) were followed in order to structure the review.

Eligibility Criteria

Population, Intervention, Comparator, Outcomes, Study Design (PICOS)

**Population.** Participants were aged 16 or over, with insomnia or sleep difficulties as indicated by valid and reliable insomnia measures such as Insomnia Severity Index (ISI; Morin, 1993) or meeting research diagnostic criteria for insomnia (Edinger et al., 2004) and who also have a diagnosis of PTSD or, participants who have been assessed for PTSD symptomology in non-clinical populations using a PTSD measure such as the PTSD Checklist for DSM-5 (PCL-5) (Weathers, et al., 2013). No limitations were placed on the severity of PTSD or insomnia symptoms, and populations with comorbid mental health problems were eligible for inclusion.

**Intervention.** Psychological or psychosocial interventions to treat sleep disturbances were identified as the intervention target. Studies that treated insomnia as a secondary outcome measure or used an intervention to treat a comorbid mental health problem whilst measuring the impact on insomnia were excluded from the review. No limitations were placed on type of health professional delivering the psychological or psychosocial intervention nor the setting of treatment delivery.

**Comparator.** Only studies that used a control or comparison group were included in the current review, as per the guidance by Cochrane Handbook for Systematic Review of Interventions, which recommends to only include rigorous studies e.g., randomised trials (O’Connor, Green, & Higgins, 2011).
Outcome. Studies using primary outcome measurements of sleep difficulties using standardised, validated self-report or clinician administered measures producing continuous data were included in the review, such as the Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).

Study Design. Study designs were included that are randomised controlled trials (RCT) that used active and inactive controls. To include inactive controls, the study enabled the effect of the psychological intervention to be isolated, such as ‘psychological intervention vs control’ (no-treatment control, wait-list control, treatment as usual) and studies were excluded if a different methodology was used, such as pre-post designs without a comparison or control group. Both published and unpublished studies were included in the review, including unpublished doctoral dissertations.

Information Sources
Eligible studies were identified through a search of relevant databases (EMBASE, Medline, PsychInfo) and by scanning the reference lists of previous systematic reviews and meta-analyses.

Search Strategy
Databases were searched on 13th January 2018 and full details of the search strategy can be found in Appendix B. Key search terms included ‘Post Traumatic Stress Disorder’ intersected with ‘Psychological Therapy’ AND ‘Randomised controlled trial’.

Study Selection
Studies were selected on the basis of meeting the PICOS criteria and initial assessment was by title and abstract. A full text screen was then completed for
potentially eligible studies, which were further assessed against the inclusion/exclusion criteria.

A second rater also reviewed six studies at the full text screening stage making an independent yes/no decision regarding whether the study should be included or excluded from the review based on PICOS criteria. The second rater and author agreed on all six of the studies selected for second review.

**Data Collection Process**

In order to extract data from the included studies, a data extraction form was used, based on the guidance from the Cochrane Handbook for Systematic Reviews of Interventions (Higgins & Deeks, 2011). Data was extracted by the lead researcher and a summary of the extracted data is available in Table 1.

**Data Items**

Information was extracted for each study including the identification features of the study (title and authors); the study design and setting; participant characteristics such as diagnosis, age, sex and country; description of the interventions and comparisons (control method, individual/group, length of treatment, frequency of sessions); primary outcome measurements (quality of outcome measurements) and main results.

**Risk of Bias in Individual Studies**

Risk of bias was assessed for all studies included in the review, by using the Cochrane Collaboration’s tool (Higgins & Altman, 2008). Studies were judged on their risk of bias and assigned a score of either low, medium, high or unclear risk. Risk of bias in included studies will be summarised in the results section including allocation, blinding, incomplete outcome data, selective reporting, and other potential sources of bias. Studies with a high risk of bias will be excluded from the review. The
quality of studies was assessed using the Quality Assessment Tool (QAT) for Quantitative Studies from the Effective Public Health Project was used (Armijo-Olivo, Stiles, Hagen, Biondo, & Cummings, 2012; Appendix C) and is reported in the summary of findings table (Table 2). An independent rater reviewed three studies at random and an inter-rater reliability of $r = 1.0$ was calculated, indicating that the criteria has been adhered to.

**Synthesis of Results**

A summary of the main findings of the effects is presented as well as a descriptive account of the results, which includes descriptions of the characteristics of included studies such as study participants, setting, interventions, comparisons and outcome measures, as well as key differences among the studies (Schunemann et al., 2011).

**Results**

**Search Results**

In the initial search, 443 articles were identified, of which 76 were duplicates, leaving 367 articles to screen. Six further articles were identified by scanning the reference lists of existing systematic reviews and meta-analyses. A total of three-hundred and seventy-three articles were screened by their title and abstract against the inclusion and exclusion criteria, using the process described in the PRISMA guidelines (Appendix A). This resulted in the exclusion of 325 records, leaving 48 for full-text review. Forty-eight full-text articles were screened and 37 were excluded, leaving 12 to be included in the review (Figure 1). During the data extraction process it became apparent that one of the 12 studies did not include results of primary outcomes due to a large attrition rate. Therefore, due to methodological and bias concerns, this study was excluded from the review at this stage. A total of 11 studies
were included in the synthesis. A second rater screened a random sample of studies (n = 6) and an inter-rater reliability was computed (r = 1.0).

![Figure 1. PRISMA Flow Diagram.](image)

**Study Characteristics**

A total of 11 studies were included in the current review and study characteristics are included in Table 1.
<table>
<thead>
<tr>
<th>Number</th>
<th>Study</th>
<th>Methods</th>
<th>Participants</th>
<th>Intervention/ Control Groups</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ulmer, et al., (2011)</td>
<td>Randomised Controlled Trial</td>
<td>N = 22 Setting: Clinical (Veterans Affairs Hospital) Health Status: PTSD Diagnosis and insomnia disorder with nightmares. Age: M = 45.96 (SD = 11.06) Sex: 15 men and 7 women Country: US</td>
<td>Intervention: CBT-I/IRT Received 6 bi-weekly 1 hour individual intervention sessions over 12 weeks, including 3 sessions of CBT for insomnia and 3 sessions of Imagery Rehearsal Therapy (IRT). Also eligible to receive same elements as usual care. Usual Care Control Group: Treatment by primary care provider, consisting of psychotropic medication.</td>
<td>Sleep measures: ISI, PSQI, PSQI-A PTSD: PCL-M Timepoints: Baseline and then after 6th session (12 weeks).</td>
</tr>
<tr>
<td>3</td>
<td>Margolies et al., (2013)</td>
<td>Randomised Controlled Trial</td>
<td>N = 40 Setting: Clinical (Veterans Affairs clinic) Health status: PTSD and current sleep disturbance Age: M = 37.7 (9.1) Sex: 90% Male; 10 % Female Country: US</td>
<td>Intervention: CBT-I/IRT 4 x 60 min weekly individual sessions of CBT-I/IRT and posttreatment assessment. Wait-list Control: Six-week waitlist period where participants were contacted weekly, a follow-up assessment and the option to participate in treatment.</td>
<td>Sleep measures: ISI, DBAS-16, PSQI, PSQI-A PTSD: PSS-SR Intervention condition completed baseline questionnaires and completed again two weeks after 4th session. Participants in control group completed baseline questionnaires, 6 week waitlist period where they were contracted weekly, and follow up assessment including baseline measures.</td>
</tr>
<tr>
<td>4</td>
<td>Krakow et al., (2001)</td>
<td>Randomised Controlled Trial</td>
<td>N = 168 Setting: Non-clinical Health status: 95% had moderate-severe PTSD; 5% had mild PTSD. Age: Completer control group (N = 60; M = 36; SD = 9.3) Completer treatment group (N = 54; M = 40; SD = 11.2). Sex: Female Country: US</td>
<td>Intervention: IRT 3 x weekly group sessions (two 3-hour sessions and 1-hour follow up 3 weeks later). Wait list control: No details of input.</td>
<td>Sleep measures: PSQI, PSQI-A, NES, NDQ PTSD: PSS, CAPS The NFQ, PSQI, and PSS were administered at 3 points. All others were at baseline and 6 month follow up.</td>
</tr>
<tr>
<td>Number</td>
<td>Study</td>
<td>Methods</td>
<td>Participants</td>
<td>Intervention/ Control Groups</td>
<td>Outcomes</td>
</tr>
<tr>
<td>--------</td>
<td>------------------------------</td>
<td>----------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>5</td>
<td>Davis et al., (2011)</td>
<td>Randomised Clinical Trial</td>
<td>N = 47</td>
<td>Intervention: ERRT 2 hours weekly over 3 weeks. Wait list control (delayed treatment) Initial assessment then not contacted for 3 weeks apart from phone call to schedule time for re-assessment.</td>
<td>Sleep measures: PSQI, TRNS PSTD: CAPS, TSI</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Setting: Non-clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Health status: PTSD diagnosis (37% moderate; 14% severe; 25% extreme symptoms of PTSD); and sleep difficulties.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age: Treatment group (M =38.80; SD = 38.49); Control group (M =38.17, SD = 38.49).</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sex: Mixed (75% female)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Country: US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Germain et al., (2012)</td>
<td>Randomised Controlled Trial - placebo and Prazosin controlled</td>
<td>N = 50</td>
<td>Intervention: Behavioural Sleep Intervention (BSI) 8 x sessions weekly over 8 week period, including at least 5 weekly in-person sessions and up to 3 telephone contacts. All individual sessions were 45 mins. Comparison: Prazosin took oral dose of 4 capsules each night or placebo.</td>
<td>Sleep measures: ISI; PSQI; PSQI-A PSTD: PCL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Setting: Armed Forces Veterans; Clinical and Non-clinical</td>
<td></td>
<td>Completed at baseline, post-treatment and 4 month follow up.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Health status: Mild to moderate daytime PTSD symptom severity and clinically meaningful sleep disturbances. 58% met all DSM-IV criteria for current PTSD, whereas 42% endorsed sub threshold symptoms. 30% met diagnostic criteria for comorbid insomnia.</td>
<td></td>
<td>Four months posttreatment, measures of clinical improvement and self-report measures of sleep and psychiatric symptoms were obtained.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age: M = 40.9 (SD = 13.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sex: 90% were men</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Country: US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Davis &amp; Wright (2007)</td>
<td>Randomised Clinical Trial</td>
<td>N = 27</td>
<td>Intervention: ERRT 2 hours a week for 3 consecutive weeks. Control: No input.</td>
<td>Sleep measures: PSQI, TRNS PSTD: TAA, SCID, MPSS-SR.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Setting: Non-clinical</td>
<td></td>
<td>Baseline and 1 week post-treatment. Also follow up analysis on N = 19 completers.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Health status: Mean number of traumatic events, M = 4.6 (DS = 2.0) and sleep difficulties - 67.3% had PTSD diagnosis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age: M = 40 (SD = 12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sex: Men (18.4%); Women (81.6%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Country: US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Germain et al., (2014)</td>
<td>Preliminary Randomised Controlled Trial</td>
<td>N = 40</td>
<td>Intervention: Brief Behavioural Treatment of Insomnia - military version (BBTI-MV) 4 weeks: Two in-person visits (week 1 = 45 mins &amp; week 3 = &lt;30 mins) and two telephone contacts (week 2 &amp; 4 = &lt;20 min each).</td>
<td>Sleep measures: ISI; PSQI; PSQI-A PSTD: CAPS; PCL-C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Setting: Clinical - Veterans</td>
<td></td>
<td>ISI, PSQI completed at baseline, post-treatment and 6 month follow up.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Health status: PTSD (50% had current symptoms) and primary or comorbid insomnia.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Age: Mean = 38.4 (SD = 11.69)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SELF-COMPASSION AND PTSD IN ARMED FORCES VETERANS

<table>
<thead>
<tr>
<th>Number</th>
<th>Study</th>
<th>Methods</th>
<th>Participants</th>
<th>Intervention/ Control Groups</th>
<th>Outcomes</th>
</tr>
</thead>
</table>
| 9      | Mack (2013) | Pilot study with control conditions | N = 34  
Sex: Men (85%)  
Country: US  
Setting: Clinical (Combat Veterans enrolled in Veterans Association Medical Centre PTSD clinic).  
Health status: Diagnosis of PTSD and met criteria for chronic insomnia  
Age: M = 58.91 (SD = 9.02)  
Sex: 97.1% Male  
Country: US  
Information Control:  
4 weeks: 1 individual in-person visit (approx. 30 mins), brief telephone appointments during weeks 2 and 4 (<20 mins each) and a booster in-person visit at week 3 (<20 mins). Received two brochures on insomnia and health sleep practices at week 1.  | Intervention: CBT-I/IRT  
6 x 90 minute combined CBT-I and IRT over 6 weeks. (7 groups in total).  
Waitlist control.  
Participants were called bi-weekly to keep them engaged.  | Sleep and psychiatric outcomes at baseline, 10 days posttreatment and 6 month follow up.  
Sleep measures: ISI; PSQI; PSQI-A; DBAS-16 PTSD; PSS; PSS-SR, ITEQ (only administered posttreatment). |
| 10     | Ustinov (2013) | Randomised Controlled Trial | N = 65  
Sex: Men (92.9%)  
Country: US  
Setting: Clinical (Veterans Affairs Medical Centre - residential and outpatient).  
Health status: PTSD diagnosis and subthreshold PTSD and sleep difficulties.  
Age: M = 53.60 years (SD = 10.76).  
Sex: Men = 92.9%  
Country: US  
Intervention: CBT-I  
4 x 60 min weekly group treatment sessions of CBT-i.  
Waitlist control:  
5 weeks of treatment as usual.  | Intervention: CBT-I  
4 x 60 min weekly group treatment sessions of CBT-i.  
Waitlist control:  
5 weeks of treatment as usual.  | Sleep measures: ISI, DBAS-16 PTSD: PCL-M  
CBT-I completed assessments at baseline and posttreatment. Participants in WL completed assessments at time intervals matched to the CBT-I group (at baseline and 5 weeks after baseline). |
| 11     | Nakamura et al., (2011) | Pilot Randomised Controlled Trial | N = 63  
Sex: Men (95.2%)  
Country: US  
Setting: Clinical (Veterans Affairs Primary Care Clinic)  
Health status: PTSD symptoms and sleep disturbance  
Age: M = 51.85 (SD = 10.35)  
Sex: Men = 95.2%  
Country: US  
Intervention: Mind-body bridging (MBB) (Non-CBT)  
2 x 1.5 hour weekly sessions  
Waitlist: Sleep Hygiene  
2 x 1 hour weekly sessions  | Intervention: Mind-body bridging (MBB) (Non-CBT)  
2 x 1.5 hour weekly sessions  
Waitlist: Sleep Hygiene  
2 x 1 hour weekly sessions  | Sleep measures: MOS-SS PTSD: PCL-M  
Completed 1 week prior to the first session and at least 7 days after the second session. MOS-SS was also completed at Week 1 prior to the start of the second session. |

Notes: CAPS = PTSD Clinician-Administered PTSD Scale; DBAS-16 = Dysfunctional Beliefs and Attitudes about Sleep Scale; ESS = Epworth Sleepiness Scale; ISI = Insomnia Severity Index; ITEQ = Insomnia Treatment Evaluation Questionnaire; MOS-SS = Medical Outcomes Study – Sleep Scale; MPSS-SR = The Modified PTSD Symptom Scale Self Report; NDQ = Nightmare Distress Questionnaire; NES = Nightmare Effects Survey; NM = Nightmares; PCL = PTSD Checklist; PCL-C = PTSD Checklist (Civilian Version); PCL-M = PTSD Checklist-Military Version; PSQI = Pittsburgh Sleep Quality Index; PSQI-A = Pittsburgh Sleep Quality Index-Addendum; PSS = PTSD Symptom Scale; PSS-SR = PTSD Symptom Scale-Self Report; SCID = The Structured Clinical Interview for DSM-IV: PTSD Module; TAA = Trauma Assessment for Adults; TRNS = Trauma Related Nightmare Survey; TSI = Trauma Symptom Inventory.
**Design.** All of the studies in the review used a randomised controlled trial design and all included a control or comparison group. Randomisation to groups was explicitly detailed in seven of the studies (2, 4, 5, 6, 8, 9, 11). The other four studies did not include details of random sequence generation (1, 3, 7, 10).

**Sample sizes.** Sample sizes mostly ranged between 22 to 65 participants, though one study had a large sample of 168 participants (4).

**Participants.** Approximately half of the studies conducted the trial in a clinical setting such as a hospital or mental health clinic (1, 3, 8, 9, 10, 11), whereas four conducted the study in non-clinical settings (2, 4, 5, 7) and one conducted the group in both a clinical and non-clinical setting (6).

In approximately half of the studies, all of the participants were assessed for PTSD through rigorous clinical assessment as indicated by the Clinician-Administered PTSD Scale (CAPS) (Blake et al., 1995) or the Structured Clinical Interview for DSM-IV (SCID; First, Spitzer, Williams, & Gibbon, 1996) (1, 2, 4, 6, 7, 8). Two studies recruited participants from PTSD treatment clinics, but no details were given regarding how PTSD diagnoses were established (3, 5). One study recruited participants from a PTSD treatment clinic and required participants to score over 53 on the PCL-M and also met DSM criteria for PTSD (9). Two studies relied on self-report of PTSD symptoms using the PCL-M (10, 11), and in one of the studies, those that didn’t fully meet criteria were included if they scored over 45 on the PCL-M (10) whereas the other study placed no emphasis on PCL-M score (11).

Studies included only participants who had a diagnosis of PTSD (1, 3, 4, 9), those with PTSD or subthreshold PTSD symptoms (6), those with PTSD or partial PTSD operationalised by past diagnosis and symptoms in cluster B and either C or D (DSM-IV) (2) or whose PTSD was in partial remission or controlled with
medication, or with symptoms that did not meet full diagnostic criteria, but were included if they met clinical cut-off of 45 or greater on the PCL-M (10). In one study (11) the level of PTSD in participants was unclear. Some studies included a mixed sample including PTSD and those with other anxiety disorders (5, 7, 8).

All of the studies apart from one (6), included only participants who had insomnia or symptoms of insomnia. Insomnia was established by meeting diagnostic criteria for Insomnia Disorder as per Duke Structured Sleep Interview (1), or research diagnostic criteria e.g., Edinger et al., 2004 (2, 3) or criteria for comorbid or primary insomnia as defined by the International Classification of Sleep Disorders (Hauri & Sateia, 2005) (8). Others used diagnostic screening criteria adapted from the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition, Text Revision (DSM-IV-TR; American Psychiatric Association, 2000) and who also scored above the suggested clinical cut-off on the Insomnia Severity Index (ISI) (10). Some studies used self-report symptoms of insomnia (3, 4, 11) or a combination of self-report insomnia and nightmares (5, 7). One study included participants of which 70% did not meet diagnostic criteria for insomnia (6).

Participants mean age in included studies ranged from M = 36 years (SD = 9.3) (5) to M = 58.91 (SD = 9.02) (9). Some studies had all female participants (4) whereas most studies were mixed gender (1, 2, 5, 6, 7, 8, 9, 10, 11), although some of these had mostly male participants 85% - 97.1% (6, 8, 9, 10, 11). Seven out of the 11 studies included Armed Forces Veterans (1, 3, 5, 5, 8, 9, 10, 11) who had experienced combat in areas of conflict. All 11 studies were conducted in the United States.

**Interventions.** Only interventions that used MBB and CBT were identified, and used either just one therapeutic approach (e.g., MBB (11), CBT-I (2, 10), IRT
or a combination of both CBT-I and IRT (1, 3, 9). Two of the studies used exposure, relaxation and rescripting therapy (ERRT) (5, 7) and there were two other behavioural variants: Behavioural Sleep Intervention (BSI) (6) and Brief Behavioural Treatment of Insomnia – Military Version (BBTI-MV) (8).

The interventions were delivered in either an individual session format (1, 2, 3, 6, 8) or in group sessions (4, 9, 10). Information was not provided about whether EERT was provided in a group or individual format in three of the studies (5, 7, 11).

The number of intervention sessions varied and studies delivered the intervention over 2 sessions (11), 3 sessions (4, 7), 4 sessions (3, 8, 10), 6 sessions (1, 3, 9), and 8 sessions (2, 6). The duration of intervention sessions ranged from brief 20-minute telephone contacts between longer face-to-face sessions (8), 45-minute sessions (6), 1-hour sessions (1, 3), 1.5-hour sessions (11), and 2-hour group sessions (4, 5, 7, 9). One study did not report the duration of each treatment session (2). All of the treatment sessions were delivered on a weekly (2, 3, 4, 5, 6, 7, 8, 9, 10, 11) or bi-weekly basis (1).

The control groups varied across the studies and included treatment as usual (1, 10), sleep and symptom monitoring (2), wait-list control (3, 4, 5, 7, 9), a sleep hygiene program (11), Prazosin or Placebo control (6) and an information control group where people were given brochures with information on insomnia and health sleep practices to review (8).

Outcomes. All of the studies used outcome measures with well-established psychometric properties as a measure of insomnia such as the Insomnia Severity Index (ISI) or Pittsburgh Sleep Quality Index (PSQI).
Excluded Studies

Studies were excluded from the current review due to reasons such as the primary outcome measure being PTSD, the treatment was not an evidence-based psychological therapy intervention (i.e., hypnosis), the treatment was targeting PTSD rather than insomnia and insomnia was measured as a secondary outcome or the study was not an RCT. Following the data extraction process, one further study was excluded (Rose, 2013) due to a large attrition rate which meant that the hypothesis for the study could not be empirically evaluated and as well, there were concerns about the methodological and reporting quality and therefore the study was deemed to have a high risk of bias.

Risk of Bias in Included Studies

Risk of bias in the included studies was assessed using the Cochrane collaboration tool (Higgins & Altman, 2008) and results are presented in Table 2. For three of the studies there was an ‘unclear’ risk of bias, due to a lack of information about the study procedure, especially with regards to blinding of participants and study personnel to conditions (9, 10, 11). The other eight studies included in the review had a ‘low’ risk of bias.
### Table 2. Risk of Bias in Included Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Authors</th>
<th>Random sequence generation</th>
<th>Allocation concealment</th>
<th>Blinding of participants/personnel</th>
<th>Blinding of outcome assessment</th>
<th>Incomplete outcome data</th>
<th>Selective reporting</th>
<th>Other sources of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ulmer, et al., (2011)</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>4</td>
<td>Krakow et al., (2001)</td>
<td>Low</td>
<td>High</td>
<td>High</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>5</td>
<td>Davis et al., (2011)</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>7</td>
<td>Davis &amp; Wright (2007)</td>
<td>Unclear</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>8</td>
<td>Germain et al., (2014)</td>
<td>Low</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>High</td>
<td>Low</td>
</tr>
<tr>
<td>9</td>
<td>Mack (2013)</td>
<td>Low</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>10</td>
<td>Ustinov (2013)</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>High</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>11</td>
<td>Nakamura et al., (2011)</td>
<td>Low</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Low</td>
<td>Unclear</td>
<td>Low</td>
</tr>
</tbody>
</table>
Effects of Interventions/ Synthesis of Results

The results of the studies can be found in Table 3, including main findings, test statistics, effect size and main conclusions.

Insomnia. Seven studies (1, 2, 3, 6, 8, 9, 10) specifically measured insomnia using the Insomnia Severity Index (ISI), and there were improvements in the treatment groups of six of the seven studies. Effect sizes were large in four studies (1, 2, 3, 9). In one study where a CBT-I group treatment approach was adopted, there were no improvements in insomnia (10), whereas the others used a combined CBT-I/IRT approach (1, 3, 9), pure CBT-I (2), BSI (6), or BBTI-MV (8) which all found a significant reduction in insomnia in the treatment condition following intervention. One study that used MBB measured insomnia using the MOS-SS and found a significant improvement in sleep with a large effect size (11).

Overall CBT approaches including CBT-I/IRT, pure CBT-I, and behavioural interventions (BSI and BBTI-MV) and a non-CBT approach i.e., MBB were successful in improving insomnia following the intervention, however one study that used CBT-I in a group format did not find a reduction in insomnia.

Sleep Quality. Sleep quality was assessed in nine studies using the PSQI which focuses on insomnia symptoms but also ‘bad dreams’, ‘having pain’, and the impact of sleep difficulties on daily functioning (Buysse, et al., 1989). Seven of the nine studies found significant improvements in sleep quality in the intervention condition (1, 2, 3, 4, 5, 8, 9) and found large effect sizes (1, 2, 3, 5, 9) or a medium effect size (4). Of the studies that found an increase in sleep quality in the treatment condition, three of the interventions used a combined CBT/IRT approach (1, 3, 9), one used a pure CBT-I approach (2), one used a pure IRT approach (4), one used BBTI-MV (8) and another used EERT (5). In two of the studies, interventions
targeted nightmares specifically (4, 5), two focused purely on insomnia (2, 8) and
three provided a combination of CBT-I and IRT to target both insomnia and
nightmares (1, 3, 9). Two studies did not find an improvement in sleep quality for the
treatment groups, which used BSI (6) to target insomnia and EERT which provided
sleep hygiene and also targeted nightmares (7). The ESS was also used by one
study (2) to assess daytime sleepiness and there was a significant reduction in the
treatment group.

Overall, studies found improvements in sleep quality following intervention,
which included CBT-I/IRT, pure CBT-I, pure IRT and behavioural and exposure
interventions (EERT and BBTI-MV).

**PTSD Specific Sleep Difficulties.** PTSD specific sleep difficulties\(^2\) were
measured using the PSQI-A in seven of the studies. There was a significant
reduction in the intervention condition in only three studies (2, 3, 4); one of which
used a CBT-I approach in a pure format which unlike IRT did not include a focus on
nightmares. Despite this, they found a moderate effect of CBT-I in reducing PTSD
specific sleep difficulties. The other two studies found a significant reduction in
nightmares, either through combined CBT-I and IRT (3), or pure IRT (4). Both
studies found a moderate (3) and large effect size (4) for nightmare improvements in
the treatment group.

Two studies that combined CBT-I and IRT and therefore included a nightmare
element in the intervention, did not find reductions in PTSD specific sleep difficulties
compared to control groups (1, 9). Additionally, the study that used a Brief
Behavioural Treatment of Insomnia - military version (BBTI-MV) (8) did not find

\(^2\) such as nightmares, episodes of terror during sleep or acting out dreams such as kicking running or
screaming (Germain, Hall, Krakow, Shear, & Buysse, 2005)
reductions in PTSD sleep specific difficulties, nor did a Behavioural Sleep
Intervention (BSI) (6) both of which integrated techniques such as stimulus control
and sleep restriction.

Overall, only a small proportion of the studies that measured PTSD specific
sleep difficulties (approximately 40%) found a significant reduction post intervention.

**Nightmares.** Nightmares were measured as an outcome in three out of the
eleven studies and all three studies found a reduction in nightmares following the
intervention (4, 5, 7). The two studies that measured nightmares using the TRNS (5, 7) both found significant reductions in the treatment group compared with the control
group, for ‘nights per week with nightmares’ and ‘nightmare severity’, however there
was not a reduction for the ‘number of nightmares per week’. This may be due to the
lack of internal reliability of the TRNS, as the ‘frequency of nightmares’ item has a
test-retest coefficient of $r = .64$ which may explain the discrepancy in findings.

Nightmares were also assessed in Krakow et al., (2001) (4) by the NES and NDQ,
which found significant reductions in ‘nightmare effects’ and ‘nightmare distress’ in
the treatment group. All three studies specifically targeted nightmares as part of the
intervention, using interventions consisting of IRT (4) and EERT (5, 7).

Overall, all three of the studies that targeted nightmares in the treatment
intervention and measured nightmares as an outcome found a reduction in
nightmares following the intervention condition. However, for two of the studies (5, 7)
findings were mixed as there was a reduction of nights per week with nightmares
and nightmare severity, but not for number of nightmares per week, which may
suggest that although the number of nights experiencing nightmares decreased, the
frequency of nightmares did not.
Overall

In summary, CBT approaches for sleep difficulties were successful in reducing insomnia and improving sleep quality in PTSD suffers with comorbid insomnia. Most of the studies found a reduction in insomnia following the intervention (1, 2, 3, 6, 8, 9) and an improvement in sleep quality (1, 2, 3, 4, 5, 8, 9). One study that used a non-CBT approach (i.e., MBB) (11), was also successful in reducing symptoms of insomnia after only two treatment sessions.

There were mixed findings for the reduction of PTSD specific sleep difficulties. Three studies using CBI-I, CBT-I/IRT or IRT found a reduction in PTSD specific sleep difficulties (2, 3, 4), whereas others that used BSI (6), BBTI-MV (8) and CBT-I/IRT (1, 9) did not find reductions following intervention. This suggests that treatments that had a cognitive component, were more successful in reducing PTSD specific sleep difficulties, than those that only used behavioural techniques.

Treatments that are tailored specifically for nightmares such as IRT and EERT, were successful for the treatment of nightmares in PTSD sufferers with comorbid sleep difficulties (4, 5, 7). However, despite the frequency of nightmares reducing in two studies, sleep quality did not improve following the intervention (5, 7).
### Table 3. Results of Studies.

<table>
<thead>
<tr>
<th>Number</th>
<th>Study</th>
<th>Outcomes</th>
<th>Results</th>
<th>Effect size</th>
<th>Key Findings</th>
<th>QAT Ratings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Ulmer, et al.,  (2011)</td>
<td>ISI</td>
<td>Significant condition x time (baseline, post-intervention) interaction, $F(1, 21) = 11.80, p = 0.003$</td>
<td>$d = -2.15$</td>
<td>Veterans with PTSD and comorbid insomnia had a reduction in insomnia and increase in sleep quality following a combined CBT-I/IRT intervention delivered on an individual basis, compared to a usual care control group.</td>
<td>A: Strong</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSQI</td>
<td>Significant condition x time (baseline, post-intervention) interaction, $F(1, 21) = 17.31, p = 0.0005$</td>
<td>$d = -1.60$</td>
<td>However, there was no reduction in specific PTSD sleep difficulties such as nightmares, or episodes of terror during sleep.</td>
<td>B: Weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSQI-A</td>
<td>No significant difference for condition x time (baseline, post-intervention) interaction, $F(1, 21) = 0.76, p &gt; 0.05$</td>
<td>$d = -0.30$</td>
<td>Conclusions: Support for combined CBT-I/IRT individual treatment to reduce insomnia, and improve sleep quality.</td>
<td>C: Strong</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(Intent to treat analysis)</td>
<td></td>
<td>No evidence to support CBT-I/IRT to reduce PTSD-related sleep quality.</td>
<td>D: Moderate</td>
</tr>
<tr>
<td>2</td>
<td>Talbot, et al.,  (2014)</td>
<td>ISI</td>
<td>Significant condition x time (baseline, mid treatment, posttreatment) interaction, $F(2, 80) = 19.75, p &lt; 0.001$</td>
<td>$\eta^2 = 0.33$</td>
<td>Adults with PTSD and comorbid insomnia had a reduction in insomnia, daytime sleepiness and specific PTSD sleep difficulties and an increase in sleep quality following a CBT-I group treatment compared with a monitor only waitlist control group.</td>
<td>A: Strong</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSQI</td>
<td>Significant condition x time (baseline, mid treatment, posttreatment) interaction, $F(2, 80) = 22.13, p = 0.001$</td>
<td>$\eta^2 = 0.36$</td>
<td>Conclusions: Support for group CBT-I treatment to reduce symptoms of insomnia, daytime sleepiness and specific PTSD sleep difficulties and increase sleep quality for individuals with PTSD and comorbid insomnia.</td>
<td>B: Strong</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ESS</td>
<td>ESS Significant condition x time (baseline, mid treatment, posttreatment) interaction, $F(2, 70) = 5.74, p = 0.005$</td>
<td>$\eta^2 = 0.14$</td>
<td></td>
<td>C: Strong</td>
</tr>
</tbody>
</table>

Global: Strong
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Measure</th>
<th>Effect Size</th>
<th>Findings</th>
<th>Study Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margolies et al., (2013)</td>
<td>PSQI</td>
<td>Significant condition x time (baseline, mid treatment, posttreatment) interaction, $F(2, 80) = 9.74, \ p = 0.001$</td>
<td>$\eta^2 = 0.19$</td>
<td>Veterans with PTSD and sleep disturbances had a reduction in insomnia and PTSD current insomnia, and an increase in sleep quality following a CBT-I intervention delivered on an individual basis, compared with a waitlist control group. However there was not a reduction of dysfunctional beliefs and attitudes about sleep.</td>
<td>A: Strong</td>
</tr>
<tr>
<td></td>
<td>ISI</td>
<td>Significant condition x time (baseline, posttreatment) interaction, $F(1, 35) = 16.24, \ p &lt; .001$</td>
<td>$\eta^2 = 0.32$</td>
<td>Conclusions: Individual CBT-I is effective in reducing insomnia and PTSD specific sleep difficulties, and increasing sleep quality in Veterans with PTSD and comorbid insomnia, but does not reduce dysfunctional beliefs and attitudes about sleep.</td>
<td>A: Strong</td>
</tr>
<tr>
<td></td>
<td>PSQI</td>
<td>Significant condition x time (baseline, posttreatment) interaction $F(1, 35) = 25.28, \ p &lt; .001$</td>
<td>$\eta^2 = 0.42$</td>
<td></td>
<td>B: Strong</td>
</tr>
<tr>
<td></td>
<td>PSQI-A</td>
<td>Significant condition x time (baseline, posttreatment) interaction $F(1, 24) = 7.32, \ p = 0.01$</td>
<td>$\eta^2 = 0.24$</td>
<td></td>
<td>C: Strong</td>
</tr>
<tr>
<td></td>
<td>DBAS-16</td>
<td>Non-significant condition x time (baseline, posttreatment) interaction, $F(1, 34) = 3.42, \ p = 0.07$</td>
<td>$\eta^2 = 0.09$</td>
<td>(Intent to treat analysis)</td>
<td>D: Moderate</td>
</tr>
<tr>
<td>Krakow et al., (2001)</td>
<td>PSQI</td>
<td>Significant condition x time (baseline, endpoint = 3 or 6 month follow up) interaction, $F(1, 109) = 8.10, \ p = 0.001$</td>
<td>$d = 0.67$</td>
<td>Sexual assault survivors with PTSD and chronic nightmares who received a group IRT treatment, had an increase in sleep quality, decrease in PTSD specific sleep difficulties and nightmare effects and distress, compared with a waitlist control group.</td>
<td>A: Strong</td>
</tr>
<tr>
<td></td>
<td>PSQI-A</td>
<td>Significant condition x time (baseline, endpoint = 3 or 6 month follow up) interaction, $d = 1.15$</td>
<td></td>
<td>Conclusions: Group IRT is effective in reducing</td>
<td>A: Strong</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Intent to treat analysis)</td>
<td></td>
<td></td>
<td>B: Weak</td>
</tr>
</tbody>
</table>

Global: Moderate
<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Study</th>
<th>Year</th>
<th>Methodology</th>
<th>Condition x Time Interaction</th>
<th>Effect Size</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>NES</td>
<td></td>
<td></td>
<td></td>
<td>Significant condition x time (baseline, endpoint = 3 or 6 month follow up) interaction, $F(1, 109) = 23.75, p = 0.001$</td>
<td>$d = 1.07$</td>
<td>PTSD specific sleep difficulties and nightmare effects and distress and increasing sleep quality.</td>
</tr>
<tr>
<td>NDQ</td>
<td></td>
<td></td>
<td></td>
<td>Significant condition x time (baseline, endpoint = 3 or 6 month follow up) interaction, $F(1, 110) = 19.85, p &lt; 0.001$</td>
<td>$d = 1.31$</td>
<td></td>
</tr>
<tr>
<td>Davis et al., (2011)</td>
<td>PSQI</td>
<td></td>
<td></td>
<td>Significant condition x time (baseline, 1 week posttreatment) interaction, $F(1,47) = 13.68, p &lt; 0.001$</td>
<td>$d = 0.92$</td>
<td>Adults with PTSD (37% moderate; 14% severe; 25% extreme symptoms of PTSD) and sleep difficulties (nightmares) had an increase in sleep quality, and a decrease in number of nights per week with nightmares and nightmare severity following an EERT intervention, compared with a waitlist control group.</td>
</tr>
<tr>
<td></td>
<td>TRNS</td>
<td></td>
<td></td>
<td>Significant condition x time (baseline, 1 week posttreatment) interaction, $F(1,47) = 4.10, p &lt; 0.05$</td>
<td>$d = 0.68$</td>
<td>Conclusions:</td>
</tr>
<tr>
<td></td>
<td>Nights per week with NM</td>
<td></td>
<td></td>
<td>Non-significant condition x time (baseline, 1 week posttreatment) interaction, $F(1,47) = 0.49, p &gt; 0.05$</td>
<td>$d = 0.21$</td>
<td>EERT was effective in increasing sleep quality, and reducing number of nights per week with nightmares and nightmare severity, but not for reducing the number of nightmares per week.</td>
</tr>
<tr>
<td></td>
<td>NM per week</td>
<td></td>
<td></td>
<td>Significant condition x time (baseline, 1 week posttreatment) interaction, $F(1,47) = 8.05, p &lt; 0.01$</td>
<td>$d = 0.87$</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NM Severity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Germain et al., (2012)</td>
<td>ISI</td>
<td>Significant condition x time (baseline, 1 week posttreatment) interaction for BSI and prazosin, $F(2, 37.0) = 6.06, p &lt; 0.01$</td>
<td>Not available</td>
<td>Veterans (58% with PTSD; 42% subthreshold PTSD) with clinically meaningful sleep disturbance had a decrease in insomnia following individual BSI treatment compared to control groups (prazosin or placebo). However there was not difference for sleep quality or PTSD specific sleep difficulties.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSQI</td>
<td>No significant condition x time (baseline, 1 week posttreatment) interaction, $F(2, 37.0) = 2.38, p = 0.11$</td>
<td>Conclusion: BSI shows some indication that it can be effective in reducing insomnia in Veterans with PTSD or subthreshold PTSD and comorbid sleep disturbance. However, BSI was no more effective at improving sleep quality or reducing PTSD specific sleep difficulties. Follow up worth reporting</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PSQI-A</td>
<td>No significant condition x time (baseline, 1 week posttreatment) interaction, $F(2, 37.0) = 0.83, p = 0.44$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>Davis &amp; Wright (2007)</td>
<td>PSQI</td>
<td>No significant condition x time (baseline, 1 week posttreatment) interaction, $F(1, 41) = 1.62, p &gt; 0.05$</td>
<td>$d = 0.24$</td>
<td>Trauma exposed adults with sleep difficulties had a reduction in nights per week with nightmares and nightmare severity following an EERT intervention compared with the control group. However, there was no improvement in sleep quality or number of nightmares per week.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TRNS Nights per week with NM</td>
<td>Significant condition x time (baseline, 1 week posttreatment) interaction, $F(1, 41) = 9.26, p &lt; 0.01$</td>
<td>$d = 0.84$</td>
<td>Conclusion: EERT shows some evidence of being effective to reduce number of nights per week with nightmares and nightmare severity. However, EERT was not effective in improving sleep quality or number of nightmares per week.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NM per week</td>
<td>No significant condition x time (baseline, 1 week posttreatment) interaction, $F(1, 41) = 2.17, p &gt; 0.05$</td>
<td>$d = 0.50$</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NM Severity</td>
<td>Significant condition x time (baseline, 1 week posttreatment) interaction, $F(1, 41) = 6.92, p &lt; 0.05$</td>
<td>$d = 0.64$</td>
<td></td>
<td></td>
<td>(Intent to treat analysis)</td>
</tr>
<tr>
<td>8</td>
<td>Germain et al., (2014)</td>
<td>ISI</td>
<td>Pre to post treatment improvements were significantly greater in the BBTI-MV condition compared to the information control, $t(47) = 2.22, p = 0.03$</td>
<td>Not available</td>
<td>Veterans with insomnia (50% had current PTSD) who received a BBTI-MV intervention had a reduction in insomnia and improvement in sleep quality compared with an information control group. However, there was no change in PTSD specific sleep difficulties.</td>
<td>A: Weak</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>9</td>
<td>Mack (2013)</td>
<td>ISI</td>
<td>Significant condition x time (pretreatment, posttreatment) interaction, $F(1, 32) = 13.62, p = 0.001$</td>
<td>$\eta^2_p = 0.299$</td>
<td>Veterans with PTSD and insomnia, who received a combined CBT/IRT group treatment had a reduction in insomnia and an improvement in sleep quality, compared with a waitlist control group. However, there was no reduction in PTSD specific sleep difficulties, or in dysfunctional beliefs and attitudes about sleep.</td>
<td>A: Moderate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSQI</td>
<td>Significant condition x time (pretreatment, posttreatment) interaction, $F(1, 32) = 12.54, p = 0.001$</td>
<td>$\eta^2_p = 0.282$</td>
<td>Conclusions: A combined CBT/IRT group intervention is successful in reducing insomnia and improving sleep quality in Veterans with PTSD and comorbid insomnia. However, there is no evidence to suggest that it reduces PTSD specific sleep difficulties.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>PSQI-A</td>
<td>Non-significant condition x time (pretreatment,</td>
<td>$\eta^2_p = 0.000$</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DBAS-16
Non-significant condition x time (pretreatment, posttreatment) interaction, F(1,31) = .002, p = .965
ηp² = 0.082
difficulties or dysfunctional beliefs and attitudes about sleep.

10
Ustinov (2013) ISI
Non-significant condition x time (baseline, 1 week posttreatment) interaction F(1,63) = 0.03, p = .858
ηp² = .001
Veterans with PTSD or subthreshold PTSD, who received a CBT-I group treatment did not show a reduction in insomnia or dysfunctional beliefs and attitudes about sleep, compared with a waitlist control group.
Conclusions: There is no evidence to suggest that a CBT-I group treatment is effective in reducing insomnia symptoms or reducing dysfunctional beliefs and attitudes about sleep.
A: Weak
B: Strong
C: Strong
D: Moderate
E: Strong
F: Strong
Global: Moderate

11
Nakamura et al., 2011 MOS-SS
Significant condition x time (week 1) interaction [MBB (21.0, ES = 1.3) vs. SH (12.8, ES = .73); p = .047]
Significant condition x time (posttreatment) interaction [MBB (28.0, ES = 1.89) vs. SH (14.8, ES = .71); p = .012]
Veterans with PTSD and insomnia had reduced patient-reported sleep disturbance and PTSD symptoms after MBB than those in the standard-of-care SH intervention.
Conclusions: MBB is successful in reducing sleep disturbance and PTSD symptoms after two sessions, compared to a sleep hygiene intervention.
A: Weak
B: Strong
C: Strong
D: Weak
E: Strong
F: Strong
Global: Weak

Notes: d = Cohen’s d effect size (d = 0.2, small; d = 0.5, medium; d = 0.8, large); DBAS-16 = Dysfunctional Beliefs and Attitudes about Sleep Scale; ESS = Epworth Sleepiness Scale; ISI = Insomnia Severity Index; ηp² = Partial Eta squared (0.01 = small; 0.09 = moderate; 0.25 = large); NDQ = Nightmare Distress Questionnaire; NES = Nightmare Effects Survey; NM = Nightmares; PSQI = Pittsburgh Sleep Quality Index; PSQI-A = Pittsburgh Sleep Quality Index-Addendum; TRNS = Trauma Related Nightmare Survey.
Discussion

The aims of the current review were to present a recent systematic review of the effectiveness of psychological therapies to treat sleep disturbances (such as insomnia and nightmares) in PTSD sufferers and to investigate whether differences exist between the effectiveness of different psychological therapies, including within specific therapy modalities such as different CBT approaches i.e., CBT-I and IRT. Eleven studies were included in the review, all of which were randomised controlled trial designs and all used psychological interventions to treat sleep difficulties in PTSD sufferers.

There was a large range of diversity in the studies included, as although all of the interventions (apart from one that used a non-CBT approach of MBB i.e., study 11) used a CBT approach, the specific interventions varied and included pure CBT-I (2, 10), three combined CBT-I and IRT (1, 3, 9) one used only IRT (4) and one used MBB (11). Two used exposure, relaxation and rescripting therapy (EERT) (6, 7), one used a behavioural sleep intervention (BSI) (6) and another used a brief behavioural treatment of insomnia – military version (BBTI-MV) (8). This meant that the second aim of the study was not achieved i.e., to investigate whether differences exist between the effectiveness of different psychological therapies, especially as the non-CBT study (11) only measured insomnia and did not measure sleep quality, PTSD specific sleep difficulties or nightmares. Despite findings from the non-CBT study showing a significant improvement in sleep and achieving a large effect size (comparative to four of the CBT studies that also achieved a large effect size (1, 2, 3, 9)), firm conclusions cannot be drawn by comparing a predominantly CBT body of research to one non-CBT based study, especially as the MBB study only used two
intervention sessions and additionally, research supporting MBB is in its infancy and therefore limited (e.g., Nakamura, et al., 2010).

There was also diversity in the participant samples of included studies, and they included Armed Forces veterans or civilians, and exposure to very different traumatic experiences (such as war or sexual assault). The studies were conducted in a variety of settings including clinical settings such as hospitals and non-clinical settings. Participants were recruited in different ways via advertising and flyers or through attendance at a mental health clinic such as US Veterans Affairs treatment centres.

The studies included in the current review varied in effectiveness and some of the findings contradicted each other. For example, one study found that CBT/IRT improved PTSD specific sleep difficulties, whereas an additional two studies that used CBT/IRT did not find the same improvements. Studies that targeted nightmares and included a nightmare outcome measure found an improvement in nightmare severity and frequency and reduced distress of nightmares following the intervention, but not in number of nightmares per week. However, this was a small number of studies and therefore this finding needs to be interpreted with caution.

Symptom expression in PTSD sufferers with comorbid sleep difficulties is heterogeneous (Wallace, Iyengar, Bramoweth, Frank, & Germain, 2015) and in the studies included in the current review, sleep difficulties were operationalised in four ways, namely ‘insomnia’, ‘sleep quality’, ‘PTSD specific sleep difficulties’ and ‘nightmares’.

The effectiveness of the interventions varied in their effectiveness in reducing all four variants of sleep difficulties. All of the interventions apart from one, demonstrated a reduction in insomnia following the intervention, although the studies
that targeted nightmares did not measure insomnia. However, these studies did measure sleep quality, and generally this improved following intervention, apart from one study that used EERT where sleep quality was not improved. Sleep quality improved following intervention in almost all of the other studies, suggesting that the interventions were effective in targeting different aspect of sleep difficulties in PTSD sufferers. However, the varying results of the included studies might mean that there are conceptual differences in PTSD symptom expression and therefore specific approaches may be more effective than others in treating different sleep difficulties.

As aforementioned, the second aim of the review was not possible to evaluate. There were only a small number of studies for each type of CBT treatment, which meant that firm conclusions cannot be drawn regarding the effectiveness of these interventions. For example, some studies indicate that insomnia and sleep quality is improved by behavioural approaches including CBT-I, which incorporates stimulus control, sleep restriction, sleep hygiene and cognitive restructuring (Morin, 1993). In contrast, some studies indicate that PTSD specific sleep difficulties and nightmares might benefit from approaches that target these symptoms (such as EERT or IRT), which utilise exposure and rewriting of nightmare content (Davis & Wright, 2006). However, due to the small number of studies and as most studies used inactive control groups, it is not possible to say with confidence that any effects are due to treatment modality rather than simply receiving therapeutic input (e.g., Karlsson & Bergmark, 2014).

Dose-response effects have been investigated previously in CBT-I for insomnia, and the results suggested that four individual biweekly sessions were the optimal dose (Edinger, Wohlgemuth, Radtke, Coffman & Carney, 2007). However, in the current review although the intervention frequency varied across studies, this did
not seem to determine whether the intervention was effective or not, as some studies used as few as two weekly sessions, whereas others used eight weekly sessions and both successfully reduced insomnia and improved sleep quality.

Using CBT-I for PTSD specific sleep difficulties may be effective, but more intensive intervention might be needed, as Talbot et al., (2014) found that an 8-week group CBT-I intervention successfully reduced PTSD specific sleep difficulties whereas a 4-week group CBT-I intervention did not (Ustinov, et al., 2013). There is also evidence that combining the two approaches and targeting both sleep difficulties and nightmares has benefit for both insomnia and nightmares (Margolies et al., 2013). However, the evidence suggests that the intervention format should be delivered on an individual basis and over a longer duration (e.g., Margolies et al., 2013) rather than delivered in a group format and over a shorter period of time (e.g., Mack, 2013) in order to successfully reduce nightmares and PTSD specific sleep difficulties.

The difference in treatment effectiveness identified in the current study, may signify conceptual differences in symptom expression of PTSD specific sleep difficulties (such as episodes of terror during sleep). For example, Ulmer et al., (2011) found that insomnia and sleep quality reduced following psychological intervention whereas nightmares did not. Differences in symptom expression might indicate differences in PTSD severity, which may differentiate between symptom profiles, with more severe PTSD exhibiting the most difficulties with disruptive nocturnal behaviours and poor sleep quality (Wallace et al., 2015).

**Strengths and Limitations**

A strength of the current review is that it offers an updated systematic evaluation of the available evidence for psychological interventions to treat sleep
difficulties in PTSD sufferers. Past reviews that have investigated the evidence are outdated as a systematic review has not been conducted for two years which only included studies published before 2014 (Ho et al., 2016). It was notable that despite two years elapsing since the last review (Ho, et al., 2016) and the differences in search terms and methodology between the two reviews, only one further study was identified which is of an acceptable design and quality to use in a systematic review (i.e., Germain, et al, 2014) i.e., using RCT design (Cochrane Guidance, 2017). The fact that only eleven studies of adequate nature were identified in the current review, is testament to the small evidence base and lack of rigorous studies conducted in this population of PTSD sufferers with comorbid sleep difficulties, which highlights the need for further research in this area.

As aforementioned, sleep difficulties are heterogeneous in their presentation in PTSD sufferers, which has made it difficult to determine which approaches are beneficial for different sleep difficulties. Past reviews have encompassed all PTSD sleep difficulties under 'insomnia' and 'nightmares’ or have neglected to report outcomes on nightmares and PTSD specific sleep difficulties, but in the current review, it was felt that this was an overly simplistic account and does not appreciate the diversity in symptom expression in PTSD sufferers (e.g., Wallace et al., 2015). Idiosyncrasies regarding treatment effectiveness seem to exist for different PTSD presentations, and therefore the results of the current review were described for each of these presentations.

Given that mostly CBT interventions were identified for the current review, it was not possible to make comparisons regarding the effectiveness of different psychological therapies e.g., CBT vs non-CBT psychological therapies. Other non-CBT interventions were not selected for the current review as firstly there was a
parsimony of studies and secondly, when studies were identified they did not meet
the inclusion criteria i.e., they did not use a RCT design. Within the studies identified
for the current review, firm conclusions cannot be drawn about comparisons
regarding the effectiveness of different CBT approaches, such as CBT-I or IRT for
the four different elements of sleep disturbance in PTSD sufferers. This is in part due
to the large range of diversity in the study characteristics such as participant
characteristics, study setting, duration and frequency of intervention, and also there
were only a small number of studies for each intervention which therefore limits the
generalisability of results in the current review.

Additionally, there were methodological concerns regarding some of the study
designs included in the review, as although generally the quality of studies was
good, across almost all of the studies there were issues with allocation concealment
due to the nature of the RCT waitlist control condition. Additionally, some of the
outcome measures, including the TRNS, have questionable validity which could
explain why some of the results, especially regarding nightmares, seemed to
contradict each other. Other nightmare measures that have satisfactory reliability
and validity could have been used such as the newly developed Nightmare Distress
and Impact Questionnaire which has demonstrated adequate reliability (Chronbach’s
a = .75) (NDIQ; Kunze, Lancee, Morina, Kindt & Amtz, 2016).

**Further Research**

Individual differences inherent in this population of PTSD sufferers (Wallace,
et al., 2015) should be considered in future research such as gender differences, as
men tend to report more frequent nightmares than women (King, Street, Gradus,
Vogt, & Resick, 2013). Some studies suggest that vocation may even be a stronger
moderating factor in PTSD development such as being in the military (Brewin,
Andrews & Valentine, 2000) and also is a stronger predictor of PTSD symptom expression (King et al., 2013), so it would be worthwhile conducting further research into which treatments are most effective for different symptoms profiles (Wallace et al., 2015) and if further dose-specific effects are observed (Edinger et al., 2007).

Studies have identified that disturbed sleep prior to trauma exposure and immediately after trauma exposure increases PTSD vulnerability (e.g., Gehrman et al., 2013), therefore future research could investigate the effectiveness of psychological therapies in treating insomnia immediately after a trauma and the impact this has on the development of PTSD. Additionally, if insomnia following a trauma is exacerbated by adverse conditions such as soldiers on deployment in a war zone or blue light services working long shifts, it could be important for organisations to consider this in mental health prevention strategies, as improving insomnia symptoms reduces PTSD symptoms (Ho, et al., 2016) and treating insomnia soon after exposure to a trauma could prevent the development of PTSD and/or accelerate recovery (Germain, 2013).

Further studies should also investigate the effectiveness of different approaches such as CBT-I or IRT for the different elements of sleep disturbances in PTSD sufferers.

**Conclusion**

The current systematic review has provided a recent review of the effectiveness of psychological interventions for treating sleep difficulties in PTSD sufferers. Focusing on and treating sleep difficulties in PTSD sufferers is important as disturbed sleep impacts the severity of PTSD symptoms (Belleville et al., 2009) and can increase vulnerability to development of PTSD (e.g., Gehrman et al., 2013; Mellman, et al., 2002). Improving sleep difficulties in PTSD sufferers improves quality
of life (Margolies, 2011) and can also reduce PTSD symptoms without targeting PTSD symptoms specifically (Ho et al., 2016).

The current review has demonstrated that sleep difficulties are reduced by psychological therapies, which offer an alternative to pharmacology which has limited efficacy (Edinger et al., 2009; Lipinska, Baldwin, & Thomas, 2016). Different CBT interventions such as CBT-I or EERT and IRT may be better suited to treat insomnia and nightmares respectively and further research should be conducted into which of these approaches are beneficial for different PTSD specific sleep difficulties.
References


*Study was included in the synthesis*
with primary insomnia or insomnia associated predominantly with mixed psychiatric disorders: a randomized clinical trial. *Sleep*, 32, 499-510.


Appendices

This section includes information supplementing the main manuscript.

Appendix A – PRISMA Statement

Appendix B – Search Terms

Appendix C – Quality Assessment Tool

Appendix D. Journal of Behavior Therapy – Instructions for Authors
# Appendix A

## PRISMA Statement (Moher et al., 2009)

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TITLE</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Identify the report as a systematic review, meta-analysis, or both.</td>
</tr>
<tr>
<td><strong>ABSTRACT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Structured summary</td>
<td>2</td>
<td>Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.</td>
</tr>
<tr>
<td><strong>INTRODUCTION</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rationale</td>
<td>3</td>
<td>Describe the rationale for the review in the context of what is already known.</td>
</tr>
<tr>
<td>Objectives</td>
<td>4</td>
<td>Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).</td>
</tr>
<tr>
<td><strong>METHODS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protocol and registration</td>
<td>5</td>
<td>Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.</td>
</tr>
<tr>
<td>Eligibility criteria</td>
<td>6</td>
<td>Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.</td>
</tr>
<tr>
<td>Information sources</td>
<td>7</td>
<td>Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.</td>
</tr>
<tr>
<td>Search</td>
<td>8</td>
<td>Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.</td>
</tr>
<tr>
<td>Study selection</td>
<td>9</td>
<td>State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).</td>
</tr>
<tr>
<td>Section/topic</td>
<td>#</td>
<td>Checklist item</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>-----</td>
<td>-------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Data collection process</td>
<td>10</td>
<td>Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.</td>
</tr>
<tr>
<td>Data items</td>
<td>11</td>
<td>List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.</td>
</tr>
<tr>
<td>Risk of bias in individual studies</td>
<td>12</td>
<td>Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.</td>
</tr>
<tr>
<td>Summary measures</td>
<td>13</td>
<td>State the principal summary measures (e.g., risk ratio, difference in means).</td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>14</td>
<td>Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.</td>
</tr>
</tbody>
</table>

### RESULTS

<table>
<thead>
<tr>
<th>Section/topic</th>
<th>#</th>
<th>Checklist item</th>
<th>Reported on page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study selection</td>
<td>17</td>
<td>Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.</td>
<td></td>
</tr>
<tr>
<td>Study characteristics</td>
<td>18</td>
<td>For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.</td>
<td></td>
</tr>
<tr>
<td>Risk of bias within studies</td>
<td>19</td>
<td>Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).</td>
<td></td>
</tr>
<tr>
<td>Results of individual studies</td>
<td>20</td>
<td>For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.</td>
<td></td>
</tr>
<tr>
<td>Synthesis of results</td>
<td>21</td>
<td>Present results of each meta-analysis done, including confidence intervals and measures of consistency.</td>
<td></td>
</tr>
<tr>
<td>Risk of bias across studies</td>
<td>22</td>
<td>Present results of any assessment of risk of bias across studies (see Item 15).</td>
<td></td>
</tr>
<tr>
<td>Additional analysis</td>
<td>23</td>
<td>Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).</td>
<td></td>
</tr>
</tbody>
</table>
**DISCUSSION**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Summary of evidence</td>
<td>24</td>
</tr>
<tr>
<td>Limitations</td>
<td>25</td>
</tr>
<tr>
<td>Conclusions</td>
<td>26</td>
</tr>
</tbody>
</table>

**FUNDING**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Funding</td>
<td>27</td>
</tr>
</tbody>
</table>


For more information, visit: [www.prisma-statement.org](http://www.prisma-statement.org)
Appendix B

Search Terms

**Population:** PTSD or post-trauma* or trauma or disaster
Insomnia* or sleep*

**Intervention:** Psycho* therapy* or CBT or Cognitive behavio* therapy or psychological therapy or treatment* or therap* or behavio* or cognitive or program* or intervent*

**Study type:** Random* or controlled trial or RCT or Randomi*ed control* trial or *trial or quasi-experimental or experimental or random allocation

**RANDOMISED CONTROLLED TRIALS**
The search filter used by SIGN to retrieve randomised controlled trials has been adapted from the first two sections of strategy designed by the Cochrane Collaboration identifying RCTs for systematic review.

**Medline**
1. Randomized Controlled Trials as Topic/
2. randomized controlled trial/
3. Random Allocation/
4. Double Blind Method/
5. Single Blind Method/
6. clinical trial/
7. clinical trial, phase i.pt
8. clinical trial, phase ii.pt
9. clinical trial, phase iii.pt
10. clinical trial, phase iv.pt
11. controlled clinical trial.pt
12. randomized controlled trial.pt
13. multicenter study.pt
14. clinical trial.pt
15. exp Clinical Trials as topic/
16. or/1-15
17. (clinical adj trial$).tw
18. ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw
19. PLACEBOS/
20. placebo$.tw
21. randomly allocated.tw
22. (allocated adj2 random$).tw
23. or/17-22
24. 16 or 23
25. case report.tw
26. letter/
27. historical article/
28. or/25-27
29. 24 not 28

**Embase**
1. Clinical Trial/ (505836)
2. Randomized Controlled Trial/ (430740)
3. controlled clinical trial/ (91696)
4. multicenter study/ (211094)
5. Phase 3 clinical trial/ (0)
6. Phase 4 clinical trial/ (0)
7. exp RANDOMIZATION/ (88833)
SELF-COMPASSION AND PTSD IN ARMED FORCES VETERANS

8 Single Blind Procedure/ (0)
9 Double Blind Procedure/ (0)
10 Crossover Procedure/ (0)
11 PLACEBO/ (0)
12 random?ed controlled trial$.tw. (118033)
13 rct.tw. (13355)
14 (random$ adj2 allocat$).tw. (26671)
15 single blind$.tw. (14081)
16 double blind$.tw. (131298)
17 ((treble or triple) adj blind$).tw. (496)
18 placebo$.tw. (184669)
19 Prospective Study/ (431057)
20 or/1-19 (1362945)
21 Case Study/ (1825273)
22 case report.tw. (246534)
23 abstract report/ or letter/ (941014)
24 Conference proceeding.pt. (0)
25 Conference abstract.pt. (0)
26 Editorial.pt. (418735)
27 Letter.pt. (941014)
28 Note.pt. (0)
29 or/21-28 (3053616)
30 20 not 29 (1330027)
CINAHL for EBSCO (created by Mark Clowes)
# Query
S12 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11 TX allocat* random*
S10 (MH "Quantitative Studies")
S9 (MH "Placebos")
S8 TX placebo*
S7 TX random* allocat*
S6 (MH "Random Assignment")
S5 TX random* control* trial*
S4 TX ((singl* n1 blind*) or (singl* n1 mask*))
or TX ((doubl* n1 blind*) or (doubl* n1 mask*))
or TX ((tripl* n1 blind*) or (tripl* n1 mask*))
or TX ((trebl* n1 blind*) or (trebl* n1 mask*))
S3 TX clinic* n1 trial*
S2 PT Clinical trial
S1 (MH "Clinical Trials+")
Appendix C

Quality Assessment Tool (QAT) for Quantitative Studies from the Effective Public Health Project (Armijo-Olivo, Stiles, Hagen, Biondo, & Cummings, 2012)
C) CONFOUNDERS

(Q1) Were there important differences between groups prior to the intervention?
1 Yes
2 No
3 Can’t tell

The following are examples of confounders:
1 Race
2 Sex
3 Marital status/family
4 Age
5 SES (income or class)
6 Education
7 Health status
8 Pre-intervention score on outcome measure

(Q2) If yes, indicate the percentage of relevant confounders that were controlled (either in the design (e.g. stratification, matching) or analysis)?
1 80 – 100% (most)
2 60 – 79% (some)
3 Less than 60% (few or none)
4 Can’t Tell

RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3

D) BLINDING

(Q1) Was (were) the outcome assessor(s) aware of the intervention or exposure status of participants?
1 Yes
2 No
3 Can’t tell

(Q2) Were the study participants aware of the research question?
1 Yes
2 No
3 Can’t tell

RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3

E) DATA COLLECTION METHODS

(Q1) Were data collection tools shown to be valid?
1 Yes
2 No
3 Can’t tell

(Q2) Were data collection tools shown to be reliable?
1 Yes
2 No
3 Can’t tell

RATE THIS SECTION STRONG MODERATE WEAK
See dictionary 1 2 3
F) WITHDRAWALS AND DROP-OUTS

(Q1) Were withdrawals and drop-outs reported in terms of numbers and/or reasons per group?
   1. Yes
   2. No
   3. Can't tell
   4. Not Applicable (i.e. one time surveys or interviews)

(Q2) Indicate the percentage of participants completing the study. (If the percentage differs by groups, record the lowest).
   1. 80 - 100%
   2. 60 - 79%
   3. less than 60%
   4. Can't tell
   5. Not Applicable (i.e. Retrospective case-control)

G) INTERVENTION INTEGRITY

(Q1) What percentage of participants received the allocated intervention or exposure of interest?
   1. 80 - 100%
   2. 60 - 79%
   3. less than 60%
   4. Can't tell

(Q2) Was the consistency of the intervention measured?
   1. Yes
   2. No
   3. Can't tell

(Q3) Is it likely that subjects received an unintended intervention (contamination or co-intervention) that may influence the results?
   4. Yes
   5. No
   6. Can't tell

H) ANALYSES

(Q1) Indicate the unit of allocation (circle one)
   community   organization/institution   practice/office   individual

(Q2) Indicate the unit of analysis (circle one)
   community   organization/institution   practice/office   individual

(Q3) Are the statistical methods appropriate for the study design?
   1. Yes
   2. No
   3. Can't tell

(Q4) Is the analysis performed by intervention allocation status (i.e. intention to treat) rather than the actual intervention received?
   1. Yes
   2. No
   3. Can't tell
### Global Rating

**Component Ratings**
Please transcribe the information from the gray boxes on pages 1-4 onto this page. See dictionary on how to rate this section.

<table>
<thead>
<tr>
<th>A</th>
<th>Selection Bias</th>
<th>Strong</th>
<th>Moderate</th>
<th>Weak</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>B</td>
<td>Study Design</td>
<td>Strong</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>C</td>
<td>Confounders</td>
<td>Strong</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>D</td>
<td>Blinding</td>
<td>Strong</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>E</td>
<td>Data Collection Method</td>
<td>Strong</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>F</td>
<td>Withdrawals and Dropouts</td>
<td>Strong</td>
<td>Moderate</td>
<td>Weak</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

**Global Rating for This Paper** (circle one):

1. Strong (no Weak ratings)
2. Moderate (one Weak rating)
3. Weak (two or more Weak ratings)

With both reviewers discussing the ratings:

Is there a discrepancy between the two reviewers with respect to the component (A-F) ratings?

1. No
2. Yes

If yes, indicate the reason for the discrepancy:

1. Oversight
2. Differences in interpretation of criteria
3. Differences in interpretation of study

**Final decision of both reviewers** (circle one):

1. Strong
2. Moderate
3. Weak
Appendix D

Journal of Behavior Therapy – Instructions for Authors

**BEHAVIOR THERAPY**

**AUTHOR INFORMATION PACK**

**TABLE OF CONTENTS**

- Description p.1
- Impact Factor p.1
- Abstracting and Indexing p.1
- Editorial Board p.2
- Guide for Authors p.4

**DESCRIPTION**

*Behavior Therapy*, published six times a year, is an international journal devoted to the application of the behavioral and cognitive sciences to the conceptualization, assessment, and treatment of psychopathology and related clinical problems. It is intended for mental health professionals and students from all related disciplines who wish to remain current in these areas and provides a vehicle for scientist-practitioners and clinical scientists to report the results of their original empirical research. Although the major emphasis is placed upon empirical research, methodological and theoretical papers as well as evaluative reviews of the literature will also be published. Controlled single-case designs and clinical replication series are welcome.

**Benefits to authors**

We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services.

Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.

**IMPACT FACTOR**

2016: 3.434 © Clarivate Analytics Journal Citation Reports 2017

**ABSTRACTING AND INDEXING**

BIOSIS Previews
Current Contents/Social & Behavioral Sciences
EBSCO
Google Scholar
MEDLINE®
PsycINFO
Scopus
GUIDE FOR AUTHORS

Introduction

Behavior Therapy, published six times a year, is an international journal devoted to the application of the behavioral and cognitive sciences to the conceptualization, assessment, and treatment of psychopathology and related clinical problems. It is intended for mental health professionals and students from all related disciplines who wish to remain current in these areas and provides a vehicle for scientist-practitioners and clinical scientists to report the results of their original empirical research. Although the major emphasis is placed upon empirical research, methodological and theoretical papers as well as evaluative reviews of the literature will also be published. Controlled single-case designs and clinical replication series are welcome.

Contact details

Questions about a possible manuscript for Behavior Therapy may be discussed with the editor-elect:

Denise M. Sloan, Ph.D.
Associate Director, Behavioral Science Division, National Center for PTSD
Professor of Psychiatry, Boston University School of Medicine

Phone: +1 857 364 6333
Email: Denise.Sloan@va.gov

Submission checklist

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:

Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print

Graphical Abstracts / Highlights files (where applicable)

Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN

Ethics in publishing

Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.
Human and animal rights

If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform Requirements for manuscripts submitted to Biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed.

Policy and ethics

All manuscripts should be prepared in conformity with the format described in the Publication Manual of the American Psychological Association, Sixth Edition, (2009), and it is the responsibility of the author that manuscripts adhere to the format and other requirements of Behavior Therapy. Medical Journals, manuscripts should follow the guidelines of the Publication Manual of the American Psychological Society as opposed to the Uniform Requirements for Manuscripts Submitted to Medical Journals.

The Council of Science Editors (CSE) has produced "Editorial Policy Statements" that cover the responsibilities and rights of editors of peer-reviewed journals. Publishers who would like to incorporate these Statements into their review and publication process are encouraged to link to: http://www.councilofscienceeditors.org/services/draft_approved.cfm

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Preprints

Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Authorship

Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors.
Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Copyright
Upon acceptance of an article, authors will be asked to transfer copyright to ABCT. This transfer will ensure the widest possible dissemination of information. A letter will be sent to the corresponding author confirming receipt of the manuscript. A form facilitating transfer of copyright will be provided. If excerpts from other copyrighted works are included, the authors(c) must obtain written permission from the copyright owner(s) and credit the source(s) in the article. Elsevier has forms for use by authors in these cases available at http://www.elsevier.com/locate/permissions phone: (+44) 1865 843830 or e-mail: permissions@elsevier.com.

Elsevier supports responsible sharing
Find out how you can share your research published in Elsevier journals.

Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of existing agreements are available online.

Open access
This journal offers authors a choice in publishing their research:

Subscription
- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
- No open access publication fee payable by authors.
- The Author is entitled to post the accepted manuscript in their institution's repository and make this public after an embargo period (known as green Open Access). The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

Gold open access
- Articles are freely available to both subscribers and the wider public with permitted reuse.
- A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is USD 3000, excluding taxes. Learn more about Elsevier’s pricing policy.

Green open access

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our green open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution’s repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.

This journal has an embargo period of 24 months.

Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier’s WebShop.

Upon request Elsevier will direct authors to an agent who can check and improve the English of their paper (before submission). Please visit our customer support site at http://service.elsevier.com for more information.

Submission

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article

Please submit your article via http://www.ees.elsevier.com/bt

Additional information

Manuscript Length: Manuscripts should not exceed 35 pages total (including cover page, abstract, text, references, tables, and figures), with margins of at least 1 in. on all sides and a standard font (e.g., Times New Roman) of 12 points (no smaller). The entire paper (text, references, tables, etc.) must be double spaced. For papers that exceed 35 pages, authors must justify the length in their cover letter (e.g., reporting of multiple studies), and in no case shall a paper exceed 40 pages total. Papers that do not conform to these guidelines will be returned to the authors without review.

NOTE: This statement should be inserted as a separate paragraph in the section on "Manuscript Requirements". It can be inserted as the third paragraph in this section - before the paragraph that begins "Authors are strongly encouraged to submit online...."

Reporting Standards: For randomized clinical trials, Behavior Therapy requires use of the CONSORT (Consolidated Standards of Reporting Trials) Guidelines. CONSORT Guidelines offer a standard way to improve the quality of such reports, and to ensure readers have the information they need to evaluate the quality of clinical trials. The CONSORT Checklist and Flowchart can be viewed at http://www.consort-statement.org

All manuscripts that report randomized clinical trials must include the Flowchart depicting the flow of participants through the various phases of the trial. The Flowchart is required for all such studies and should be included as a figure in the submitted study. The checklist should be submitted as an
appendix to the manuscript - it will not be published but is used to guide reviewers with respect to the CONSORT requirements. If a study is not fully consistent with the CONSORT guidelines, limitations should be acknowledged and commented upon in the Discussion section of the manuscript.

For follow-up studies of previously published clinical trials, authors should submit a flow diagram of the progress through the phases of the trial and follow-up. A CONSORT checklist should also be provided, with special reference to the Results and Discussion sections of the manuscript.

For nonrandomized clinical trials, Behavior Therapy encourages the use of the most recent version of the TREND guidelines (Transparent Reporting of Evaluations with Non-randomized Designs). These criteria can be found at http://www.cdc.gov/trendstatement/. These criteria are intended to provide readers with the information they need to evaluate such studies.

Masked Reviews
The journal uses a masked reviewing system for all submissions. You will be asked to provide two separate manuscript versions. The first version should be a complete manuscript which includes all author information. The second version should omit the authors' names and affiliations but should include the title of the manuscript and the date it is submitted. Footnotes containing information pertaining to the authors' identity of affiliations should not be included in the second version of the manuscript, and every effort should be made to see that the manuscript itself contains no clues to the authors' identity.

Data Access and Retention
Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data (consistent with the Hazards and Human or Animal Subjects ALPSP-STM Statement on Data and Databases), if practical, and should in any event be prepared to retain such data for a reasonable time after publication.

Hazards and Human or Animal Subjects
If the work involves chemicals, procedures, or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) have approved them and whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of humans must always be observed. Participants who are the subject of case descriptions will read the article and agree to its use in print, on the internet, etc. Authors must include a statement in the article saying they obtained informed consent and they they disclosed any conflicts of interests with study participants.

PREPARATION
Please ensure the text of your paper is double-spaced - this is an essential peer review requirement.

Peer review
This journal operates a double blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

Double-blind review
This journal uses double-blind review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors’ names, affiliations, acknowledgments and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.

Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgments) should not include any identifying information, such as the authors' names or affiliations.
Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - unnumbered sections
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Theory/calculation
A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Glossary
Please supply, as a separate list, the definitions of field-specific terms used in your article.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulas and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.
Abstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Graphical abstract

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 x 1328 pixels (h x w) or proportionally more. The image should be readable at a size of 5 x 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view Example Graphical Abstracts on our information site. Authors can make use of Elsevier’s Illustration Services to ensure the best presentation of their images and in accordance with all technical requirements.

Highlights

Highlights are mandatory for this journal. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use ‘Highlights’ in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site.

Keywords

Immediately after the abstract, provide 3-5 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, “and,” “of”). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements

For reasons of assisting with double-blind review, collate acknowledgements in a separate section on the title page beneath the author information. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Formatting of funding sources

List funding sources in this standard way to facilitate compliance to funder’s requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions of the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Figure captions
Ensure that each Illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Text graphics
Text graphics may be embedded in the text at the appropriate position. If you are working with LaTeX and have such features embedded in the text, these can be left. See further under Electronic artwork.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference management software
Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley and Zotero, as well as EndNote. Using the word processor plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:
http://open.mendeley.com/use-citation-style/behavior-therapy
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference style
Text: Citations in the text should follow the referencing style used by the American Psychological Association. You are referred to the Publication Manual of the American Psychological Association, Sixth Edition, ISBN 978-1-4338-0561-5, copies of which may be ordered online or APA Order Dept., P.O.B. 2710, Hyattsville, MD 20784, USA or APA, 3 Henrietta Street, London, WC1E 8LU, UK.
List: references should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.
Examples:
Reference to a journal publication:
Reference to a book:
Reference to a chapter in an edited book:
Reference to a website:
Reference to a dataset:
Reference to a conference paper or poster presentation:
Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.
SELF-COMPASSION AND PTSD IN ARMED FORCES VETERANS

Video
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file’s content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and print version for the portions of the article that refer to this content.

AudioSlides
The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

AFTER ACCEPTANCE

Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download the free Adobe Reader, version 9 (or higher). Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printed copy of your proof and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is
accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier’s Webshop. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

Additional information
Advertising Policy

For advertisers in ABCT periodicals, the following is the procedure:
Staff will include ABCT’s nondiscrimination policy in advertising rate sheets. Staff will provide advertisers with the nondiscrimination policy and require statements from them on how they differ from our policy. This will apply to some, but not all, advertisers. It applies only to those who are advertising job or training opportunities (so booksellers and publishers, unless they’re looking for someone to sell books or help with redaction, are exempt, as long as they’re advertising books, journals, conferences, and the like). The following statement will appear on the advertising rate sheet:
It is the policy of the Board of Directors of ABCT that all advertisers for jobs or training positions review the ABCT nondiscrimination policy. The Association for Behavioral and Cognitive Therapies is committed to a policy of equal opportunity in all of its activities, including employment. ABCT does not discriminate on the basis of race, color, creed, religion, national or ethnic origin, sex, sexual orientation, gender identity or expression, age, disability, or veteran status. If the advertiser’s own policy differs from the ABCT policy, then that must be stated in the ad. We recommend that wording similar to the following be used: “Please note the nondiscrimination policy of xxx differs from the ABCT policy in that it does not include age, sexual orientation, or gender identity and expression”. This wording appears only if your non-discrimination policy differs from ABCT’s. For those advertisers who are not offering jobs or training opportunities (for instance, book sellers or VR distributors), this does not apply.

Following is our accepted advertising Policy in ABCT’s policy and procedure manual.

Policies Regarding Advertising
Advertisements must meet all relevant legal, professional and ethical guidelines. ABCT publications are published for, and on behalf of, the membership and the cognitive and behavioral therapies community.

The Association reserves the right to unilaterally reject, omit, or cancel advertising which, by its tone, content, or appearance, is not in keeping with the essentially scientific, scholarly, and professional nature of its publications or the goals of the organization. The Association reserves the right to refuse ads that, because of omissions or inaccuracies, provide misleading or incorrect information. The Director of Communications, acting on behalf of the Editor, has the full and final authority for approving advertisements and enforcing advertising policy for those ads submitted to the Association.
Ads submitted to Elsevier running in multiple journals fall under the purview of Elsevier’s publisher or its representative.
Publication of any advertisement by ABCT is neither an endorsement of the advertiser nor of the products or services advertised. ABCT is not responsible for any claims made in an advertisement. Advertisers and advertising agencies assume liability for all content (including text representation and illustrations) of advertisements printed, and also assume responsibility for any claims arising therefrom made against the Publisher. The Publisher’s liability for any error will not exceed the charge for the advertisement in question.

Correspondence
Readers may submit comments or criticisms about published articles to our sister publication, the Behavior Therapist. The authors of articles discussed in correspondence will be given an opportunity to respond, preferably in the same issue in which the original correspondence appears.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com

AUTHOR INFORMATION PACK 14 May 2018 www.elsevier.com/locate/bt
SCHOOL OF PSYCHOLOGY
DOCTORATE IN CLINICAL PSYCHOLOGY

EMPIRICAL PAPER

Can Self-compassion Be Elicited in Armed Forces Veterans?

Trainee Name: Samantha Gerdes
Primary Research Supervisor: Dr Anke Karl
  Senior Lecturer in Clinical Psychology, Mood Disorders Centre, University of Exeter
Secondary Research Supervisor: A/Professor Huw Williams
  Associate Professor of Clinical Neuropsychology, University of Exeter
Target Journal: Journal of Consulting and Clinical Psychology
Word Count: 8473 words (excluding abstract, table of contents, list of figures, references, footnotes, appendices)

Submitted in partial fulfilment of requirements for the Doctorate Degree in Clinical Psychology, University of Exeter
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title Page</td>
<td>78</td>
</tr>
<tr>
<td>Contents</td>
<td>79</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>81</td>
</tr>
<tr>
<td>Abstract</td>
<td>82</td>
</tr>
<tr>
<td><strong>Introduction</strong></td>
<td>83</td>
</tr>
<tr>
<td>Hyperarousal/Hypervigilance and PTSD</td>
<td>85</td>
</tr>
<tr>
<td>Social Connectedness and PTSD</td>
<td>85</td>
</tr>
<tr>
<td>Self-compassion</td>
<td>88</td>
</tr>
<tr>
<td>Self-compassion and PTSD</td>
<td>89</td>
</tr>
<tr>
<td>Self-compassion and the Armed Forces population</td>
<td>92</td>
</tr>
<tr>
<td>Loving Kindness Meditation</td>
<td>93</td>
</tr>
<tr>
<td>Current Study, Aims and Rationale</td>
<td>94</td>
</tr>
<tr>
<td>Research Questions and Hypotheses</td>
<td>95</td>
</tr>
<tr>
<td><strong>Method</strong></td>
<td>95</td>
</tr>
<tr>
<td>Participants Characteristics</td>
<td>95</td>
</tr>
<tr>
<td>Sampling Procedures</td>
<td>97</td>
</tr>
<tr>
<td>Study Procedure</td>
<td>98</td>
</tr>
<tr>
<td>Ethical approval and safety monitoring</td>
<td>98</td>
</tr>
<tr>
<td>Sample Size</td>
<td>98</td>
</tr>
<tr>
<td>Measures</td>
<td>98</td>
</tr>
<tr>
<td>Demographic information</td>
<td>98</td>
</tr>
<tr>
<td>TBI assessment</td>
<td>98</td>
</tr>
<tr>
<td>Posttraumatic stress disorder</td>
<td>99</td>
</tr>
</tbody>
</table>
Acknowledgements

Firstly, I would like to thank all of the veterans that took part in this study. Your generosity and willingness to help others is admirable. I would also like to thank all of the veteran charities, NHS services and other organisations who supported recruitment for the study. I would like to thank my supervisors, Dr Anke Karl and Dr Huw Williams, for their support, enthusiasm and encouragement throughout the study. And last but not least, I would like to thank my love ones – you know who you are. Without your unwavering support I would not have achieved this.
Abstract

Initial studies demonstrate that self-compassion reduces symptoms of PTSD in Armed Forces Veterans (AFV), however the use of self-compassion approaches in AFV is under-researched. The current study utilised self-report and psychophysiological measures to investigate whether a single self-compassion experimental induction reduced hyperarousal symptoms (PTSD Cluster E symptoms) and increased feelings of social connectedness in AFV. The study hypothesised that there would be a decrease in hyperarousal symptoms and an increase in social connectedness, which would be associated with PTSD severity.

Fifty-three AFV who had been deployed to a combat zone took part in the study, of which \( n = 15 \) (28.3%) currently met criteria for PTSD and \( n = 4 \) (7.5%) met criteria for Subsyndromal PTSD\(^4\) on the PCL-5. Participants listened to a recording of a Loving Kindness Meditation for self-compassion (LKM-S) and psychophysiological recordings were taken throughout. Participants completed state measures of hyperarousal and social connectedness before and after the LKM-S. Findings partially demonstrated that self-compassion can be elicited in an AFV population. However, changes on the self-report measures were largely not supported by psychophysiological measures, apart from skin conductance levels (SCL). The longevity of the effects observed in the study were not measured and should be investigated in future studies. Although this study has demonstrated that self-compassion can be elicited within the AFV population, further research is needed including to test a longer self-compassion intervention.

Keywords: PTSD, self-compassion, loving kindness, Armed Forces Veterans.

---

\(^4\) Subsyndromal PTSD is categorised as endorsing one Cluster B symptom (invasion symptoms), and one of either cluster C (avoidance), D (negative alterations in cognitions), or E (hyperarousal).
Introduction

The impact of war-related trauma on soldiers is well recognised and leads to the development of posttraumatic stress disorder (PTSD) (Fontana & Rosenheck, 1993). Being in the Armed Forces can include exposure to traumatic events and people risk developing PTSD as a result of carrying out their occupational duties (Dunn, Brooks, Rubin, & Greenberg, 2015). The multitude of threats experienced by soldiers whilst on deployment to a combat zone, along with long periods of separation from family and friends, are a common experience to soldiers and are significant predictors of PTSD (King, King, Gudanowski, & Vreven, 1995). PTSD is characterised by symptoms including intrusive memories, avoidance of associations with the traumatic event, negative alterations in cognitions and mood and marked alterations in arousal and reactivity (see Appendix A, APA; American Psychiatric Association, 2013).

Reports of PTSD prevalence rates in the Armed Forces population vary (Kok, Herell, Thomas, & Hoge, 2012) and some have estimated rates in currently serving Armed Forces personnel at 4% (Hotopf et al., 2003; Fear et al., 2010) and for personnel prior to deployment or those who are not exposed to stressors in combat such as firefights at 3.3-6.1% (Hoge et al., 2004). However, studies that focus on only soldiers that held combat roles reveal high rates of PTSD (Kok, et al., 2012) and rates of PTSD rise exponentially when soldiers are exposed to combat during deployments (11.9% - 22.5%) (Kang, Natelson, Mahan, Lee & Murphy, 2003). PTSD rates increase with greater exposure to enemy contact and firefights e.g., 4.5% developed PTSD who engaged in no firefights, up to 19.3% who engaged in more than five firefights (Hoge et al., 2004). Humanitarian and peacekeeping missions also pose risk for developing PTSD and prevalence rates are similar to those who
have experienced combat i.e., 16.8% of veterans who were deployed to Cambodia, Rwanda or Somalia developed PTSD (Forbes et al., 2016).

The hypervigilance symptomology of combat PTSD is different to other types of trauma including those found in civilian populations (Kimble, Fleming & Bennion, 2013), as individuals report enhanced physiological reactivity, an overactive startle response and emotional numbness compared with those who experience civilian events (Prescott, 2012). Elevated hypervigilance and being in a threatened state might maintain PTSD in combat veterans as it can prevent changes to the nature and appraisal of trauma memories (see Figure 1) (Ehlers & Clark, 2000).

Additionally, hypervigilance could be self-reinforcing as coping strategies and avoidance symptoms such as constantly being on high alert and on the lookout for danger (Conoscenti, Vine, Papa, & Litz, 2009) lead individuals to feel safe and protected. This might make it more difficult to engage in psychological therapies where exposure to traumatic memories may increase feelings of threat and therefore increase hypervigilant behaviours.

Figure 1. Ehlers and Clark (2000) Cognitive Model of PTSD.
Hyperarousal/Hypervigilance and PTSD

Hypervigilance is highly adaptive for soldiers in war zones however it can be maladaptive when taken out of context, as the individual is on constant ‘high alert’ even when threat is low (Kimble et al., 2013). In soldiers, hypervigilant behaviour in war zones includes constant sensory scanning and searching e.g., listening for footsteps and weapon sounds or looking for rising dust and shadows (Army Field Manual, AFM 21-75) which is endured for long periods of time due to the constant threat to life or of serious physical injury (Kimble, et al., 2013). Hypervigilance is reinforced whilst on deployment and it can become habitual to the extent where it is triggered easily and difficult to eradicate once back in civilian life where it can be problematic as it can include over-alertness, reacting quickly if threat is perceived, restlessness, irritability (Conoscenti, et al., 2009), aggression (Taft et al., 2007) and sleep problems (Germain, & Neilsen, 2003).

Hypervigilance and other PTSD symptoms can also leave people feeling detached and estranged from others and have a difficulty experiencing positive feelings (APA, 2013). This can be distressing and often people report a feeling of difference, or ‘having changed’ since the traumatic event (Demers, 2011). This can lead to difficulties in maintaining relationships (King, Taft, King, Hammond & Stone, 2006) resulting in a lack of social support which can contribute to a deterioration in mental health (Freedman, Gilad, Ankri, Roziner, & Shalev, 2015).

Social Connectedness and PTSD

Social support and social connectedness are both important factors to consider in the prevention and alleviation of PTSD. Social support is negatively related to PTSD both in combat veterans (e.g., Pietrzak, Johnson, Goldstein, Malley, & Southwick, 2009) and civilian populations (e.g., Schumm, Briggs-Phillips,
Hobfoll, 2006). The role of social support and secure attachment in recovery from trauma has been well established and diminished social support can contribute to PTSD development and severity (e.g., Freedman et al., 2015; Pearlman & Curtois, 2005). Social connectedness has been shown to be negatively associated with PTSD and other psychological pathology and a persistent and pervasive lack of belongingness and social connection is psychologically distressing and is associated with psychological problems (Baumeister & Leary, 1995). Conceptually, social support and social connectedness are distinct constructs, though they likely interact with each other. Social support is defined as ‘perceived or actual instrumental and/or expressive provisions supplied by the community, social networks, and confiding partners’ (Lin, 1986, p.18) whereas ‘social connectedness’ is a person’s opinion of the self in relation to other people, including the emotional distance or connectedness between themselves and others (Lee & Robbins, 1995). Social connectedness is associated with a sense of one’s own ability to connect to others, a type of relational schema (Lee & Robbins, 1998) rather than being defined by group membership (Baumeister & Leary, 1995), and perception of social connection is more important than actual social connection (Heinrich & Gullone 2006).

Serving in the Armed Forces can provide a sense of social connectedness, which arguably is needed in order for people to engage in war (Wessely, 2006). The Armed Forces community can provide a strong sense of group cohesion and social connectedness (Tick, 2005), which has been shown to increase both psychological and physical wellbeing (De Vries, Glasper, & Detillion, 2003). However, the masculinised culture of the Armed Forces (Reit, 2009) can prevent people from sharing emotional distress, and this may be further compounded during civilian life whereby veterans may feel alone in their experiences (Demers, 2011). Transitioning
from the Armed Forces to civilian life is a major life event and involves changing
social experiences, resources and networks (Hatch et al., 2013). A loss of social
embeddedness and group cohesion provided by the military membership, can
impede successful transition to civilian life (Hatch et al., 2003) where the sense of
social support and community might be less available (Hachey, Sudom, Sweet,
MacLean & VanTil, 2016).

Generally, high rates of PTSD are reported in the UK Armed Forces Veteran\(^5\)
(AFV) population compared to currently serving personnel, with estimates between
15% (Palmer, 2012) to 70% (van Hoorn et al., 2013). This could be explained by the
stigma of help seeking whilst serving in the Armed Forces which would lead to
underreporting during active service (Sharp et al., 2015), or the onset of PTSD could
be delayed or might develop, or simply become more of a problem, once individuals
leave the Armed Forces, due to reduced social support and adapting to civilian life
(Hachey, et al., 2016).

Lack of social support, difficulties in social relationships, or threats to social
connection contribute to PTSD severity (Freedman, et al., 2015) and activate the
same stress response system as physical threats to survival i.e. the flight/flight
response, including the sympathetic nervous system (SNS) and the Hypothalamus-
pituitary-adrenal (HPA) axis (Eisenberger, & Cole, 2012). The link between an
elevated flight/flight response and mental health problems is well established
(Southwick, Vythilingam & Charney, 2005) and an elevated HPA response has been
identified in people with PTSD. This elevated flight/flight state (i.e., hyperarousal)
and constant activation of threat mode (i.e., hypervigilance), combined with a lack of

\(^5\) The definition of an Armed Forces Veteran (AFV) is those who have served for at least one day in
the HM Armed Forces, whether as a Regular or Reservist (Armed Forces Covenant, MOD).
social support may maintain PTSD in combat veterans, as individuals might be stuck in 'current threat' mode (Ehlers & Clark, 2000). Therefore, therapeutic approaches that emphasise reducing hyperarousal and the stress response as well as building social connectedness might reduce PTSD symptoms. By increasing positive social connections, recovery from PTSD is enhanced (e.g., Freedman et al., 2015) and also, by reducing hyperarousal, this may firstly facilitate social connections but also reduce symptoms of PTSD and enable the processing of trauma memories (e.g., Cloitre et al., 2012).

**Self-compassion**

Compassion based therapies use strategies that reduce the 'threat' emotional system and facilitate activation of the 'soothing' emotional system, which facilitates social connection (Figure 2) (Gilbert 2009a). Self-compassion can be described as "an intimate awareness of the suffering by oneself and others with the wish to alleviate it" (Germer & Neff, 2013) and has been conceptualised as: self-kindness versus self-judgement, common humanity versus isolation and mindfulness versus over-identification (Germer & Neff, 2013). Reviews demonstrate that self-compassion is negatively related to psychopathology (Barnard & Curry, 2011; MacBeth & Gumley, 2012) and self-compassion in therapeutic settings is gaining popularity to treat a number of mental health difficulties (e.g., Germer & Neff, 2013; 2015) including PTSD and shame based flashbacks (Lee, 2009) as well as other shame-based difficulties (Leaviss & Uttley, 2015).
**Figure 2.** Gilbert (2009a). *Three types of affect regulation system.*

**Self-compassion and PTSD.** Self-compassion might be beneficial for the treatment of PTSD for two reasons: Firstly, aetiological models of PTSD and supporting empirical research indicate that negative self-appraisals prevent adaptive processing and integration of the traumatic experience into the individual’s autobiographical memory leading to symptom maintenance (Ehlers & Clark, 2000). The individual is stuck in the ‘threat’ mode of emotion regulation (see Figure 2, Gilbert, 2009a), which detects threat and uses survival mechanisms such as the fight/flight response and activates the sympathetic part of the autonomic nervous system (as indicated by increased heart rate (HR) and skin conductance level (SCL), e.g. Pole et al., 2007), to protect against danger (MacBeth & Gumley, 2012). In contrast, facilitating self-compassion activates the soothing and contentment system (Gilbert, 2009a) characterised by a calm and content positive state and increased parasympathetic activation (as indicated by increased heart rate variability; HRV, Kirschner et al., 2016). This allows the individual to activate self-soothing and kindness and to feel safe and socially connected which reduces the fight/flight state
This effect has been demonstrated by Kirschner (2016) who found that the one-off short-term Loving Kindness Meditation for self-compassion (LKM-S) used in the current study, in a sample of healthy individuals, reduced physiological arousal symptoms; (i.e. reduced HR, SCL) and increased parasympathetic activation (i.e., increased HRV). Storr (2015) also found that civilian trauma survivors with and without PTSD who followed the same LKM-S had a reduction in self-reported negative self and physiological arousal and in the non-symptomatic group there was an increase in positive self. Similarly, Kirschner (2016) found for individuals with a history of recurrent depression, the LKM-S reduced negative perceptions of the self and increased positive self-perception. Additionally, a physiological pattern of calm and content positive affect (reduced HR and SCL and increased HRV) was detected in those patients with recurrent depression who had completed an 8-week MBCT course (Kirschner, 2016). These past studies demonstrate that the LKM-S is effective in firstly eliciting self-compassion in individuals, but also to reduce arousal and increase parasympathetic activation, in clinical and non-clinical samples.

In other treatments for PTSD such as Eye-Movement Desensitisation and Reprocessing (EMDR), reduced psychophysiological responses (HR and SCL) and increased parasympathetic tone (HRV) has also been found for individuals with PTSD following treatment (Sack, 2007; Sack, 2008). Patients who continued to meet PTSD diagnostic criteria following EMDR treatment, compared to those who remitted, held elevated levels of psychophysiological response and may have benefitted from further intervention in order to see reduced psychophysiological arousal and increased parasympathetic tone (Hogberg, et al., 2008). As PTSD causes a chronic overreaction of the threat mode (e.g., Ehlers and Clark, 2000)
people with enduring/more severe PTSD might find it more difficult to benefit from psychological therapies. Therefore, in the current study, the one-off self-compassion experimental induction (i.e., the LKM-S), which activates the soothing and contentment system will be more challenging to those who have higher levels of PTSD which might result in a dose-response effect of that ability i.e., higher levels of PTSD will need more effort and a longer intervention to reduce HR, SCL and increase HRV compared with lower levels of PTSD.

Being in a ‘safe’ state, enables more adaptive coping with stressful and adverse events and leads to a reduction in perceived distress and biological stress response (Gilbert, 2010). This increased ability to tolerate negative emotions and adverse events helps with effective processing of the traumatic event, as for example targeted in exposure-based trauma focused CBT (Cloitre et al., 2012). This first possible mechanism of self-compassion facilitation can be described as reduction of chronic stress by improved emotion regulation and coping, which is on a biological level of reducing the physical stress response and enables effective processing of the event.

Secondly, self-compassion could reduce PTSD symptomology by increasing feelings of social connectedness (e.g., Freedman et al., 2015; Pearlman & Curtois, 2005) and studies have shown that social support is negatively related to PTSD in combat veterans (e.g., Pietrzak, et al., 2009). Serving personnel may feel a sense of safety and security which could help them to regulate emotions more effectively but upon leaving the Armed Forces, the sense of belongingness and social cohesion might be less available (Hachey, et al., 2016). Studies have found that additional personal stress of civilian life can contribute to risk factors of PTSD (Polusny et al., 2011). Facilitating self-compassion in a one-off meditation, has been shown to
increase perceived interpersonal connectedness (Hutcherson, Seppala, & Gross, 2008) and state secure attachment (Kirschner, Karl, & Kuyken, 2013). Therefore, a second mechanism of self-compassion facilitation relevant for AFV is the effect on one of the most consistent risk factors i.e., lack of perceived social support and isolation.

**Self-compassion and the Armed Forces.** The use of self-compassion with AFV with PTSD is in its infancy, however initial studies have found that self-compassion is negatively associated with PTSD (Dahm et al., 2015). Self-compassion levels are predictive of PTSD symptom severity (Hiraoka et al., 2015), and it is negatively related to maladaptive coping strategies such as impulsivity in military recruits (Mantzios, 2014). A study that investigated the effects of a 12-week course of loving kindness meditation (LKM) in veterans with PTSD found that self-compassion increased while symptoms of PTSD decreased (Kearney et al., 2013).

More extensive inquiry has been conducted into moral injury and in particular the relationship between PTSD symptoms and shame in civilian and the AFV population (Saraiya & Lopez-Castro, 2016; Linz et al., 2009). Shame forms an integral part of moral injury and is linked to mental health difficulties in AFV (Linz, et al 2009), which is consistent with the self-compassion literature (Gilbert, 2009a). Shame is significantly associated with hyperarousal symptoms in PTSD (Feiring, & Taska, 2005) and leads to social withdrawal and lack of social connectedness (Litz et al., 2009). Additionally, shame and self-criticism act as a barrier to care and therefore treatments that reduce levels of shame could be beneficial for sufferers of PTSD (Gaudet, Sowers, Nugent, & Boriskin, 2016). Self-compassion has demonstrated effectiveness for shame-based difficulties including PTSD (Lee, 2009) and it may be that self-compassion interventions use mechanisms that are
potentially distinct from other traditional treatments for PTSD (Talkovsky, & Lang, 2017) as it tackles shame specifically (Lee, 2009).

**Loving Kindness Meditation**

The LKM-S used in the current study is a one-off self-compassion experimental manipulation, used in order to determine how self-compassion generates beneficial effects in an AF population. As aforementioned, this is proposed to work through the reduction of chronic stress by reduced arousal and improved emotion regulation and also through increasing social connectedness.

It is proposed that the LKM-S will reduce levels of chronic stress by reducing threat in the affect regulation system as described in Gilbert (2009a) and the sense of ‘current threat’ in Ehlers & Clark (2000) both on an internal (e.g., self-criticism) and external level (e.g., hypervigilance) (Gilbert, 2009a; Ehlers & Clark, 2000). Also, by activating the soothing and contentment system (Gilbert, 2009a), this enables better emotion regulation and coping of stressful events (Gilbert, 2009a). The reduction in arousal symptoms in turn could reduce the perception of ‘current threat’ (Ehlers and Clark, 2000) which may therefore have an effect on reducing the maintenance system of PTSD. Further, the sense of internal threat i.e., perceptions of the self, may play an important role in maintaining PTSD, especially when people find it difficult to generate self-kindness, have a lack of self-compassion and are self-critical which can contribute to the maintenance of PTSD symptoms (Harman & Lee, 2010).

Previous studies using the LKM-S have demonstrated that there is a reduction in self-reported negative self and also increased positive self-perception (Storr, 2015; Kirschner, 2016) which can lead to a ‘broadening mindset’ leading to further positive self-perceptions and building resilience (Kirschner et al., 2013) thus reducing threat systems in Gilbert’s model (2009a) and Ehlers & Clark (2000).
Secondly, facilitating self-compassion through the LKM-S is proposed to increase social connectedness, and previous studies show that a one-off meditation increased perceived interpersonal connectedness (Hutcherson, Seppala, & Gross, 2008). Kirschner et al. (in press) also demonstrated that the LKM-S leads to increased HRV and social connectedness. By activating self-soothing and kindness (i.e., the soothing/contentment system, Gilbert, 2009a) this enables people to feel safe and socially connected, which also in turn reduces the 'threat' state (Gilbert, 2010; Kirschner et al., 2016). This mechanism is likely underpinned by reducing feelings of shame, especially in terms of how one exists both in the minds of the self and of others, which may facilitate people to feel connected to others (Gilbert & Procter, 2011).

Current Study, Aims and Rationale

Little is known about the effects of self-compassion and the AFV population, especially in those with PTSD. Studies suggest that a LKM can reduce symptoms of PTSD in AFV (e.g., Kearney et al., 2013) although to our knowledge there have been no further empirical studies to support this.

The aim of the current study is to investigate the effects of a short-term one-off self-compassion LKM-S in AFV who have been exposed to danger whilst on deployment to a combat zone.

The study will explore pre-post changes on self-report hyperarousal symptoms (DSM-5, PTSD Cluster E) and feelings of social connectedness. As well, exploring physiological reactions before, during and after the meditation will measure the effects of the self-compassion meditation on the fight/flight response.

---

6 The LKM-S focuses first on compassion for a loved one and then for several minutes on the self. This is different from typical LKM where the focus is firstly on the self, then a loved one, then a neutral one and then a difficult person.
Research Questions (RQ) and Hypotheses (H)

RQ1. Does a single self-compassion induction reduce hyperarousal symptoms in AFV, as indicated by a reduction in self-reported hyperarousal symptoms and reduced sympathetic arousal?

H1. It was hypothesised that there would be a decrease in self-reported hyperarousal symptoms following the LKM-S and a reduction in HR and SCL.

RQ2. Does a single self-compassion induction increase feelings of social connectedness in AFV, as indicated by an increase in self-report feelings of social connectedness and parasympathetic activation?

H2. It was hypothesised that there would be an increase in self-reported social connectedness and there would be an increase in HRV.

RQ3. Are PTSD symptoms associated with the extent of change in questions 1 & 2, following the LKM-S?

H3. It was hypothesised that PTSD severity will be associated with the extent of change in questions 1 & 2, given that more severe PTSD presentations can take longer to respond to psychological interventions (Hogberg et al., 2008).

It was also anticipated that self-compassion would be cultivated in AFV, in both those who did and did not have PTSD as indicated by an increase on the self-compassion questions.

Method

Participants Characteristics

Participants were recruited between November 2017 and April 2018 through local veteran charities, NHS services and online via social media platforms (see Appendix B for recruitment strategy). Fifty-three UK AFV (49 men, 4 women) were recruited for the current study. Eligibility criteria included being an AFV and having
deployed to a combat zone during their career which included exposure to danger. Participants were excluded if they had a severe mental health problem such as Schizophrenia or were actively suicidal. Risk was assessed and if participants scored positively on question 9 of the PHQ-9\(^7\) then a full risk assessment was completed. If participants were deemed to be high risk, they were excluded from the study, provided with contact details of Samaritans and advised to contact their mental health service. The researchers gained permission from participants to call their GP to inform them of risk if necessary. Participants were also excluded if they were not able to attend a testing session at the University of Exeter (see Appendix C for full eligibility criteria).

Ages ranged from 30 to 75 and the mean age was M = 52.04 (SD = 13.21).

The prevalence of PTSD was \(n = 19\) in the current sample (those who had received a previous diagnosis from a psychiatrist). Based on scores on the PCL-5, \(n = 15\) (28.3%) currently met criteria for PTSD, \(n = 4\) (7.5%) met criteria for Subsyndromal PTSD\(^8\) on the PCL-5 and \(n = 34\) (64.2%) did not have PTSD. All apart from one of the participants had PTSD symptoms as a result of their deployment experiences to a war zone, \(n = 18\) (34%). One participant had PTSD as a result of an accident on a training operation during a non-combat deployment.

All participants had been deployed to a combat zone which included conflicts such as the Falkland Islands, Northern Ireland, Kosovo, Iraq, and Afghanistan. Deployment length ranged from approximately two months to three years (including leave periods). There was an average of M = 4.06 (SD = 2.61) (Median and Mode = 3) deployments to combat zones per participant. There were \(n = 24\) (45.3%)

---

\(^7\) PHQ-9 Question 9: thoughts that you would be better off dead or hurting yourself in some way.

\(^8\) Subsyndromal PTSD is categorised as endorsing one Cluster B symptom (intrusion symptoms), and one of either cluster C (avoidance), D (negative alterations in cognitions), or E (hyperarousal).
participants who had sustained a physical injury whilst on deployment. Forty-two participants (79.2%) had experienced at least one Traumatic Brain Injury (TBI) (see Table 2).

**Sampling Procedures**

Participants were self-selected and were recruited from a range of veteran organisations and charities in the South West of England, NHS services in Devon and online social media adverts (see Appendix B). Nighty-two people expressed an interest in the study and eighty-one people completed the telephone screening. Sixty-seven participants were eligible and signed up to take part in the study, fourteen participants dropped out at this stage due to reasons such as work commitments and illness. A total of fifty-three participants completed the study (see Figure 3.

**Figure 3. Flow of Participants through the Study.**
Study Procedure

Eligible participants were booked in for a testing session at the University of Exeter following a telephone screening call. The study procedure included collecting demographic information, completing psychometric measures, and listening to the LKM-S (see Figure 4). All participants were paid a small sum of £10 for taking part.

Ethical approval and safety monitoring. Ethical approval was gained by NHS Health Research Authority (17/SW/0158) (see Appendix D) in order to recruit participants from local NHS services. Ethical approval was also gained from the School of Psychology ethics committee at University of Exeter (see Appendix D). Safety monitoring procedures for risk were in place throughout the study, a full risk assessment was completed if risk was identified and a letter was sent to the participant’s General Practitioner (see Appendix E).

Sample Size

Sample size for the current study was determined using G*Power (Faul, Erdfelder, Bucher & Lang, 2009) to calculate a-priori the required sample size. Based on a medium effect size, it was calculated that 55 participants were needed for a statistical power of .8 and alpha = .05 (see Appendix F for details).

Measures

Demographic information. Demographic information (see Appendix G) was collected (see Table 1) including age, gender, and current employment and information about their Armed Forces career such as deployments, time served and reason for discharge.

TBI assessment. Due to associations between brain injury and combat related PTSD (e.g., Belanger, Kretzmer, Vanderploeg & French, 2009), participants
were assessed for TBI and it was classified as per the work of Williams, Cordan, Mewse Tonks & Burgess (2010) (see Appendix H) (see Table 2).

**Posttraumatic stress disorder.** PTSD was measured by the PTSD Checklist for DSM-5 (PCL-5; Weathers, et al., 2013) (see Appendix I). Validation studies for the PCL-5 show strong internal consistency (α = .94), test-retest reliability (r = .82), and convergent (rs = .74 to .85) and discriminant validity (rs = .31 to .60) (Blevins, Weathers, Davis, Witte & Domino, 2015).

**Patient Health Questionnaire for Depression.** The Patient Health Questionnaire for depression (PHQ-9; Kroenke, Spitzer & Williams, 2001) (see Appendix I) was used to establish levels of depression as well as to screen for suicidal risk, as per the exclusion criteria. The PHQ-9 has excellent reliability, internal = .89 and test re-test = .84 and validity for detecting depression = .95 (Solomon et al., 2000).

**Emotional Regulation Questionnaire.** The Emotional Regulation Questionnaire (ERQ, Gross & John, 2003) (see Appendix I) was used to determine participants’ ability to regulate their emotions in terms of cognitive reappraisal and expressive suppression. Differences in these traits may affect the course of trauma, therefore this is important to measure at baseline. Prior research has shown that the ERQ has high internal reliability, and convergent and discriminant validity (Gross & John, 2003).

**Trait self-compassion.** To measure differences in participants’ trait level of self-compassion prior to the LKM-S, a short form of the Self-Compassion Scale (SCS; Neff, 2011) was used (SCS-SF; Raes, Pommier, Neff & Van Gucht, 2011).

---

9 Cognitive Reappraisal is cognitive change which can alter how we interpret a situation and therefore changes the emotional response (Lazarus & Alfert, 1964).

10 Expressive Suppression is the ability to inhibit the emotive-expressive behaviour triggered by an emotional response (Gross, 1998).
Loving kindness meditation (LKM-S). A self-compassion LKM-S (see Appendix J) was used to induce self-compassion in the current study. The LKM-S has been developed by the ACCEPT clinic, at the University of Exeter Mood Disorder Centre. The LKM-S audio clip was recorded by an experienced mindfulness practitioner, and the LKM-S has been used in prior research (e.g., Kirschner, 2013). Participants are asked to direct loving/friendly feelings towards themselves and others and the audio is 11.5 minutes in length.

Experimental Measures

Visual analogue scales. Visual Analogue scales (VAS, ranging from 0-100) (see Appendix K) were used to establish state levels of self-compassion, hyperarousal and social connectedness before and after the LKM-S. This measure is adapted from Kirschner, et al., (2013) and questions are taken from the Self-Compassion Scale (SCS; Neff, 2003a), social connectedness questions are based on the state adult attachment measure (SAAM; Gillath, Noftle, & Stockdale, 2009) and four adapted items from the PCL-5 have been added to measure state hyperarousal. The VAS has been used in previous studies (Kirschner et al., 2016) which found Cronbach’s α = .66 for state affiliative affect, state self-compassion (Cronbach’s α = .73 in this sample) and state self-criticism (Cronbach’s alpha in this sample was .73 for the inadequate self, .76 for the hated self, and .77 for the reassure self).
Physiological measurement. All physiological parameters were recorded continuously using a BIOPAC MP150 system using the AcqKnowledge 4.2 (BIOPAC Systems; Goleta, CA) software.

Heart rate (HR) and heart rate variability (HRV). HR and HRV was determined from the electrocardiogram (ECG) using standard procedures (Berntson et al., 1997, 1998). ECG was recorded from below the participant’s right collar bone and the participant’s left lower ribcage using a BIOPAC ECG100C amplifier at a sampling rate of 1 kHz with a low pass filter of .5 Hz and a high pass filter of 35 Hz.

Skin conductance levels (SCL). SCL was recorded using a BIOPAC SCL100C amplifier and a skin resistant transducer (TSD203) from the middle phalanx of the first and second fingers of the participant’s non-dominant hand at a sampling rate of 500 Hz with a low pass filter of 1.0 Hz. SCL was pre-processed using recommended procedures (Lykken et al., 1966).

Data Collection

Data was collected by the principle investigator as part of the Doctorate in Clinical Psychology programme and third year BSc Psychology students from the University of Exeter.

Research Design

The study used a repeated measures design to test the hypotheses, using outcome score at Time 1 (pre-LKM-S) and Time 2 (post-LKM-S) as dependent variables. The variables are hyperarousal, social connectedness, self-compassion, HR, HRV and SCL. To test hypothesis 3, residualised gains scores (RGS) were calculated for hyperarousal and social connectedness, which were used as outcome variables, with PCL scores, SCL, social connectedness and hyperarousal as
predictors. State self-compassion was used as a manipulation check to determine whether the LKM-S induced self-compassion in participants.

**Experimental Procedure**

The experimental procedure (see Figure 4) included answering demographic questions, completing psychometric measures and listening to the LKM-S, all of which lasted approximately 1-1.5 hours. Standardised instructions were given for the VAS questions and LKM-S audio.

---

**Figure 4. Experimental Procedure.**
**Statistical Methods**

There was missing psychophysiological data for one participant therefore the analysis for psychophysiological data is based on 52 participants. No other missing data was detected in the data set.

**Assumption testing.** Outliers were detected after examining boxplots: inspection of their values did not reveal them to be extreme, so they were kept in the analysis. These data points were changed to the next closest value that was under the cut off which is a technique for dealing with outliers, whilst maintaining the shape of the sample distribution, but the outliers do not distort the data (Tabachnick & Fidell, 2007). Assumptions of normality were not violated. For the regression analysis, assumptions of independence of observations, linearity, homoscedacity, normality and multicollinearity were all fulfilled (see Appendix L) for a detailed description of assumption testing).

**Physiological Data Processing**

Data pre-processing and further statistical analyses of the psychophysiological data followed established procedures; i.e., determining the size of the response in relation to a pre-induction baseline as per previous studies (Kirschner et al., 2013, 2016; Storr et al., 2015) (see Appendix M, for detailed description).

**Manipulation Checks and Hypothesis Testing**

To test the hypotheses, paired sample t-tests were used to examine pre and post scores and one sample t-tests were used for the psychophysiological data to determine whether scores differed from zero (i.e., HR, HRV; as index of parasympathetic activation and SCL as measure of sympathetic arousal). For self-report measures of hyperarousal, social connectedness and self-compassion on the
VAS, the data was collected at two time points (pre and post the LKM-S). Correlations and regression analysis were used to examine the influence of PTSD severity on scores on the outcome variables.

Results

Sample Characteristics and Analyses

Demographic information for participants is displayed in Table 1, results from the TBI screening are displayed in Table 2 (see Appendix N), and continuous data for each of the primary outcome measures is displayed in Table 3. Zero-order correlations for all variables are included in Table 4 (see Appendix O).

Table 1.

Demographic Information.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N = 53</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, no. %</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>4 (7.55)</td>
</tr>
<tr>
<td>Male</td>
<td>49 (92.5)</td>
</tr>
<tr>
<td>Age, mean (SD), years</td>
<td>52.0 (13.2)</td>
</tr>
<tr>
<td>Marital Status, no. %</td>
<td></td>
</tr>
<tr>
<td>Married</td>
<td>36 (67.9)</td>
</tr>
<tr>
<td>Single</td>
<td>5 (9.43)</td>
</tr>
<tr>
<td>Divorced/separated</td>
<td>5 (9.43)</td>
</tr>
<tr>
<td>Cohabiting</td>
<td>4 (7.55)</td>
</tr>
<tr>
<td>Engaged</td>
<td>3 (5.66)</td>
</tr>
<tr>
<td>Religion, no. %</td>
<td></td>
</tr>
<tr>
<td>No religion</td>
<td>20 (37.7)</td>
</tr>
<tr>
<td>Church of England</td>
<td>23 (43.4)</td>
</tr>
<tr>
<td>Catholic</td>
<td>3 (5.66)</td>
</tr>
<tr>
<td>Buddhist</td>
<td>2 (3.77)</td>
</tr>
<tr>
<td>Methodist</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Other</td>
<td>2 (3.77)</td>
</tr>
<tr>
<td>Not stated</td>
<td>2 (3.77)</td>
</tr>
</tbody>
</table>
### Table 1: Demographic Characteristics of Veterans sample N = 53

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Occupation, no. %</strong></td>
<td></td>
</tr>
<tr>
<td>Employed Full-Time</td>
<td>24 (45.3)</td>
</tr>
<tr>
<td>Employed Part-Time</td>
<td>13 (24.5)</td>
</tr>
<tr>
<td>Retired</td>
<td>15 (28.3)</td>
</tr>
<tr>
<td>Unemployed</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td><strong>Nationality, no. %</strong></td>
<td></td>
</tr>
<tr>
<td>British</td>
<td>51 (96.2)</td>
</tr>
<tr>
<td>Dual British Nationality</td>
<td>2 (3.77)</td>
</tr>
<tr>
<td><strong>Armed Forces Branch, no. %</strong></td>
<td></td>
</tr>
<tr>
<td>British Army</td>
<td>5 (9.43)</td>
</tr>
<tr>
<td>Royal Navy</td>
<td>27 (50.9)</td>
</tr>
<tr>
<td>Royal Marines</td>
<td>5 (9.43)</td>
</tr>
<tr>
<td>Royal Air Force</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Army Reserves</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Royal Marines Reserves</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Special Forces</td>
<td></td>
</tr>
<tr>
<td><strong>Rank at Discharge, no. %</strong></td>
<td></td>
</tr>
<tr>
<td>Colonel</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Lieutenant-Colonel</td>
<td>4 (7.55)</td>
</tr>
<tr>
<td>Major/ Lieutenant Commander</td>
<td>5 (9.43)</td>
</tr>
<tr>
<td>Captain/ Flight Lieutenant</td>
<td>7 (13.2)</td>
</tr>
<tr>
<td>Sub-Lieutenant</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Sergeant Major</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Warrant Officer 1st Class</td>
<td>3 (5.66)</td>
</tr>
<tr>
<td>Warrant Officer 2nd Class</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>Sergeant</td>
<td>9 (17.0)</td>
</tr>
<tr>
<td>Corporal/ Leading Hand</td>
<td>9 (17.0)</td>
</tr>
<tr>
<td>Lance Corporal/ Junior technician</td>
<td>5 (9.43)</td>
</tr>
<tr>
<td>Private/Marine/Senior Aircraftman</td>
<td>6 (11.3)</td>
</tr>
<tr>
<td><strong>Physical Injury on Deployment, no. %</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>24 (45.3)</td>
</tr>
<tr>
<td>No</td>
<td>29 (54.7)</td>
</tr>
<tr>
<td><strong>PTSD from Combat Experiences, no. %</strong></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>18 (34)</td>
</tr>
<tr>
<td>No</td>
<td>35 (66)</td>
</tr>
</tbody>
</table>
Table 3.

**Primary Outcome Measures.**

<table>
<thead>
<tr>
<th>Variable</th>
<th>N = 53</th>
<th>Mean (SD)</th>
<th>N = 53</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Self-compassion manipulation</td>
<td>53</td>
<td>55.21 (25.70)</td>
<td>53</td>
<td>65.78 (22.84)</td>
</tr>
<tr>
<td>VAS Hyperarousal</td>
<td>53</td>
<td>35.56 (20.78)</td>
<td>53</td>
<td>27.33 (13.08)</td>
</tr>
<tr>
<td>VAS Social Connectedness</td>
<td>53</td>
<td>61.52 (20.13)</td>
<td>53</td>
<td>63.66 (16.79)</td>
</tr>
<tr>
<td>PCL Total</td>
<td>53</td>
<td>22.13 (20.94)</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>SCS-SF</td>
<td>53</td>
<td>36.62 (8.00)</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>PHQ9</td>
<td>53</td>
<td>6.60 (7.33)</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>ERQ Cognitive Appraisal</td>
<td>53</td>
<td>4.48 (1.36)</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>ERQ Expression Suppression</td>
<td>53</td>
<td>3.94 (1.55)</td>
<td></td>
<td>-</td>
</tr>
</tbody>
</table>

**Self-compassion Manipulation Checks**

Paired-samples t-tests were used as a manipulation check for self-compassion levels pre and post the LKM-S comprising questions 3\(^{11}\) and 4\(^{12}\) on the VAS. There was a significant increase in the score for self-compassion from pre-LKM-S (M= 55.21, SD= 25.70) to post-LKM-S (M= 65.78, SD = 22.84) conditions; \(t\) (52) = -3.68, \(p = 0.001\), Cohen’s \(d = - .51\). This indicates that the self-compassion exercise was successful in cultivating self-compassion and created a medium effect size was observed.

Q1. Does a single self-compassion induction reduce hyperarousal symptoms in AFV, as indicated by a reduction in self-reported hyperarousal symptoms and reduced physiological arousal?

\(^{11}\) ‘I do/do not feel like being kind and understanding towards myself’.

\(^{12}\) ‘I am/am not tolerant of my flaws and inadequacies’.
**Self-reported hyperarousal.** A paired-samples t-test was conducted to compare hyperarousal pre and post the LKM-S. There was a significant reduction in scores from pre-LKM (M= 35.56, SD= 20.78) to post-LKM-S (M = 27.33, SD = 13.08) conditions, t (52) = 4.14, p = .000, Cohen’s d = 0.66. This indicates that the LKM-S reduced self-reported hyperarousal symptoms and a medium effect size was observed.

**Physiological arousal.**

**Skin conductance (SCL) response.** A one-sample t-test revealed that mean SCL response (M = -0.04, SD = 0.06) was significantly lower than zero, t (51) = -4.45, p < .001, Cohen’s d = -.62. This indicates that a one-off LKM-S did significantly reduce physiological arousal as indicated by SCL and a medium effect size was observed.

**Heart rate (HR) response.** A one-sample t-test revealed that mean HR response (M = 0.68, SD = 2.56) did not significantly differ from zero, t (51) = 1.92, p = .06, Cohen’s d = .27 This indicates that a one-off LKM-S did not significantly reduce physiological arousal as indicated by HR.

Overall, hypothesis 1 was partially confirmed by significant pre-post changes in self-reported hyperarousal and reduced physiological arousal as indicated by the SCL. However, results from HR did not support hypothesis 1 as HR was not significantly reduced as a result of the LKM-S.

**Q2. Does a single self-compassion induction increase feelings of social connectedness in AFV, as indicated by an increase in self-report feelings of social connectedness and parasympathetic activation?**

**Self-reported social connectedness change.** A paired-samples t-test was conducted to compare social connectedness pre and post the LKM-S. There was not
a significant difference in the score for pre-LKM (M= 61.52, SD= 20.13) and post-
LKM-S (M= 63.66, SD = 16.79) conditions; t (52) = -1.46, p = .15, Cohen’s d = - .21.
This indicated that the LKM-S did not significantly increase social connectedness.

Parasympathetic activation.

Heart rate variability (HRV) response. A one-sample t-test revealed that
mean HRV response (M = -0.09, SD = 1.0) did not significantly differ from zero, t (51)
= - .63, p = 0.53, Cohen’s d = - .09. This indicates that a one-off LKM-S did not
significantly increase parasympathetic activation as indicated by HRV.

Overall hypothesis 2 was not confirmed as there were not significant pre-post
changes in self-reported social connectedness following the LKM-S or increased
parasympathetic activation as indicated by HRV.

Q3. Are PTSD symptoms associated with the extent of change in state
hyperarousal and social connectedness and SCL, HR and HRV response
following the LKM-S?

Self-report VAS

Hyperarousal change. Table 4 shows that hyperarousal change was
significantly positively correlated with PCL Intrusions, PCL Avoidance and negatively
correlated with social connectedness. However, hyperarousal change was not
significantly correlated with PCL total score.

A multiple regression was run to test if change in social connectedness, PCL
intrusions and PCL avoidance significantly predicted change in hyperarousal
following the LKM-S. The overall model was significant with $R^2 = 0.16, F (3,49) =
3.07, p = 0.04$ and explained 16% of variance. Only social connectedness change
was a significant predictor ($\beta = -.27, p = 0.05$) but PCL Intrusions ($\beta = 0.24, p =$
0.41) and PCL Avoidance ($\beta = - .002, p = .99$) did not significantly explain change in hyperarousal. This indicates that higher increases in social connectedness were associated with greater reductions in state hyperarousal to LKM-S but PTSD symptoms intrusions and avoidance did not contribute to explain state hyperarousal change.

**Social connectedness change.** Table 4 shows that social connectedness change was significantly negatively correlated with change in hyperarousal, and Mean SCL response, and significantly positively correlated with self-compassion score. However, social connectedness was not significantly correlated with PCL total score.

A multiple regression was run to test if change in hyperarousal, self-compassion score and Mean SCL response significantly predicted change in social connectedness following the LKM-S. The overall model was significant with $R^2 = 0.26$, $F (3,48) = 5.58$, $p = 0.02$, and explained 26% of variance. SCL Mean response was the only significant predictor ($\beta = - .33, p = 0.01$) for change in state social connectedness. Self-compassion was not a significant predictor ($\beta = .25, p = 0.054$) and change in hyperarousal did not make a significant contribution ($\beta = - .22, p = 0.10$). This indicates that greater reductions in SCL were associated with greater increases in state social connectedness whereas neither change in state hyperarousal to LKM-S, self-compassion score, nor PTSD symptoms explained significant variance.

**Physiological arousal.**

**Mean SCL response.** Mean SCL response was significantly positively correlated with PCL avoidance and social connectedness, but it was not significantly correlated with the PCL total score.
A multiple regression was run with Mean SCL response as the outcome, and change in social connectedness and PCL avoidance as predictors. The overall model was significant with $R^2 = .18$, $F(2,49) = 5.24$, $p = 0.009$, and explained 18% of variance. Only change in social connectedness significantly predicted Mean SCL response (Beta = -.30, $p = 0.03$) whereas PCL avoidance ($\beta = .23$, $p = .10$) did not significant explain variance. As described above, greater reductions in SCL were associated with higher increases in social connectedness whereas PTSD symptoms did not explain LKM-S related SCL changes.

**Mean HR response.** Table 4 indicates that Mean HR was not significantly correlated with total PCL score or with PCL subscales nor was it associated with any other self-report measure (see Table 4). Therefore, no regression analyses was performed.

**Parasympathetic activation.**

**Mean HRV.** Table 4 indicates that Mean HRV was not significantly correlated with total PCL score or with PCL subscales nor was it associated with any other self-report measure (see Table 4). Therefore, no regression analysis was performed.

Overall, hypothesis 3 was only partially confirmed as hyperarousal change was associated with PTSD intrusions and avoidance symptoms and social connectedness change however, in the regression only social connectedness change came out a significant predictor.

Social connectedness change was significantly negatively correlated with change in hyperarousal, and SCL response, and significantly positively correlated with self-compassion score however, in the regression SCL response was the only significant predictor.
Mean SCL response was the only psychophysiological measures associated with PCL avoidance and social connectedness, but in the regression, only social connectedness was the significant predictor.

**Exploratory Findings**

**ERQ (Expression and suppression).** ERQ (emotional suppression) was positively correlated with PCL total and all PCL subscales, and negatively with self-compassion (Table 4, see Appendix O).

**Discussion**

The current study investigated self-report and psychophysiological effects of a one-off self-compassion meditation (LKM-S) in AFV who had been exposed to combat with varying levels of PTSD symptom severity. In line with previous research conducted in both healthy and clinical samples with recurrent depression (Kirschner, 2016) and in trauma survivors with and without PTSD (Storr, 2015), this study found that self-reported state self-compassion was significantly increased following a one-off self-compassion meditation. Extending previous research (e.g., Kirschner, 2016), the LKM-S was not only accompanied by a reduction in skin conductance but also self-reported hyperarousal symptoms.

Contrary to previous research (Hutcherson, et al., 2008; Kirschner, 2016) the study failed to reveal a significant reduction in HR and a significant increase in state social connectedness and parasympathetic activation as indicated by HRV following the self-compassion meditation. In addition, contrary to the hypotheses, LKM-S induced self-report and physiological changes were largely not associated with PTSD severity, apart from PCL avoidance which was positively associated with SCL mean response, and reduction of hyperarousal was associated with lower PCL intrusion and avoidance symptoms. Although zero order correlations indicated that
the reduction of hyperarousal following the LKM-S is associated with lower PTSD symptoms (intrusions and avoidance), and PCL avoidance score is associated with reduced sympathetic activation i.e., Mean SCL score, in the regression these variables did not come out as significant predictors.

Associations between PTSD severity and key variables were largely not found following the LKM-S. This may be explained by the type of trauma experienced by participants in the current study as combat related PTSD can present with elevated hyperarousal symptoms compared with civilian traumas (Kimble et al., 2013; Prescott, 2012) and arguably leads to more severe PTSD compared with non-interpersonal trauma (Yoo, et al., 2018). In the current study, participants with and without PTSD had all experienced deployment to a combat zone where interpersonal trauma and a need to remain hypervigilant is commonplace (Conoscenti, et al., 2009). Additionally, bearing witness to ‘human-caused’ traumatic events can lead to a breakdown in a sense of safety and social norms and compromise trust in others (Charuvastra & Cloitre, 2009) therefore this might have made it difficult to cultivate feelings of safety and social connectedness in the LKM-S.

The associations between PCL avoidance and SCL mean response might mean that those with higher sympathetic arousal levels utilise avoidance strategies (e.g., avoiding memories related to the trauma) more so than those with lower sympathetic responses. Additionally, the PCL total score was correlated with ERQ emotion suppression score (e.g., ‘I control my emotions by not expressing them’). This might suggest that avoiding reminders of the traumatic event, as well as suppressing emotions, leads to an elevated threat state (Gilbert, 2009a) and forms part of the maintenance cycle in PTSD (e.g., Ehlers & Clark, 2000).
Self-compassion was also negatively related to emotion suppression and also PCL total score which might suggest that people with higher levels of PTSD and those who tend to suppress their emotions, might find self-compassion difficult to engage with. Previous studies have demonstrated that some have a fearful response to self-compassion particularly if people have experienced childhood adversity (Gilbert, 2010a). Additionally, PTSD cluster D symptoms\textsuperscript{13} which could indicate an increased sense of threat from the self and others was negatively associated with trait self-compassion score.

This is in line with previous research (e.g., Gilbert, 2009a), whereby some people find affiliative emotions threatening rather than pleasant (Gilbert, 2010) and self-compassion inductions can lower HRV especially in self-critical people (Glover, 2008). Therefore, in the current study high levels of self-criticism may have prevented an increase in parasympathetic activation as indicated by HRV and self-report social connectedness. However, associations were not found between the key variables and PTSD cluster D symptoms which was expected given that PTSD has been related to negative posttraumatic cognitions about the world and others (Ehlers & Clark, 2000).

Although significant changes were not found in social connectedness pre-post the LKM-S, the change in social connectedness was associated with both a change in hyperarousal and also mean SCL. Despite it not being supported by an increase in parasympathetic activation (i.e., HR and HRV), there was a relationship between social connectedness change and reduction in sympathetic response and self-reported hyperarousal. These changes in part, support our predictions of where the

\textsuperscript{13}i.e., Persistent and exaggerated negative beliefs or expectations about oneself, others, or the world (APA, 2013)
LKM-S would work in already established models (Gilbert, 2009a; Ehlers & Clark, 2000), whereby the LKM-S elicited a reduction in arousal and the ‘threat’ systems in the affect regulation model (Gilbert, 2009a) and cognitive model of PTSD (Ehlers & Clark, 2000). However, as significant changes were not found for social connectedness, this might mean that a longer intervention might be needed in order to increase feelings of social connectedness and also have an increase in HRV, in AFV whereby the ‘soothing/contentment system’ is activated as per the affect regulation model (Gilbert, 2009a).

The discrepancy between the self-report measures and physiological measures means that results should be interpreted with caution and has been noted in previous studies, where changes were not observed on all physiological measures of parasympathetic activation following the LKM-S (e.g, Kirschner, 2016; Storr, 2015). However, studies show that after an 8-week Mindfulness Based Cognitive Therapy (Kirschner, 2016), participants demonstrated concordant results of self-report measures and psychophysiological response, therefore, further investigation is warranted into the conditions in which the LKM-S facilitates concordant changes in self-report and psychophysiological measures in AFV, which may include an intervention of longer duration as per previous studies (e.g., Kok, et al., 2013; Kearney et al., 2013). Also, as PTSD is associated with lower levels of baseline/resting HRV and poor autonomic functioning (Dennis et al., 2014), a longer intervention may be needed in order to elicit parasympathetic activation in AFV. By activating self-compassion i.e., the soothing and parasympathetic nervous system (Kirschner, 2016), this may enable people to engage with difficult emotions without judgement which can lead to healthier psychological functioning (Schanche, Stiles, McCollough, Swartberg, & Nielsen, 2011) and may be important in alleviating PTSD.
symptoms in AFV. In addition, social connectedness and experiencing safety among others, may have the capacity to inhibit circuits implicated in the fight/flight response (Williamson et al., 2015).

Overall, the results from the current study demonstrate that a one-off, LKM-S can temporarily reduce self-reported symptoms of hyperarousal and sympathetic arousal as indicated by skin conductance, which may be useful in treatment of PTSD. In future settings, it may be beneficial for self-compassion interventions to be utilised as a stand-alone PTSD treatment (e.g., Lee, 2009) or if hyperarousal symptoms remain after PTSD specific therapy (Zayfert, & DeViva, 2004).

Strengths, Limitations and Future Research

This is the first study to investigate the effects of a one-off self-compassion meditation in an AFV population, using measures of psychophysiology, self-compassion and self-report state measures. A large sample was recruited in a short time-frame (5 months) and participants travelled from outside of the UK to participate, which shows promise for recruitment in future AFV studies.

In the current study, changes in state self-compassion, state-hyperarousal and state social-connectedness were assessed, which is different from previous research (e.g., Storr, 2015) that used trait and dispositional measures which are not susceptible to change. In addition, self-report measures were complemented with psychophysiological measures which provides an objective measure of sympathetic and parasympathetic activation. In addition, the correlational approach used in the current study provides an understanding of the relationships between self-report state measures, PTSD and psychophysiological results.

Limitations of the current study include that the recruitment target was not achieved (by two participants), therefore the results should be interpreted with
caution and need to be replicated in a larger sample. Our sample was predominantly male (92.5%) which did not enable us to test for gender differences as discussed in Crum-Cianflone & Jacobson (2014).

Additionally, the correlational approach taken and absence of a control group without combat exposure, or comparison of a control group with a PTSD group, means that conclusions about the impact of self-compassion on a PTSD group versus a control sample cannot be established.

The study only measured changes in self-compassion immediately after the session and did not include a follow-up session at a later date. Therefore, there is the possibility that the shift in self-compassion is only temporary and the gains are not maintained. In more intensive interventions with longer duration shown to elicit self-compassion, changes in self-compassion is long lasting and it is maintained at 6-month and 1-year follow-up (e.g., Germer & Neff, 2013).

Participant trauma history was restricted to time in the Armed Forces however studies investigating childhood adversity in AFV have established that early trauma experiences can contribute to the development PTSD (Iverson et al., 2007). Assessing childhood trauma was outside the remit of ethical approval in the current study, however, in future it would be important to measure to establish whether this affects individuals’ ability to elicit self-compassion (e.g., Gilbert, 2010). This may be important for establishing dose-response effects or treatment adaptations.

**Conclusion**

The study has partially demonstrated that self-compassion can be elicited in AFV who have experienced combat, after just a short LKM-S. Our findings support other studies that have investigated self-compassion (e.g., Kirschner, 2016) and self-compassion in AFV (e.g., Kearney et al., 2013). However, the evidence base for self-
compassion in the AFV population is small and further studies are needed in order to
establish whether self-compassion interventions are a suitable treatment option for
PTSD.

To our knowledge, this is the first study of its kind, and it is hoped that this will,
along with other studies (e.g., Kearney et al., 2013) enable further investigation into
self-compassion approaches to treat PTSD. Psychological therapies are less
effective for combat trauma compared with other types of trauma (Bradley, Greene,
Russ, Dutra, & Westen, 2005) and therefore further research needs to be conducted
in order to establish effective treatments for PTSD in the AFV population.

The study has highlighted that although self-compassion can be elicited in
AFV, new interventions need to be implemented with caution, as differences exist
such as the severity of hypervigilance symptoms (Prescott, 2012).

Moving forward, future research should investigate the effects of longer-term
self-compassion interventions in the AFV population as per the work of Neff and
colleagues (e.g., Germer & Neff, 2015).
References


Neff, K. D., & Germer, C. K. (2013). A pilot study and randomized controlled trial of
the mindful self-compassion program. *Journal of Clinical Psychology, 00*, 1-17.


framework: Relational treatment of complex trauma. *Journal of Traumatic
Stress, 18*, 449-459.

Pietrzak, R. H., Johnson, D. C., Goldstein, M. B., Malley, J. C., & Southwick, S. M.
(2009). Psychological resilience and postdeployment social support protect
against traumatic stress and depressive symptoms in soldiers returning from
operations enduring freedom and Iraqi freedom. *Depression and Anxiety, 26*,
745-751.


(2011). Prospective risk factors of new-onset posttraumatic stress disorder in
National Guard soldiers deployed to Iraq. *Psychological Medicine, 41*, 687-
698.

Prescott, M. R. (2012). The differences between war and civilian related traumatic
events and the presentation of posttraumatic stress disorder and suicidal
ideation in a sample of National Guard soldiers (Doctoral dissertation,
Mailman School of Public Health).
Retrieved from
https://deepblue.lib.umich.edu/bitstream/handle/2027.42/91481/mrpresco_1.pdf?sequence=1


Appendices

This section includes information supplementing the main manuscript.

Appendix A. Posttraumatic Stress Disorder Diagnostic Criteria (Diagnostic and statistical manual of mental disorders (5th ed.); APA, 2013) 133

Appendix B. Recruitment Strategy 134

Appendix C. Inclusion and Exclusion Criteria 136

Appendix D. Ethical Approval Documents 137

Appendix E. Example Letter to GP 150

Appendix F. Power Calculation 151

Appendix G. Demographic Information Questionnaire 152

Appendix H. TBI Assessment 154

Appendix I. PCL-5, PHQ-9, SCS-SF, ERQ 155

Appendix J. LKM-S 160

Appendix K. VAS 162

Appendix L. Assumption Testing 163

Appendix M. Physiological Data Processing 165

Appendix N. TBI Results (Table 2). 167

Appendix O. Zero Order Correltaions (Table 4). 168

Appendix P. Dissemination Statement 170

Appendix Q. Journal of Clinical and Consulting Psychology Instructions for Authors 171
## Appendix A

### Posttraumatic Stress Disorder Diagnostic Criteria (Diagnostic and statistical manual of mental disorders (5th ed.); APA, 2013)

<table>
<thead>
<tr>
<th>Criterion</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
<td>Exposure to actual or threatened death, serious injury, or sexual violence in one (or more) of the following ways: 1. Directly experiencing the traumatic event(s). 2. Witnessing, in person, the event(s) as it occurred to others. 3. Learning that the traumatic events(s) occurred to a close family member or close friend. In cases of actual or threatened death of a family member or death, the event(s) must have been violent or accidental. 4. Experiencing repeated or extreme exposure to aversive details of the traumatic event(s) (e.g., first responders collecting human remains; police officers repeatedly exposed to details of child abuse).</td>
</tr>
<tr>
<td><strong>B</strong></td>
<td>Presence of one (or more) of the following intrusion symptoms associated with the traumatic event(s), beginning after the traumatic event(s) occurred: 1. Recurrent, involuntary, and intrusive distressing memories of the traumatic event(s). Note: In children older than 6 years, repetitive play may occur in which themes or aspects of the traumatic event(s) are expressed. 2. Recurrent distressing dreams in which the content and/or affect of the dream are related to the traumatic event(s). Note: In children, there may be frightening dreams without recognizable content. 3. Dissociative reactions (e.g., flashbacks) in which the individual feels or acts as if the traumatic event(s) were recurring. (Such reactions may occur on a continuum, with the most extreme expression being a complete loss of awareness of present surroundings.) Note: In children, trauma-specific re-enactment may occur in play. 4. Intense or prolonged psychological distress at exposure to internal or external cues that symbolize or resemble an aspect of the traumatic event(s). 5. Marked physiological reactions to internal or external cues that symbolize or resemble an aspect of the traumatic event(s).</td>
</tr>
<tr>
<td><strong>C</strong></td>
<td>Persistent avoidance of stimuli associated with the traumatic event(s), beginning after the traumatic event(s) occurred, as evidenced by one or both of the following: 1. Avoidance of or efforts to avoid external reminders (people, places, conversations, activities, objects, situations) that arouse distressing memories, thoughts, or feelings about or closely associated with the traumatic event(s). 2. Avoidance of or efforts to avoid external reminders (people, places, conversations, activities, objects, situations) that arouse distressing memories, thoughts, or feelings about or closely associated with the traumatic event(s).</td>
</tr>
<tr>
<td><strong>D</strong></td>
<td>Negative alterations in cognitions and mood associated with the traumatic event(s), beginning or worsening after the traumatic event(s) occurred, as evidence by two (or more) of the following: 1. Inability to remember an important aspect of the traumatic event(s) (typically due to dissociative amnesia and not to other factors such as head injury, alcohol, or drugs). 2. Persistent and exaggerated negative beliefs or expectations about oneself, others, or the world (e.g., “I am bad,” “No one can be trusted,” “The world is completely dangerous,” “My who nervous system is permanently ruined”). 3. Persistent, distorted cognitions about the cause or consequences of the traumatic event(s) that lead the individual to blame himself/herself or others. 4. Persistent negative emotional state (e.g., fear, horror, anger, guilt, or shame). 5. Markedly diminished interest or participation in significant activities. 6. Feelings of detachment or estrangements from others. 7. Persistent inability to experience positive emotions (e.g., inability to experience happiness, satisfaction, or loving feelings).</td>
</tr>
<tr>
<td><strong>E</strong></td>
<td>Marked alterations in arousal and reactivity associated with the traumatic event(s), beginning or worsening after the traumatic event(s) occurred, as evidence by two (or more) of the following: 1. Irritable behaviour and angry outbursts (with little or no provocation) typically expressed as verbal or physical aggression toward people or objects. 2. Reducless or self-destructive behaviour. 3. Hypervigilance. 4. Exaggerated startle response. 5. Problems with concentration. 6. Sleep disturbance (e.g., difficulty falling or staying asleep or restless sleep).</td>
</tr>
<tr>
<td><strong>F</strong></td>
<td>Duration of the disturbance (Criteria B, C, D, and E) is more than 1 month.</td>
</tr>
<tr>
<td><strong>G</strong></td>
<td>The disturbance causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.</td>
</tr>
<tr>
<td><strong>H</strong></td>
<td>The disturbance is not attributable to the physiological effects of a substance (e.g., medication, alcohol) or another medical condition.</td>
</tr>
</tbody>
</table>
### Appendix B

**Recruitment Strategy**

#### Poster Distribution

<table>
<thead>
<tr>
<th>Black Horse</th>
<th>Phoenix Sound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bowling Green</td>
<td>Waterstones</td>
</tr>
<tr>
<td>Henry's</td>
<td>Steve's Gym</td>
</tr>
<tr>
<td>Co-Op on Penny C road</td>
<td>Newton Abbot Library</td>
</tr>
<tr>
<td>Boston Tea Party</td>
<td>Newton Abbot Train Station</td>
</tr>
<tr>
<td>Sainsburys in the Guildhall</td>
<td>Knotts deli &amp; Bakery</td>
</tr>
<tr>
<td>The Plant Café</td>
<td>Nature's Bounty health shop</td>
</tr>
<tr>
<td>Guildhall leaflet stand</td>
<td>Newton Barbers</td>
</tr>
<tr>
<td>Devon Coffee notice board</td>
<td>Coffee Couture</td>
</tr>
<tr>
<td>Cathedral staff notice board</td>
<td>Argos- staff board</td>
</tr>
<tr>
<td>Oxfam notice board x 2</td>
<td>British Heart Foundation-staff board</td>
</tr>
<tr>
<td>RSPCA</td>
<td>Spar- staff board</td>
</tr>
<tr>
<td>Hair a No.5</td>
<td>St David's Community Centre</td>
</tr>
<tr>
<td>London Town Barbers</td>
<td>Queens building</td>
</tr>
<tr>
<td>Waterstones notice board</td>
<td>Camper Coffee</td>
</tr>
<tr>
<td>City Barbers</td>
<td>The Kit Shop</td>
</tr>
<tr>
<td>Trail Outdoors</td>
<td></td>
</tr>
</tbody>
</table>

**Online Advertising**

- CTC Lympstone family support group.
- Royal Marine Partners support group.
- Stonehouse 30 Commando Support Group
- UK Wags
- Post on personal facebook, shared 3 times.

**Other Advertising**

- The Warrior Programme – Hannah's House Newton Abbott
- Devon Partnership Trust (DPT):
- Meeting with clinicians at Veterans Service, poster displayed in Psychological Therapies Service (waiting room), email to all clinicians at Psychology Department, meeting with Devon Anxiety and Depression Service (poster/leaflets disseminated to service leads), dissemination at Audit Research and Implementation meeting (service leads across DPT), dissemination at Psychology Governance meeting (service leads across DPT).
- Correspondence with the Royal Marine Association
- Correspondence with Exeter Association of WRENS.
- Combat Stress – sent posters to display.
- Correspondence with Dr Sarah Bulmer (Military Afterlives Project, University of Exeter).
- Post on personal Facebook.
- Post on Linkedin account.
- Post on Twitter account.
- Advert displayed on Mood Disorders Centre webpage
- Advert sent out in university news bulletin email
| Advert sent out to DPT staff through news bulletin (HUB bites) and advertised on HUB page. Breaking Ground – correspondence and sent posters/flyers to advertise. The White Ensign Club – correspondence and posters sent. Correspondence with NIHR Clinical Research Network South West Peninsula: GP practices – sent posters to 8 x practices. | Advert placed in Pathfinder magazine and promoted through their social media pages. Meeting with DPT Research and Development and Comms Dept to promote on internal website (Daisy), in internal news bulletin, on external DPT website as news item and on DPT Research project page. DPT promoted through twitter and Facebook pages. |
Appendix C

Inclusion and Exclusion Criteria

Fifty-five Armed Forces Veterans, who served in the Army, Royal Navy, Royal Air Force including Reserves, and have been deployed to a combat zone such as Northern Ireland, Iraq or Afghanistan, will be recruited for the study.

Risk will be assessed and if participants score positively on question 9 of the PHQ-9 (PHQ-9 Question 9: thoughts that you would be better off dead or hurting yourself in some way) then a full risk assessment will be completed. If participants are deemed to be high risk (i.e., actively suicidal), they will be excluded from the study and provided with contact details of Samaritans and asked to contact their mental health service and the researchers will contact their GP. Participants will be asked if they have acquired a traumatic brain injury (TBI) and the frequency and severity will be classified as per the work of Williams, Cordan, Mewse Tonks & Burgess (2010). If participants have a severe TBI of which they continue to experience symptoms, then they will be excluded from the study. Further inclusion and exclusion criteria is presented below.

Inclusion/Exclusion Criteria

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion</td>
<td>The position held whilst on deployment must have involved exposure to foot patrols indicating having experienced danger during deployment, such as being under enemy fire.</td>
<td>Participants will be excluded if they have been exposed to traumatic experiences other than whilst on deployment to combat-zones, or if their role did not involve exposure to threat or danger to their safety.</td>
</tr>
<tr>
<td>Exclusion</td>
<td>Participants will be excluded if they are a currently serving member of the Armed Forces, including being a Reservist.</td>
<td>Participants will be excluded if they have received a diagnosis for a severe mental health problem such as Schizophrenia.</td>
</tr>
</tbody>
</table>
Appendix D

Ethical Approval Documents

1. UoE School of Psychology Ethical Approval 132
2. HRA Approval 133
3. Devon Partnership Trust - Confirmation of Capacity and Capability 141
UoE School of Psychology - Ethical Approval

From: ethics@exeter.ac.uk <ethics@exeter.ac.uk>
Sent: 01 November 2017 10:29
To: Gerdes, Samantha
Cc: Karl, Anke
Subject: Samantha Gerdes e-Ethics Application outcome decided (eCLESPsy000142 v4.1)

Dear Samantha Gerdes,

Application ID: eCLESPsy000142 v4.1
Title: Can Self-Compassion Be Cultivated in Individuals who have been exposed to life-threatening or prolonged stressors such as Armed Forces Veterans?

Your e-Ethics application has been reviewed by the CLES Psychology Ethics Committee.

The outcome of the decision is: **Favourable**

**Potential Outcomes**

<table>
<thead>
<tr>
<th><strong>Favourable:</strong></th>
<th>The application has been granted ethical approval by the Committee. The application will be flagged as Closed in the system. To view it again, please select the tick box: View completed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Favourable, with conditions:</strong></td>
<td>The application has been granted ethical approval by the Committee under the provision of certain conditions. These conditions are detailed below.</td>
</tr>
<tr>
<td><strong>Provisional:</strong></td>
<td>You have not been granted ethical approval. The application needs to be amended in light of the Committee's comments and re-submitted for Ethical review.</td>
</tr>
<tr>
<td><strong>Unfavourable:</strong></td>
<td>You have not been granted ethical approval. The application has been rejected by the Committee. The application needs to be amended in light of the Committee's comments and resubmitted / or you need to complete a new application.</td>
</tr>
</tbody>
</table>

Please view your application [here](#) and respond to comments as required. You can download your outcome letter by clicking on the 'PDF' button on your eEthics Dashboard.

If you have any queries please contact the CLES Psychology Ethics Chair: **Lisa Leaver** L.A.Leaver@exeter.ac.uk

Kind regards,
CLES Psychology Ethics Committee
Health Research Authority Approval

Miss Samantha Gerdes  
Trainee Clinical Psychologist  
Taunton and Somerset NHS Foundation Trust  
College of Life and Environmental Sciences (CLES), Psychology  
University of Exeter Washington Singer Laboratories  
Perry Road, Exeter  
EX4 4QG

06 October 2017

Dear

Study title: Can Self-Compassion Be Cultivated in Individuals who have been exposed to life-threatening or prolonged stressors such as Armed Forces Veterans?

IRAS project ID: 220845  
Protocol number: 1617/18  
REC reference: 17/SW/0158  
Sponsor University of Exeter

I am pleased to confirm that HRA Approval has been given for the above referenced study, on the basis described in the application form, protocol, supporting documentation and any clarifications noted in this letter.

Participation of NHS Organisations in England

The sponsor should now provide a copy of this letter to all participating NHS organisations in England.

Appendix B provides important information for sponsors and participating NHS organisations in England for arranging and confirming capacity and capability. Please read Appendix B carefully, in particular the following sections:

- Participating NHS organisations in England – this clarifies the types of participating organisations in the study and whether or not all organisations will be undertaking the same activities
- Confirmation of capacity and capability - this confirms whether or not each type of participating NHS organisation in England is expected to give formal confirmation of capacity and capability. Where formal confirmation is not expected, the section also provides details on the time limit given to participating organisations to opt out of the study, or request additional time, before their participation is assumed.
- Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment criteria) - this provides detail on the form of agreement to be used in the study to confirm capacity and capability, where applicable.
Further information on funding, HR processes, and compliance with HRA criteria and standards is also provided.

It is critical that you involve both the research management function (e.g. R&D office) supporting each organisation and the local research team (where there is one) in setting up your study. Contact details and further information about working with the research management function for each organisation can be accessed from www.hra.nhs.uk/hra-approval.

Appendices
The HRA Approval letter contains the following appendices:
- A – List of documents reviewed during HRA assessment
- B – Summary of HRA assessment

After HRA Approval
The document “After Ethical Review – guidance for sponsors and investigators”, issued with your REC favourable opinion, gives detailed guidance on reporting expectations for studies, including:
- Registration of research
- Notifying amendments
- Notifying the end of the study

The HRA website also provides guidance on these topics, and is updated in the light of changes in reporting expectations or procedures.

In addition to the guidance in the above, please note the following:
- HRA Approval applies for the duration of your REC favourable opinion, unless otherwise notified in writing by the HRA.
- Substantial amendments should be submitted directly to the Research Ethics Committee, as detailed in the After Ethical Review document. Non-substantial amendments should be submitted for review by the HRA using the form provided on the HRA website, and emailed to hra.amendments@nhs.net.
- The HRA will categorise amendments (substantial and non-substantial) and issue confirmation of continued HRA Approval. Further details can be found on the HRA website.

Scope
HRA Approval provides an approval for research involving patients or staff in NHS organisations in England.

If your study involves NHS organisations in other countries in the UK, please contact the relevant national coordinating functions for support and advice. Further information can be found at http://www.hra.nhs.uk/resources/applying-for-reviews/nhs-hsc-rd-review/

If there are participating non-NHS organisations, local agreement should be obtained in accordance with the procedures of the local participating non-NHS organisation.
User Feedback
The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/.

HRA Training
We are pleased to welcome researchers and research management staff at our training days – see details at http://www.hra.nhs.uk/hra-training/

Your IRAS project ID is 220845. Please quote this on all correspondence.

Yours sincerely

Nabeela Iqbal
Assessor

Email: hra.approval@nhs.net

Copy to: Ms G M Seymour, University of Exeter, Sponsor contact
Sarah Laidler, Devon Partnership Trust - Research and Development - Lead NHS R&D contact
Appendix A - List of Documents

The final document set assessed and approved by HRA Approval is listed below.

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copies of advertisement materials for research participants</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_Advert_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Copies of advertisement materials for research participants</td>
<td>2</td>
<td>17 August 2017</td>
</tr>
<tr>
<td>[220845_Advert]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evidence of Sponsor insurance or indemnity (non NHS Sponsors only)</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_GERDES_Sponsor_letter_to_CI-non-CTIMP]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GP/consultant information sheets or letters</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_GP_Risk_Letter_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRA Schedule of Events [SOE validated]</td>
<td>1.0</td>
<td>06 October 2017</td>
</tr>
<tr>
<td>[220845_GP_Risk_Letter_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HRA Statement of Activities [SOA validated]</td>
<td>1.0</td>
<td>06 October 2017</td>
</tr>
<tr>
<td>[220845_GP_Risk_Letter_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IRAS Application Form [IRAS_Form_05072017]</td>
<td></td>
<td>05 July 2017</td>
</tr>
<tr>
<td>Letter from sponsor [220845_Sponsorship_confirmation_letter_non-CTIMP]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>Non-validated questionnaire</td>
<td>Version 1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_Visual_Analogue_Scale_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other [220845_UoE - Public Liabilityto31Oct17]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>Other [220845_UoE - Professional Indemnityto31Oct17]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>Other [220845_MDC_Risk_Assessment_Version_1_15062017]</td>
<td>Version 1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>Other [220845_Participant_Debrief_Sheet]</td>
<td>2</td>
<td>17 August 2017</td>
</tr>
<tr>
<td>Participant consent form</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_Participant_Consent_Form_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participant information sheet (PIS)</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_Participant_Information_Sheet_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research protocol or project proposal</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_Study_Protocol_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary CV for Chief Investigator (CI)</td>
<td>Version 1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_CV_Gerdes_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary CV for student [220845_CV_Phillips_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>Summary CV for supervisor (student research)</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_CV_Karl_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary CV for supervisor (student research) [220845_CV_Williams_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>Validated questionnaire [220845_SCS_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_SCS_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [220845_PHQ-9_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_PHQ-9_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [220845_PCL-5_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_PCL-5_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [220845_ERQ_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_ERQ_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [220845_CES_Version_1_15062017]</td>
<td>1</td>
<td>15 June 2017</td>
</tr>
<tr>
<td>[220845_CES_Version_1_15062017]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Page 4 of 8
Appendix B - Summary of HRA Assessment

This appendix provides assurance to you, the sponsor and the NHS in England that the study, as reviewed for HRA Approval, is compliant with relevant standards. It also provides information and clarification, where appropriate, to participating NHS organisations in England to assist in assessing and arranging capacity and capability.

For information on how the sponsor should be working with participating NHS organisations in England, please refer to the, participating NHS organisations, capacity and capability and Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment criteria) sections in this appendix.

The following person is the sponsor contact for the purpose of addressing participating organisation questions relating to the study:

Name: Ms G M Seymour
Tel: 01392726621
Email: g.m.seymour@exeter.ac.uk

HRA assessment criteria

<table>
<thead>
<tr>
<th>Section</th>
<th>HRA Assessment Criteria</th>
<th>Compliant with Standards</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>IRAS application completed correctly</td>
<td>Yes</td>
<td>No comments</td>
</tr>
<tr>
<td>2.1</td>
<td>Participant information/consent documents and consent process</td>
<td>Yes</td>
<td>No comments</td>
</tr>
<tr>
<td>3.1</td>
<td>Protocol assessment</td>
<td>Yes</td>
<td>No comments</td>
</tr>
<tr>
<td>4.1</td>
<td>Allocation of responsibilities and rights are agreed and documented</td>
<td>Yes</td>
<td>The SOA will act as an agreement with sites.</td>
</tr>
<tr>
<td>4.2</td>
<td>Insurance/indemnity arrangements assessed</td>
<td>Yes</td>
<td>Where applicable, independent contractors (e.g. General Practitioners) should ensure that the professional indemnity provided by their medical defence organisation covers the activities expected of them for this</td>
</tr>
<tr>
<td>Section</td>
<td>HRA Assessment Criteria</td>
<td>Compliant with Standards</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>-------------------------</td>
<td>--------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>4.3</td>
<td>Financial arrangements assessed</td>
<td>Yes</td>
<td>This is a PhD study and no funding will be available to sites, as detailed in Schedule 1 of the SOA.</td>
</tr>
<tr>
<td>5.1</td>
<td>Compliance with the Data Protection Act and data security issues assessed</td>
<td>Yes</td>
<td>No comments</td>
</tr>
<tr>
<td>5.2</td>
<td>CTIMPS – Arrangements for compliance with the Clinical Trials Regulations assessed</td>
<td>Not Applicable</td>
<td>No comments</td>
</tr>
<tr>
<td>5.3</td>
<td>Compliance with any applicable laws or regulations</td>
<td>Yes</td>
<td>No comments</td>
</tr>
<tr>
<td>6.1</td>
<td>NHS Research Ethics Committee favourable opinion received for applicable studies</td>
<td>Yes</td>
<td>REC FO issued on the 4th September 2017.</td>
</tr>
<tr>
<td>6.2</td>
<td>CTIMPS – Clinical Trials Authorisation (CTA) letter received</td>
<td>Not Applicable</td>
<td>No comments</td>
</tr>
<tr>
<td>6.3</td>
<td>Devices – MHRA notice of no objection received</td>
<td>Not Applicable</td>
<td>No comments</td>
</tr>
<tr>
<td>6.4</td>
<td>Other regulatory approvals and authorisations received</td>
<td>Not Applicable</td>
<td>No comments</td>
</tr>
</tbody>
</table>
Participating NHS Organisations in England

This provides detail on the types of participating NHS organisations in the study and a statement as to whether the activities at all organisations are the same or different.

This is a single site type study where it is limited to PIC activity. The PIC activity involves identification and dissemination of PIS at assessment or review appointments by the direct clinical care team.

The Chief Investigator or sponsor should share relevant study documents with participating NHS organisations in England in order to put arrangements in place to deliver the study. The documents should be sent to both the local study team, where applicable, and the office providing the research management function at the participating organisation. For NIHR CRN Portfolio studies, the Local LCRN contact should also be copied into this correspondence. For further guidance on working with participating NHS organisations please see the HRA website.

If Chief Investigators, sponsors or Principal Investigators are asked to complete site level forms for participating NHS organisations in England which are not provided in IRAS or on the HRA website, the Chief Investigator, sponsor or Principal Investigator should notify the HRA immediately at hra.approval@nhs.net. The HRA will work with these organisations to achieve a consistent approach to information provision.

Confirmation of Capacity and Capability

This describes whether formal confirmation of capacity and capability is expected from participating NHS organisations in England.

Participating NHS organisations in England will be expected to formally confirm their capacity and capability to host this research.

- The sponsor should ensure that participating NHS organisations are provided with a copy of this letter and all relevant study documentation, and work jointly with NHS organisations to arrange capacity and capability whilst the HRA assessment is ongoing.
- Further detail on how capacity and capability will be confirmed by participating NHS organisations, following issue of the Letter of HRA Approval, is provided in the Participating NHS Organisations and Allocation of responsibilities and rights are agreed and documented (4.1 of HRA assessment criteria) sections of this appendix.
- The Assessing, Arranging, and Confirming document on the HRA website provides further information for the sponsor and NHS organisations on assessing, arranging and confirming capacity and capability.
**Principal Investigator Suitability**

This confirms whether the sponsor’s position on whether a PI, LC or neither should be in place is correct for each type of participating NHS organisation in England, and the minimum expectations for education, training and experience that PIs should meet (where applicable).

- There will be no requirement for LC or PI since activity is limited to staff disseminating PIS.
- GCP training is not a generic training expectation, in line with the HRA statement on training expectations.

---

**HR Good Practice Resource Pack Expectations**

This confirms the HR Good Practice Resource Pack expectations for the study and the pre-engagement checks that should and should not be undertaken.

- As a study undertaken by local staff, it is unlikely that letters of access or honorary research contracts will be applicable, except where local network staff employed by another Trust (or University) are involved (and then it is likely that arrangements are already in place).

---

**Other Information to Aid Study Set-up**

This details any other information that may be helpful to sponsors and participating NHS organisations in England in study set-up.

- The applicant has indicated that they do not intend to apply for inclusion on the NIHR CRN Portfolio.
11 October 2017

Samantha Gerdes
Trainee Clinical Psychologist
Taunton and Somerset NHS Foundation Trust
College of Life and Environmental Sciences, Psychology
University of Exeter
Washington Singer Laboratories
Perry Road
Exeter EX4 4GG

Dear Samantha,

IRAS Project ID: 220645
DPT reference: DPT0345

Study Title: Can Self-Compassion be cultivated in Armed Forces Veterans?

This letter confirms that Devon Partnership NHS Trust (DPT) has the capacity and capability to support the above referenced study, which has received approval from the appropriate regulatory bodies.

Devon Partnership Trust will be a Patient Identification Centre for the above named study.

The documents approved for use in this study are those approved by the Health Research Authority and Research Ethics Committee.

As named Investigator for the research that is being undertaken at this Trust, it is your responsibility to manage and conduct this study in accordance with:

- The requirements of the Research Governance Framework for Health and Social Care (2005) and Medicines for Human Use (Clinical Trials) Regulations 2004 (if applicable).
- ICH-GCP (Good Clinical Practice) – It is mandatory for those staff who will be consenting participants into this study to have undertaken GCP and to ensure it is updated every 2 years.
- The Data Protection Act 1998 which details the eight principles of ‘good information handling’.
- R&D Standard Operating Procedures (SCPs) and Trust policies which are available on the Trust intranet site.

As Lead Investigator for this research, you are required to ensure study specific duties are appropriately delegated and clearly documented on the study Delegation Log. This guarantees clarity...
of roles and must be signed and dated by each individual on the study and yourself as Lead Investigator.

Safety Reporting
Guidance on the classification of Adverse Events/Reactions (AEs/ARs) / Serious Adverse Events/Reactions (SAEs/SARs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) and the requirements for reporting to the sponsor can be found in the study protocol. For Devon Partnership NHS Trust sponsored studies this is also detailed in the sponsorship letter. All safety events that involve DPT patients, that require reporting to the Sponsor, must also be reported by fax marked for the attention of Sarah Laidler and sent to the R&D Office within 24 hours of becoming aware of the event (01392 6744929) alternatively via email to sarahlaidler@nhs.net.

Progress Reporting
You are required to submit regular recruitment updates to the R&D Office, as well as annual progress reports to Ethics, MHRA (where applicable) and R&D. Please note that new government and Trust targets require you to have recruited your first patient within 30 days of the date of Trust Approval and to have recruited your target number of participants within the time frame stipulated on your SSI form (Time to Target).

Monitoring and Audit
Your study may be monitored by the Sponsor and selected for audit by the R&D Office (where DPT is not the Sponsor) and Regulatory Authorities at any time. The team involved in conducting this research must ensure full co-operation with any requests from any of these bodies. Action may be taken to suspend research if it is found to not be conducted in accordance with the protocol and all applicable regulations.

Archiving
Upon completion of this Research an End of Study Report must be submitted to the Regulatory Authorities (this will be done by the CI) and a copy submitted to the R&D Office. All studies must be archived appropriately and in accordance with the applicable Law. Where DPT is the Sponsor or where the Sponsor has delegated archiving to the Investigator team, it is your responsibility to contact the R&D Office to discuss appropriate archiving arrangements.

Any publications arising from the Research conducted at this site must be sent to the R&D Office as part of the on-going Research Governance Process.

You should be aware that the Trust accepts no responsibility for the provision of any study drug outside of Clinical Trials and specifically would not fund the continuing prescription of any therapy once the trial has concluded unless there is a written agreement.

Trust Agreement to host the study is for the duration of the study. Research must commence within 6 months of Trust Agreement. If you have received an Honorary Contract or Letter of Access in order to conduct the above research at this Trust, it is important that you check the termination date on these documents and if applicable contact the R&D Office to extend the document end date.
We wish you every success with your study.

Yours sincerely

Tobit Emmens

Managing Partner, Research & Development, Devon Partnership NHS Trust
Appendix E

Example Letter to GP

Private & Confidential

University of Exeter
College of Life and Environmental Sciences
Department of Psychology
Washington Singer Laboratories
Perry Road
Exeter
EX4 4QG

Telephone: 07757 245163
Email: Samantha.gerdes@exeter.ac.uk

Date: 2018

Re. xxxx xxxx DOB: xx/xx/xxxx

Dear GP,

I am writing to inform you that xxxx xxxx took part in a research study at the University of Exeter on Friday 9th March 2018. xxxx has agreed for me to write to you to inform you of his involvement in the study. The study is investigating the effects of a short meditation on mood in Armed Forces Veterans and as part of the process we use psychometric tools to assess levels of Post Traumatic Stress Disorder (PTSD) and depression. Whilst these are not diagnostic tools, as part of the study protocol we are informing GPs of the results, so that they are able to follow up as appropriate. Please note that the clinical management of this patient remains your responsibility, but it is part of our protocol to inform you of any risks disclosed to ourselves so that you can take account of them in your care plan.

As part of the study, xxxx completed the PTSD Checklist (PCL5) questionnaire and Patient Health Questionnaire (PHQ9) for which he scored 18 and 4 respectively. As you are probably aware, scoring 18 on the PCL5 does not meet the threshold that would indicate a presence of PTSD (cut point = 33) and scoring 4 on the PHQ9 does not indicate the presence of depression. xxxx said that he has received psychological therapy through the MOD which he found helpful and his PTSD symptoms have drastically reduced as a result. xxxx felt that he was managing well currently, but he is willing to consider psychological therapy in the future if needed. I would recommend that if xxxx feels that he needs further support, that he makes an appointment with you to discuss further so that you can refer to a psychological therapy service as appropriate.

Please get in touch with me if you would like to discuss further.

Yours Sincerely,

Samantha Gerdes, Trainee Clinical Psychologist, University of Exeter
Cc: (participant address).
Appendix F

Power Calculation

Sample size for the current study was determined using G*Power (Faul, Erdfelder, Bucher & Lang, 2009) to calculate a-priori the required sample size. Due to the absence of prior research to address the research questions in the current study, power calculations and sample size considerations were based on a medium effect size. A power calculation for hypothesis 1, using a paired sample t-test with state hypervigilance at Time 1 and Time 2 as the dependent variables, assuming a medium effect size of Cohen’s $d = .5$ for a statistical power of .8 and alpha = .05, revealed that 34 participants will be needed. A power calculation for hypothesis 2 revealed that, using a paired sample t-test with social connectedness at Time 1 and Time 2 as the dependent variables assuming a medium effect size of Cohen’s $d = .5$ for a statistical power of .8 and alpha = .05, 34 participants will be needed. A power calculation for hypothesis 3 revealed that, for a regression with PCL-5 score as the predictor variable, assuming a medium effect size of $f^2 = .15$ for a statistical power of .8 and alpha = .05, 55 participants would be needed.
Appendix G

Demographic Questionnaire

Participant number:

Name:

**General questions:**

Age:

Gender:

Nationality:

Religion:

Marital Status: Single, Married, Cohabiting, Divorced, Seperated, Widowed

Highest qualification: GCSE, A-Levels, Diploma, Foundation Degree, Undergraduate Degree, Masters Degree, Doctorate.

Current employment (full time, part time etc):

**Forces experience:**

Armed Forces Branch:

Army, Army reserves, Royal Navy, Royal Navy Reserves, Royal Marines, Royal Marine Reserves, Royal Air Force.

Date joined, date left (length of service):

Rank at discharge: Junior non-commissioned officer, Senior non-commissioned officer, Junior officer, Senior officer.

Number of times deployed throughout career:

Where deployed to (Afgan, NI, Bosnia etc.):

When deployed:

Average length of tour:

Role on deployment:

Mode of discharge: Medical, At own request (PVR), Administrative, End of Engagement, Redundancy, Compulsory Discharge
Reason for medical discharge: physical injury, mental health problem, mental health problem and physical injury, other.

Sustain any physical injuries whilst on deployment?

Do you have any health problems? Cardiac disease? Medication for this?

**Mental health:**

Diagnosis (and when diagnosed):

PTSD diagnosis? As a result of combat experience?

Current and previous MH treatment (type, duration):

(Department of Community Mental Health, Private counselling, Combat Stress, NHS Primary Care, NHS Secondary Care, Help for Heroes, Specialist Services.)

Medication?

Do you drink alcohol? How much alcohol do you consume over a given week? Units? Have you ever been a heavy drinker?

Alcohol or drugs in the past 48 hours?

Do you have previous experience of meditation? Yes, what?

Would you like you GP to be informed that you are taking part in the study? Would you like the results of your questionnaires to be included?

Would you like to be contacted for future research opportunities with this project and others?

Would you like to be informed about the results of the study (Autumn 2018). How? By email/post.
Appendix H

Traumatic Brain Injury Assessment

(Williams, Cordan, Mewse Tonks & Burgess, 2010)

Participants were asked “have you ever sustained a head injury or been knocked unconscious?” If participants answered yes, they were then asked how many times they had sustained such injuries and the duration of each period of loss of consciousness (LOC). Severity was assessed using the length of LOC of the worst injury such as: 0 = no history; 1 = feeling dazed and confused but no LOC, minor concussion; 2 = LOC <10 minutes, mild TBI; 3 = LOC 10 to 30 minutes, complicated mild TBI; 4 = LOC 30 to 60 minutes, moderate/severe TBI; 5=LOC>60 minutes, very severe TBI (Williams et al., 2010).
Appendix I

Outcome Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCL-5</td>
<td>156</td>
</tr>
<tr>
<td>PHQ-9</td>
<td>157</td>
</tr>
<tr>
<td>ERQ</td>
<td>158</td>
</tr>
<tr>
<td>SCS-SF</td>
<td>159</td>
</tr>
</tbody>
</table>
**PTSD Checklist (PCL-5)**

*Instructions:* Below is a list of problems that people sometimes have in response to a very stressful experience. Please read each problem carefully and then circle one of the numbers to the right to indicate how much you have been bothered by that problem in the past month.

<table>
<thead>
<tr>
<th>In the past month, how much were you bothered by:</th>
<th>Not at all</th>
<th>A little bit</th>
<th>Moderately</th>
<th>Quite a bit</th>
<th>Extremely</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Repeated, disturbing, and unwanted memories of the stressful experience?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>2. Repeated, disturbing dreams of the stressful experience?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>3. Suddenly feeling or acting as if the stressful experience were actually happening again (as if you were actually back there reliving it)?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>4. Feeling very upset when something reminded you of the stressful experience?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>5. Having strong physical reactions when something reminded you of the stressful experience (for example, heart pounding, trouble breathing, sweating)?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>6. Avoiding memories, thoughts, or feelings related to the stressful experience?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>7. Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations)?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>8. Trouble remembering important parts of the stressful experience?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>9. Having strong negative beliefs about yourself, other people, or the world (for example, having thoughts such as: I am bad, there is something seriously wrong with me, no one can be trusted, the world is completely dangerous)?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>10. Blaming yourself or someone else for the stressful experience or what happened after it?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>11. Having strong negative feelings such as fear, horror, anger, guilt, or shame?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>12. Loss of interest in activities that you used to enjoy?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>13. Feeling distant or cut off from other people?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>14. Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you)?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>15. Irritable behavior, angry outbursts, or acting aggressively?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>16. Taking too many risks or doing things that could cause you harm?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>17. Being &quot;superalert&quot; or watchful or on guard?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>18. Feeling jumpy or easily startled?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>19. Having difficulty concentrating?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>20. Trouble falling or staying asleep?</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>
### Patient Health Questionnaire (PHQ-9)

<table>
<thead>
<tr>
<th>Over the past 2 weeks, how often have you been bothered by any of the following problems?</th>
<th>Not At all</th>
<th>Several Days</th>
<th>More Than Half the Days</th>
<th>Nearly Every Day</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Little interest or pleasure in doing things</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>2. Feeling down, depressed or hopeless</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>3. Trouble falling asleep, staying asleep, or sleeping too much</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>4. Feeling tired or having little energy</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>5. Poor appetite or overeating</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>6. Feeling bad about yourself - or that you're a failure or have let yourself or your family down</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>7. Trouble concentrating on things, such as reading the newspaper or watching television</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>8. Moving or speaking so slowly that other people could have noticed. Or, the opposite - being so fidgety or restless that you have been moving around a lot more than usual</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>9. Thoughts that you would be better off dead or of hurting yourself in some way</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
</tbody>
</table>

**Column Totals**

---

**Add Totals Together**

---
Emotional Regulation Questionnaire (ERQ; Gross & John, 2003)

Instructions and Items:
We would like to ask you some questions about your emotional life, in particular, how you control (that is, regulate and manage) your emotions. The questions below involve two distinct aspects of your emotional life. One is your emotional experience, or what you feel like inside. The other is your emotional expression, or how you show your emotions in the way you talk, gesture, or behave. Although some of the following questions may seem similar to one another, they differ in important ways. For each item, please answer using the following scale:

<table>
<thead>
<tr>
<th>Strongly Disagree</th>
<th>Neutral</th>
<th>Strongly Agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>7</td>
</tr>
</tbody>
</table>

1. ____ When I want to feel more positive emotion (such as joy or amusement), I change what I’m thinking about.
2. ____ I keep my emotions to myself.
3. ____ When I want to feel less negative emotion (such as sadness or anger), I change what I’m thinking about.
4. ____ When I am feeling positive emotions, I am careful not to express them.
5. ____ When I’m faced with a stressful situation, I make myself think about it in a way that helps me stay calm.
6. ____ I control my emotions by not expressing them.
7. ____ When I want to feel more positive emotion, I change the way I’m thinking about the situation.
8. ____ I control my emotions by changing the way I think about the situation I’m in.
9. ____ When I am feeling negative emotions, I make sure not to express them.
10. ____ When I want to feel less negative emotion, I change the way I’m thinking about the situation.

Scoring:
Items 1, 3, 5, 7, 8, 10 make up the Cognitive Reappraisal facet.
Items 2, 4, 6, 9 make up the Expressive Suppression facet.
HOW I TYPICALLY ACT TOWARDS MYSELF IN DIFFICULT TIMES

Please read each statement carefully before answering. To the left of each item, indicate how often you behave in the stated manner, using the following scale:

<table>
<thead>
<tr>
<th>Almost never</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>Almost always</th>
<th>5</th>
</tr>
</thead>
</table>

1. When I fail at something important to me I become consumed by feelings of inadequacy.
2. I try to be understanding and patient towards those aspects of my personality I don’t like.
3. When something painful happens I try to take a balanced view of the situation.
4. When I’m feeling down, I tend to feel like most other people are probably happier than I am.
5. I try to see my failings as part of the human condition.
6. When I’m going through a very hard time, I give myself the caring and tenderness I need.
7. When something upsets me I try to keep my emotions in balance.
8. When I fail at something that’s important to me, I tend to feel alone in my failure.
9. When I’m feeling down I tend to obsess and fixate on everything that’s wrong.
10. When I feel inadequate in some way, I try to remind myself that feelings of inadequacy are shared by most people.
11. I’m disapproving and judgmental about my own flaws and inadequacies.
12. I’m intolerant and impatient towards those aspects of my personality I don’t like.
Appendix J

Loving Kindness Meditation (LKM-S) Script

**Script for Loving Kindness Meditation clip**
*(In the style of Loving-Kindness for Beginners, Neff)*

Sit in a comfortable position, reasonably upright and relaxed. (Pause) Close your eyes fully or partly. (Pause) You will now be guided through a few minutes exercise.

Bring to mind a person with whom you have a positive relationship, someone who you feel naturally warmly towards. This could be a child, a grandparent, a former teacher or mentor your cat or dog - whoever naturally brings happiness to your heart. Allowing yourself to feel what it’s like to be in that being’s presence (pause for 2 sec).

(Pause)

Holding this person in mind now extending best wishes towards them. Repeat softly with this person in mind:

*May you be safe.*
*May you be peaceful.*
*May you be healthy.*
*May you live with ease.*

(Pause)

*May you be safe.*
*May you be peaceful.*
*May you be healthy.*
*May you live with ease.*

(Pause)

When you notice that your mind has wandered, return to the words and the image of the loved one you have in mind. Savour any warm feelings that may arise. Go slow.

(Pause)

Now add yourself to your circle of good will. Put your hand over your heart and feel the warmth and gentle pressure of your hand (for just a moment or for the rest of the exercise), saying:

*May I be safe.*
*May I be peaceful.*
*May I be healthy.*
*May I live with ease.*

(Pause)

*May I be safe.*
*May I be peaceful.*
*May I be healthy.*
*May I live with ease.*

(Pause)

Holding your body in awareness, notice any stress or uneasiness that may be lingering within you, and offer kindness to yourself.

*May I be safe.*
*May I be peaceful.*
*May I be healthy.*
*May I live with ease.*
Repeat the phrases inwardly with enough space between them so that they are pleasing you. As best you can, gather all your attention behind one phrase at a time. (Pause) If you find your attention wandering, don’t worry, that’s what minds do. You can simply let go of distractions and begin from here you are.

*May I be safe.*
*May I be peaceful.*
*May I be healthy.*
*May I live with ease.* (Pause)
Feelings, thoughts, or memories may come and go; allow them to arise and pass away. Let the anchor be the repetition of these phrases:

*May I be safe.*
*May I be peaceful.*
*May I be healthy.*
*May I live with ease.* (Pause)
Just rest and sit quietly in your own body, savouring the good will and compassion that flows naturally from your own heart. Know that you can return to the phrases anytime you wish.

(Pause for 15 sec)

(Pause, then end) Now, in your own time, slowly open eyes. The exercise is over.
Appendix K

Visual Analogue Scales (VAS)

Right now I feel:

<table>
<thead>
<tr>
<th>0</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>I don't feel distressed at all</td>
<td>I feel very distressed</td>
</tr>
<tr>
<td>I am feeling like not criticising myself at all</td>
<td>I am feeling like criticising myself very</td>
</tr>
<tr>
<td>I do not feel like being kind and understanding towards myself at all</td>
<td>I am feeling like being very kind and understanding towards myself</td>
</tr>
<tr>
<td>I am not tolerant of my flaws and inadequacies</td>
<td>I am very tolerant of my flaws and inadequacies</td>
</tr>
<tr>
<td>I feel jumpy or like I could be easily startled</td>
<td>I do not feel jumpy or like I might be easily startled</td>
</tr>
<tr>
<td>I feel super-alert</td>
<td>I do not feel super-alert</td>
</tr>
<tr>
<td>I feel irritable and I feel like acting aggressively</td>
<td>I do not feel irritable and I do not feel like acting aggressively</td>
</tr>
<tr>
<td>I am finding it difficult to concentrate</td>
<td>I have no difficulty concentrating</td>
</tr>
<tr>
<td>I feel isolated and apart from others</td>
<td>I feel connected to others</td>
</tr>
<tr>
<td>I don't feel loved and safe at all</td>
<td>I feel very loved and safe</td>
</tr>
<tr>
<td>I don’t need to feel loved at all</td>
<td>I really need to feel loved</td>
</tr>
<tr>
<td>The idea of being emotionally close to someone doesn’t make me nervous</td>
<td>The idea of being emotionally close to someone makes me very nervous</td>
</tr>
</tbody>
</table>
Appendix L

Assumption Testing

Prior to hypothesis testing, the assumptions were checked for violations of normality and homogeneity of variance. In the paired sample t-tests, data was checked for outliers and normality. Outliers were detected after examining boxplots: one outlier was found in the self-compassion manipulation check (participant 46) and five participants in the VAS hyperarousal (participants 20, 28, 37, 46 & 47). Inspection of their values did not reveal them to be extreme so they were kept in the analysis. These data points were changed to the next closest value that was under the cut off which is a technique for dealing with outliers, whilst maintaining the shape of the sample distribution, but the outliers do not distort the data (Tabachnick & Fidell, 2007). Results are presented after these data points were changed, however, it must be noted that this did not alter statistical significance of any of the tests.

Normality was assessed by Shapiro-Wilk's test and normality was not violated for the self-compassion manipulation check ($p = .7$) or VAS social connectedness ($p = .42$). However, Shapiro-Wilk's test for VAS hyperarousal indicated a violation of normality ($p = .002$). Visual inspection of the normal Q-Q plot however appeared approximately normally distributed for sample size $>50$, in addition, paired sample t-tests are also robust to violations of normality therefore the data was analysed using parametric tests (Laerd Statistics, 2015).

For the correlations, two outliers were identified and underwent the Winsorising process (participants 25 & 50). Assumptions of normality were not violated as assessed by Shapiro-Wilks test for RGS Hyperarousal ($p = .49$) and RGS Social Connectedness ($p = .17$)
For the regression analysis, assumptions of independence of observations, linearity, homoscedasticity, normality and multicollinearity were all fulfilled. Linearity was assessed by partial regression plots and a plot of studentized residuals against the predicted values. There was independence of residuals, as assessed by a Durbin-Watson statistic for Heart Rate Variability of .341, Skin Conductance Levels of 2.27, Heart Rate of 2.64, Hyperarousal Residualised Gains Score (RGS) of 2.02, Social Connectedness RGS of 1.16. There was homoscedasticity as assessed by visual inspection of a plot of studentized residuals versus unstandardized predicted values. There was no evidence of multicollinearity of independent variables, as assessed by tolerance values greater than 0.1. The assumption of normality was met, as assessed by a Q-Q Plot.

Examination of studentized deleted residuals revealed six outliers (participants 16, 25 30, 40, 54, 57) and therefore their score were changed to the next highest value that was not an outlier (Tabachnick & Fidell, 2007). There were five cases with leverage values greater than 0.2 ranging from 0.23 to 0.30. However these cases were left unchanged as no influential points were identified, as there were no values for Cook’s distance above 1.
Appendix M

Physiological Data Processing

**Heart Rate (HR).** The raw ECG data was filtered by applying a FIR bandpass filter between .5 and 35 Hz and 8000 coefficients. AcqKnowledge (Version 4.1., BIOPAC Systems Inc.) software was used to determine HR in beats per minute and was based on a semi-automatic R-wave detection algorithm. Any artefacts such as noisy or missing beats were identified and then deleted using a template correlation and interpolation from the adjacent R-peaks (Solem at al., 2006; Berntson, Quigley, Jang, & Boysen, 1990; Berntson & Stowell, 1998). The interpolation procedure was applied for less than 5% of the ECG data.

**Heart rate variability (HF-HRV; as index of parasympathetic activation).** HRV was determined from the artifact-free ECG (see above) by calculating a time series of the R-peaks and submitting it to a fast Fourier transformation that calculates the power spectrum of the R-R interval variation in a given time window (Berntson et al., 1997; Malik et al., 1996). Of particular interest was the frequency range between .15 Hz and .4 Hz (high frequency, HF). This high frequency band of HRV is generally considered a marker of parasympathetic input. Mean HF-HRV were then extracted for each data section using the same process as used with the HR.

**Skin conductance level (SCL) (as measure of sympathetic arousal).** Mean SCL, maximum SCL values and minimum SCL values were extracted for the same time windows and a range correction as recommended was applied to each data section for each participant to give a mean SCL corrected for individual differences (Lykken, et al., 1996). The formula for this was: Corrected SCL = (SCL mean - SCL min) / (SCL max - SCL min).
The mean scores (i.e., HR, HRV) per minute was calculated by using the R-waves for each data section, in particular 2 minutes of resting/baseline and for the meditation. Mean values for HR, HRV and SCL were determined for the duration of the 11 minute meditation in one minute segments. The one minute prior to the meditation start was used as a baseline. To determine the responses to the meditation, the baseline was subtracted from each minute of the meditation value and change from the baseline was then determined for each minute.
Appendix N

TBI Results

Table 2.

*Traumatic Brain Injury*

<table>
<thead>
<tr>
<th>Classification</th>
<th>N = 53 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 = No history</td>
<td>12 (22.6)</td>
</tr>
<tr>
<td>1 = Feeling dazed and confused but no LOC, minor concussion</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>2 = LOC &lt; 10 minutes, mild TBI</td>
<td>24 (45.3)</td>
</tr>
<tr>
<td>2a = LOC but no concussion symptoms</td>
<td>14 (26.4)</td>
</tr>
<tr>
<td>3 = LOC 10 to 30 minutes, complicated mild TBI</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>4 = LOC 30 to 60 minutes, moderate/severe TBI</td>
<td>1 (1.89)</td>
</tr>
<tr>
<td>5 = LOC &gt; 60 minutes, very severe TBI</td>
<td>0</td>
</tr>
</tbody>
</table>

*Note.* LOC = Loss of consciousness. TBI was assessed over the participant’s lifetime rather than restricted to just their Armed Forces career.
### Table 4. Intercorrelations, Means and Standard Deviations for Variables.

| Variable | 1  | 2  | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  | 14  | 15  | M   | SD  |
|----------|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 1. RGS Hyperarousal | -.01 | .96 |     |     |     |     |     |     |     |     |     |     |     |     |     | .01 | .96 |
| 2. RGS Social Connectedness | -.326* | -.03 | .87 |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 3. PCL Total | .160 | -.204 | - |     |     |     |     |     |     |     |     |     |     |     |     |     | 22.13 | 20.95 |
| 4. PCL Intrusions | .297’ | -.231 | .938” | - |     |     |     |     |     |     |     |     |     |     |     |     |     |
| 5. PCL Avoidance | .274’ | -.243 | .863“ | .889” | - |     |     |     |     |     |     |     |     |     |     |     |     |
| 6. PCL Cognitive Avoidance | .079 | -.174 | .939” | .816” | .761” | - |     |     |     |     |     |     |     |     |     |     | 7.53 | 7.77 |
| 7. PCL Physiological Arousal | .074 | -.158 | .932” | .832” | .712” | .811” | - |     |     |     |     |     |     |     |     |     | 7.43 | 7.19 |
| 8. Self-compassion Scale | -.237 | .284’ | -.609” | -.544” | -.509” | -.662” | -.495” | - |     |     |     |     |     |     |     |     | 36.62 | 8.00 |
| 9. ERQ (Cognitive Reappraisal) | -.056 | -.214 | .145 | .112 | .191 | .169 | .093 | -.088 | - |     |     |     |     |     |     |     | 4.48 | 1.36 |
| 10. ERQ (Expression & Suppression) | .037 | -.244 | .434” | .372” | .344” | .460” | .383” | -.471” | .168 | - |     |     |     |     |     |     | 3.94 | 1.55 |
| 11. HRV Mean Response | .017 | .004 | .011 | .074 | .137 | -.023 | -.042 | .146 | .027 | .063 | - |     |     |     |     |     | -.09 | 1.0 |
| 12. SCL Mean Response | .173 | -.358” | .151 | .204 | .302’ | .089 | .097 | .035 | .059 | .039 | .172 | - |     |     |     |     | -.04 | .06 |
| 13. HR Mean Response | -.002 | -.057 | -.050 | -.051 | .004 | -.073 | -.034 | .057 | .035 | .243 | -.121 | -.206 | - |     |     |     | .68 | 2.56 |

* p < .05, ** p < .01, *** p < .001
14. PHQ9 Total  .181 -.223 .889** .796** .707** .897** .807** -.702** .147 .430** .012 .070 -.047 - 6.60 7.33
15. TBI Severity -.244 .005 .161 .063 .034 .144 .255 -.050 .089 .077 .045 .105 .009 .161- - - -

*Note. N = 52 – 53. *p <.05. **p <.01
Appendix P

Dissemination Statement

The findings of this study will be disseminated in the following ways:

1. A research presentation to trainee clinical psychologists and staff at the University of Exeter (June 2018).

2. A summary of the findings will be sent to participants and organisations who helped with recruitment, who opted to be informed of the study results (August, 2018).

3. The study will be submitted to a peer reviewed journal article i.e. Journal of Consulting and Clinical Psychology (November, 2018).
Appendix Q

Journal of Clinical and Consulting Psychology – Copy of Instructions for Authors

Overview

The following instructions pertain to all journals published by APA and the Educational Publishing Foundation.

Please also visit the web page for the journal to which you plan to submit your article for submission addresses, journal-specific instructions, and exceptions.

- **Manuscript Preparation**
- **Submitting Supplemental Materials**
- **Abstract and Keywords**
- **References**
- **Figures**
- **Permissions**
- **Publication Policies**
- **Ethical Principles**
- **Other Information**
Manuscript Preparation

Prepare manuscripts according to the Publication Manual of the American Psychological Association (7th edition). Manuscripts may be copyedited for bias-free language (see Chapter 3 of the Publication Manual). Additional guidance on APA Style is available on the APA Style website.

Double-space all copy. Other formatting instructions, as well as instructions on preparing tables, figures, references, metrics, and abstracts, appear in the Manual.

Below are additional instructions regarding the preparation of display equations, computer code, and tables.

Display Equations

We strongly encourage you to use MathType (third-party software) or Equation Editor 3.0 (built into pre-2007 versions of Word) to construct your equations, rather than the equation support that is built into Word 2007 and Word 2010. Equations composed with the built-in Word 2007/Word 2010 equation support are converted to low-resolution graphics when they enter the production process and must be rekeyed by the typesetter, which may introduce errors.

To construct your equations with MathType or Equation Editor 3.0:

1. Go to the Text section of the Insert tab and select Object.
2. Select MathType or Equation Editor 3.0 in the drop-down menu.

If you have an equation that has already been produced using Microsoft Word 2007 or 2010 and you have access to the full version of MathType 6.5 or later, you can convert this equation to MathType by clicking on MathType Insert Equation. Copy the equation from Microsoft Word and paste it into the MathType box. Verify that your equation is correct, click File, and then click Update. Your equation has now been inserted into your Word file as a MathType Equation.

Use Equation Editor 3.0 or MathType only for equations or for formulas that cannot be produced as Word text using the Times or Symbol font.

Computer Code

Because altering computer code in any way (e.g., indents, line spacing, line breaks, page breaks) during the typesetting process could alter its meaning, we treat computer code differently from the rest of your article in our production process. To that end, we request separate files for computer code.

In Online Supplemental Material

We request that runnable source code be included as supplemental material to the article. For more information, visit Supplementing Your Article With Online Material.

In the Text of the Article

If you would like to include code in the text of your published manuscript, please submit a separate file with your code exactly as you want it to appear, using Courier New font with a type size of 8 points. We will make an image of each segment of code in your article that exceeds 40 characters in length. (Shorter snippets of code that appear in text will be typeset in Courier New and run in with the rest of the text.) If an appendix contains a mix of code and explanatory text, please submit a file that contains the entire appendix, with the code keyed in 8-point Courier New.

Tables

Use Word’s Insert Table function when you create tables. Using spaces or tabs in your table will create problems when the table is typeset and may result in errors.

If your manuscript was mask reviewed, please ensure that the final version for production includes a byline and full author note for typesetting.

Review APA’s Checklist for Manuscript Submission before submitting your article.
Academic Writing and English Language Editing Services

Authors who feel that their manuscript may benefit from additional academic writing or language editing support prior to submission are encouraged to seek out such services at their host institutions, engage with colleagues and subject matter experts, and/or consider several vendors that offer discounts to APA authors.

Please note that APA does not endorse or take responsibility for the service providers listed. It is strictly a referral service.

Use of such service is not mandatory for publication in an APA journal. Use of one or more of these services does not guarantee selection for peer review, manuscript acceptance, or preference for publication in any APA journal.

- Manuscript Preparation
- Submitting Supplemental Materials

APA can place supplemental materials online, available via the published article in the PsycARTICLES® database. Please see Supplementing Your Article With Online Material for more details.

- Abstract and Keywords
- References

- Abstract and Keywords

All manuscripts must include an abstract containing a maximum of 250 words typed on a separate page. After the abstract, please supply up to five keywords or brief phrases.

- References

List references in alphabetical order. Each listed reference should be cited in text, and each text citation should be listed in the References section.

Examples of basic reference formats:

* Journal Article:

* Author ed Book:

* Chapter in an Edited Book:
Figures

Graphics files are welcome if supplied as Tiff or EPS files. Multipanel figures (i.e., figures with parts labeled a, b, c, d, etc.) should be assembled into one file.

The minimum line weight for line art is 0.5 point for optimal printing.

For more information about acceptable resolutions, fonts, sizing, and other figure issues, please see the general guidelines.

When possible, please place symbol legends below the figure instead of to the side.

APA offers authors the option to publish their figures online in color without the costs associated with print publication of color figures.

The same caption will appear on both the online (color) and print (black and white) versions. To ensure that the figure can be understood in both formats, authors should add alternative wording (e.g., "the red [dark gray] bears represent") as needed.

For authors who prefer their figures to be published in color both in print and online, original color figures can be printed in color at the editor’s and publisher’s discretion provided the author agrees to pay:

* $900 for one figure
* An additional $600 for the second figure
* An additional $450 for each subsequent figure

Permissions

Authors of accepted papers must obtain and provide to the editor on final acceptance all necessary permissions to reproduce in print and electronic form any copyrighted work, including test materials (or portions thereof), photographs, and other graphic images (including those used as stimuli in experiments).

On advice of counsel, APA may decline to publish any image whose copyright status is unknown.

[DOWNLOAD PERMISSIONS ALERT FORM (PDF, 13KB)]

Publication Policies

APA policy prohibits an author from submitting the same manuscript for concurrent consideration by two or more publications.

See also APA Journals® Internet Posting Guidelines.

APA requires authors to reveal any possible conflict of interest in the conduct and reporting of research (e.g., financial interests in a test or procedure, funding by pharmaceutical companies for drug research).

* Download Disclosure of Interests Form (PDF, 38KB)

In light of changing patterns of scientific knowledge dissemination, APA requires authors to provide information on prior dissemination of the data and narrative interpretations of the data/research appearing in the manuscript (e.g., if some or all were presented at a conference or meeting, posted on a listserv, shared on a website, including academic social networks like ResearchGate, etc.). This information (2–4 sentences) must be provided as part of the Author Note.

Authors of accepted manuscripts are required to transfer the copyright to APA.

* For manuscripts not funded by the Wellcome Trust or the Research Councils UK
  Publication Rights (Copyright Transfer) Form (PDF, 83KB)
* For manuscripts funded by the Wellcome Trust or the Research Councils UK
  Wellcome Trust or Research Councils UK Publication Rights Form (PDF, 34KB)
Ethical Principles

It is a violation of APA Ethical Principles to publish "as original data, data that have been previously published" (Standard 8.13).

In addition, APA Ethical Principles specify that "after research results are published, psychologists do not withhold the data on which their conclusions are based from other competent professionals who seek to verify the substantive claims through reanalysis and who intend to use such data only for that purpose, provided that the confidentiality of the participants can be protected and unless legal rights concerning proprietary data preclude their release" (Standard 8.14).

APA expects authors to adhere to these standards. Specifically, APA expects authors to have their data available throughout the editorial review process and for at least 5 years after the date of publication.

Authors are required to state in writing that they have complied with APA ethical standards in the treatment of their sample, human or animal, or to describe the details of treatment.

* Download Certification of Compliance With APA Ethical Principles Form (PDF, 26KB)


Other Information

* Appeals Process for Manuscript Submissions
* Preparing Auxiliary Files for Production
* Document Deposit Procedures for APA Journals